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Chapter One 
General Introduction 
Introduction 
1.1 Introduction 
During early fetal development. the primitive urogenital system is 
bipotential and can develop into a male or female direction, depending on 
the chromosomal sex of the fetus. In this chapter, regulatory factors of sex 
determination and differentiation are described. The roles of two testicular 
hormones, testosterone and anti-Mullerian hormone (AMH), which are 
essential for proper differentiation of the internal genitalia, are discussed. 
1.2 Formation of the urogenital system 
The urogenital system develops from the intermediate mesoderm, which 
lies between the somites and the lateral plate (Figure 1.1). This mesoderm 
forms as a pair of thickenings on the coelome at the dorsal site of the 
embryo, running along the full length of the body cavity (Karl and Capel, 
1995). At its most anterior region, the intermediate mesoderm forms the 
pronephros, which soon disappears in vertebrates. The mesodermal 
midsection forms the mesonephros that gives rise to the mesonephric ducts 
or Wolffian ducts. The Wolffian ducts extend continuously, ending in the 
cloaca at the posterior end of the embryo, and form the anlagen of the 
male reproductive tract. Within the mesonephric region a second pair of 
ducts is formed, the paramesonephric ducts or Mullerian ducts, which are 
the anlagen of the female reproductive tract. The Mullerian ducts are 
formed in a cranial to caudal direction, alongside the Wol!!ian ducts. The 
initial formation of the Mullerian ducts starts as an invagination of the 
coelomic epithelium, and their caudal tips are fused at the urogenital sinus. 
Conflicting data exist about the role of the Wolffian ducts in Mullerian duct 
formation. It has been suggested that the Wolffian ducts serve simply as a 
guidance for early growth of the Mullerian ducts (Dohr and Tarmann, 1984), 
whereas others have proposed that the Wol!!ian ducts release epithelial 
cells that contribute to the Mullerian ducts (Grunwald, 1941; Dyche, 1979). 
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Figure 1.1. Schematic representation of the mouse E11.S urogenital ridge. 
The gonads are formed in association with the mesonephros and are 
morphologically indistinguishable between male and female fetuses. Two complete 
ductal systems form in both male and female fetuses: mesonephric (Wolffian) ducts 
and paramesonephric (Mullerian) ducts (modified from Larssen (1997)]. 
Both anlagen of the reproductive tracts, Wolffian and Mullerian ducts, 
are present in male as well as in female embryos, and their ability to 
differentiate and develop is dependent on the gonadal sex (Figure 1.2). In 
the male, the Wolffian ducts differentiate into the epididymides, vasa 
deferentia and seminal vesicles, due to the action of the testicular hormone 
testosterone. Testicular secretion of AMH causes regression of the 
Mullerian ducts (Josso and Picard, 1986). In the female, the ovaries do not 
produce AMH and the Mullerian ducts differentiate into oviducts, uterus 
and upper part of the vagina, whereas the Wolffian ducts degenerate in the 
absence of testosterone. Apparently, differentiation and development of the 
female reproductive tracl is independent of ovarian hormones. 
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Figure1.2. Schematic representation of mammalian sex differentiation. 
The indifferent stage is characterized by the presence of the bipotential gonads and 
Wolffian and MUllerian ducts, which fonn the anlagen of the male and female 
internal genitalia, respectively. In the male fetus, the gonads differentiate into 
testes, the MUllerian ducts regress due to the action of AMH, and the Wolffian ducts 
differentiate into the epididymides, vasa deferentia, and seminal vesicles due to the 
action testosterone. In the female fetus, the gonads differentiate into ovaries, the 
Wolman ducts degenerate, and the Mullerian ducts differentiate into the Fallopian 
tubes, uterus, and upper part of the vagina [modified from Wilson et a1. (1981 all. 
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Through a process of mesenchymal-epithelial induction, the indifferent 
gonads are formed along the length of the mesonephros (Karl and Capel, 
1995; Capel, 1996) (Figure 1.1). The cells of the indifferent gonads are 
bipotential, since they have the capacity to differentiate into cell types of an 
ovary or a testis. In the developing gonads several cell lineages can be 
identified: germ cells and at least three somatic cell types. The origin of the 
somatic cell types is not completely understood. It is suggested that cells 
from the mesonephric tubules contribute to the population of cells that form 
the gonads (Wartenberg, 1982; Satoh, 1985). Antibody staining of laminin, 
which is present in the basement membrane of the mesonephric tubules, 
revealed cellular bridges between the mesonephric tubules and the gonad 
(Karl and Capel, 1995). However, it is also suggested that cells from the 
coelomic epithelium invade the interior of the developing gonad (Smith and 
MacKay, 1991). Scanning electron microscopy of mouse embryos showed 
pores in the surface epithelium of the gonad, through which cells could 
invade (Capel and Lovell-Badge, 1993). The somatic cell lineages are 
defined in the adult gonad as: (i) the supporting cells, differentiating into 
Sertoli cells in the testis or granulosa cells in the ovary; (ii) the 
steroidogenic cells, which are the Leydig cells in the testis and theca cells 
in the ovary; (iii) and the connective tissue cells that constitute the testis 
tunica, blood vessels and peritubular myoid cells in males, and stromal 
cells in females (Byskov and Hoyer, 1994). An important cell lineage of the 
gonads is contributed by the primordial germ cells. In the early embryo, 
before gonadal sex determination, these primordial germ cells are 
localized at the posterior end of the primitive streak, and then migrate 
along the hindgut and dorsal mesentery into the developing genital ridge 
(Ginsburg e/ aI., 1990). The presence of primordial germ cells in the gonad 
is not essential for testis differentiation. Mutations of the genes encoding 
the receptor Kit or its ligand Stem cell factor, prevent germ cell proliferation 
and survival, resulting in gonads devoid of germ cells, but these mutations 
do not inhibit formation of a normal testicular structure (McLaren, 1985). In 
contrast, the presence of germ cells is a prerequisite for a proper 
organization of the ovary. The absence of germ cells in female gonads 
leads to the formation of so-called "streak ovaries" (Burgoyne and Palmer, 
1993). The development of the germ cells is dependent on the genetic sex 
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of the germ cells, but also on the surrounding environment (McLaren, 1995; 
Whitworth, 1998). Germ cells enclosed in the testicular tubules enter mitotic 
arrest, whereas in an ovarian environment germ cells enter the prophase of 
meiosis, independent of the genetic sex of the germ cells (McLaren, 1995). 
1.3 Molecular genetic aspects of sex determination and differentiation 
1.3.1 Mechanism of sex determination 
Proper sex differentiation depends on the mechanism by which the sex of 
the bipotential gonad is determined. The mechanism of sex determination 
varies among species. In many reptiles, the temperature at which the eggs 
are incubated determines sex (temperature·dependent sex determination) 
(Crews et al., 1994). In a variety of other species, sex determination is 
regulated at a genetic basis, either by the number of X chromosomes or by 
the presence of the Y chromosome. 
In Drosophila and C. elegans the primary determinant of sex is the 
ratio between the number of X chromosomes and the number of sets of 
autosomes (the X:A ratio). In XX females (Drosophila) or hermaphrodites 
(c. elegans), the X:A ratio is I, whereas in XY males (Drosophila) or XO 
males (c. elegans) the X:A ratio is 0.5 (Cline, 1993; Parkhurst and Meneely, 
1994). Chromosomal based sex determination is coupled to a mechanism 
of dosage compensation, the process by which the total level of X-linked 
gene expression is equalized between the sexes. The strategies used to 
accomplish dosage compensation vary. In Drosophila the level of 
transcripts produced by the single X chromosome in males is elevated to a 
level produced by two X chromosomes in females (Baker et aI., 1994). In C. 
elegans the expression of the X-linked genes in XX hermaphrodites is 
reduced (Chuang et aI., 1994). 
The sex chromosomes in birds are designated Z and W, and the male 
is the homomorphic sex (ZZ) and the female heteromorphic (ZW). It is 
suggested that sex determination in birds is by a genic balance 
mechanism, in which the ratio of autosomes to Z chromosomes is the 
crucial factor (Stevens, 1997). 
Sex determination in mammals is based on the presence or absence 
of the Y chromosome, irrespective or the number of X chromosomes 
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present. However, a dosage·dependent sex determination mechanism, in 
which the number of active copies of DAX-J versus SRY plays a role (see 
1.3.3), may still be present in mammals. X-chromosomal dosage 
compensation, an event that also occurs in mammals, is accomplished by 
inactivation of one of the two X chromosomes in female somatic cell types 
(Migeon, 1994). 
1.3.2 The role of Sry in sex determination and differentiation 
Studies by Jost on rabbit fetal development, demonstrated that ovariectomy 
had no effect on female differentiation, whereas removal of the testes led to 
feminization of the male embryo (Jost, 1947; Jost, 1953). Therefore, it was 
suggested that female differentiation follows a default pathway, whereas 
the male pathway requires the action of a testis-determining factor (TDF in 
humans or Tdy for testis-determining Y gene in mice). Loss of TDF would 
result in sex-reversal in males. Indeed, approximately 80% of XX human 
males are sex-reversed due to an aberrant X-Y translocation during 
meiosis of the father (Petit et aI., 1987). Analysis of these XX males revealed 
that the testis-determining factor gene was localized within a 35 kb Y-
chromosomal region. Through a positional cloning strategy the gene that is 
functionally equivalent to TDF was isolated (Gubbay et aJ., 1990a; Sinclair 
et al" 1990). This gene, SRY (sex-determining region of the Y) in human and 
SLY in mouse, was shown to be conserved on the Y chromosome of all 
mammals, and the presence or absence of the gene correlates with male 
versus female sex determination (Foster et aI., 1992). A number of 
mutations have been found in the SRY gene of XY individuals that develop 
as females (Table 1.1) (Berta et aI., 1990; Jager et aI., 1990; Hawkins et al., 
1992a; Hawkins et aI., 1992b; McElreavy et aI., 1992; Hawkins, 1993; 
Hawkins, 1995). Furthermore, XX SLY-transgenic mice carrying a 14 kb 
genomic DNA containing the SLY locus, develop as male mice with testes 
and male accessory sex organs, and male mating behavior (Koopman et 
al., 1991). 
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Table 1.1. Disorders in male sex determination and differentiation 
Phenotype 
Gene Disorder Gonads External genitalia Internal genitalia Role 
WT1 Denys-Drash streak female/ambiguous MD present kidney/gonad development 
syndrome WD present 
SF-1 ? (knockout) absent female MD present adrenal/gonad development 
WD present testis differentiation 
SRY 46,XY gonadal streak female MD present testis determination 
dysgenesis WD absent 
DAX-1 Adrenal hypoplasia hypogonadal male MD absent adrenaVgonad development 
congenita and WD present ovarian determination? 
hypogonadotropic 
hypogonadism 
(DSS duplication) streak/ovaries female/ambiguous MD present ovarian determination? 
46,XY gonadal WD absent 
dysgenesis 
SOX9 Campomelic streak/testes female/ambiguous MD present testis differentiation 
dysplasia WD absent 
AMH/AMHRII Persistent Mullerian testes male MD present MD regression 
duct syndrome WD present 
Androgen Androgen testes female/ambiguous MD absent WD differentiation and 
receptor insensitivity WD absent differentiation extemal 
syndrome genitalia 
;;-
Genes involved in early regulatory pathways of sex determination and differentiation are shown. Some of the gene mutations a 
result in ambiguous genitatia. In these cases, the degree of differentiation of the internal genitatia also varies. MD, MUllerian c. 
" Sl
~ ducts; WD, Wolffian ducts. o· 
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Analysis of the SRY amino acid sequence revealed the presence of a 
79 amino acid HMG (high mobility group) box type DNA binding domain. 
The HMG domain of SRY is conserved among other species, while the 
regions outside the domain show no homology (Whitfield et aJ., 1993). The 
HMG domain of SRY resembles a class of transcription factors with 
sequence specific binding properties (Travis et aJ., 1991; Van de Wetering 
et aJ., 1991). In vitro experiments have demonstrated that the HMG domain 
of SRY binds preferentially to AACAA(A(T)(G/C) and induces a sharp bend 
in the DNA (Ferrari et aJ., 1992; Van de Wetering and Clevers, 1992). In 20% 
of the patients with gonadal dysgenesis, mutations have been found in the 
HMG box, while only a few mutations were identified outside the HMG box 
region, indicating that the functional domain of SRY is located in the HMG 
domain (McElreavy et aJ., 1992; Hawkins, 1993; Poulat et aJ., 1994; Tajima et 
aJ., 1994). 
Consistent with a role for Sry in testis determination, Sry mRNA is only 
expressed by cells within the genital ridge. In the mouse, expression of Sry 
mRNA in the genital ridge is first detected at EIO.5 (days post coitum), 
peaks at EIl.5 and declines rapidly within 24 hrs (Figures l.3 and 1.4). This 
small period of Sry mRNA expression (EIO.5-12.5) coincides with the onset 
of morphological changes of testicular cells to form testis cords (Koopman 
et aJ., 1990; Hacker et aJ., 1995). The absence of Sry mRNA expression in 
germ cells suggests that this gene is expressed in a testicular somatic cell 
type. Since the SertoH cells are the first morphological distinguishable cell 
type of the testis, it is suggested that Sry triggers the onset of SertoH cell 
differentiation. Indeed, in a XX/X'l mosaic mouse, 95% of the SertoH cells 
are XY, whereas for the other somatic cell types an even distribution of XX 
and XY cells are found (Burgoyne et aJ., 1988; Palmer and Burgoyne, 1991). 
Since it is only expressed for a short period of time, Sry is not required to 
maintain the differentiated state of the testis, suggesting the involvement of 
other genes in testis differentiation, possibly induced by Sry. However, thus 
far no physiological target genes of Sry are known. 
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Figure 1.3. Genetic regulatory pathway involved in mammalian sex determination and differentiation. 
The diagr= illustrates the development of the gonads and the genes involved, at the approximate number of days post 
coitum (E) in the mouse. The time course of expression of these genes is shown at the top (male) and the hottom (female). 
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In the adult testis, Sry mRNA is expressed by the post meiotic germ 
cells, and the onset of this mRNA expression coincides with the first wave of 
spermatogenesis and the development of round spermatids (Hacker e/ al., 
1995). Nevertheless, it is believed that Sry has no critical function in 
spermatogenesis, since X'l germ cells deleted for Sry, within a founder 
male chimera, were able to give rise to offspring (Gubbay e/ al., 1990b; 
Lovell-Badge and Robertson, 1990). In the adult testis, a 1.23 kb circular Sry 
transcript is found, which may not be transcribed. In contrast, in the 
developing gonad a linear transcript of 4.8 kb is expressed. This suggest 
the presence of two promoters for the Sry gene, a proximal promoter that 
gives rise to functional transcripts in the genital ridge, and a distal 
promoter used in germ cells of adult testis resulting in circular Sry mRNA 
that may not be functional (Capel e/ aI., 1993; Hacker e/ aI., 1995; Dolci e/ 
al., 1997). 
1.3.3 Other genes involved in sex determination and differentiation 
It was expected that Sry could function as the master regulatory gene in a 
cascade of events leading to testis differentiation (Figure 1.3). However, in 
the majority of X'l patients with gonadal dysgenesis the SRY gene is not 
affected. Furthermore, some XX males lack SRY. This has led to the 
understanding that other sex-determining genes are involved in a network 
of interactions leading to gonadal determination. In addition to Sry, several 
autosomal genes and one X-linked gene have been identified in relation to 
failure in testis development (Table 1.1). These genes will be discussed 
below. 
WTt 
The Wilms' tumor gene, WTJ, encodes a transcription factor with homology 
to members of the EGR (early growih response) family (Call e/ aI., 1990; 
Gessler e/ aI., 1990). The WTI protein contains a zinc finger DNA binding 
domain at the C-terminus and a Pro/Glu rich N-terminus. This latter domain 
can function as a transcriptional repressor or activator depending on the 
promoter sequence of the target gene (Madden e/ al., 1991; Drummond e/ 
aI., 1992; Wang e/ al., 1992; Drummond e/ al., 1994). Four different WTI 
isoforms are recognized, based on the presence or absence of two 
18 
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alternatively spliced exons. The presence or absence of the exons 
determine the transcriptional repression or the DNA binding specificity, 
and subnuclear location of the WTI isoforms. It has been shown that one of 
the WTI isoforms (-KTS) can affect expression of genes involved in cellular 
proliferation and differentiation (Haber et a1., 1990; Madden et al" 1991; 
Drummond ef a1., 1992). 
The WTl gene was first identified in relation to Wilms' tumor, a 
malignant tumor of the embryonic kidney. However, mutations in WTl also 
affect other organs. Chromosomal deletions that include WTl cause the 
WAGR syndrome (Wilms' tumor, aniridia, urogenital abnormalities, and 
mental retardation). The Denys-Drash syndrome (DDS), which results from 
point mutations in the WTl gene (Pelletier et al., 199Ia), is characterized by 
the presence of Wilms' tumor, more severe urogenital abnormalities and 
varying degrees of abnormal gonadal development. Patients, that are 
heterozygous for certain point mutations display features of XY-sex 
reversed females (Hastie, 1994), suggesting a role for WTI in sex 
determination and/or sex differentiation. 
Expression of WT I mRNA is found in the developing kidney, the genital 
ridge and the fetal gonads, coinciding with their common origin, i.e. 
intermecliate mesoderm (Pritchard-Jones et al., 1990; Pelletier et aJ., 199Ib). 
Expression was detected as early as E9, prior to the mesenchyme-to-
epithelial transition (Figure 1.3) (Armstrong et a1., 1993). Generation of WTl 
null mice revealed the absence of kidneys and gonads in both sexes, due 
to a failure in mesenchymal.differentiation (Kreidberg et al., 1993). Although 
the onset of gonadal development was detected at Ell, the thickenings of 
the epithelium were reduced, and at E 14 no gonads were visible. These 
results suggest that WTI is required for early establishment of the 
bipotential gonads (Kreidberg et a1., 1993). Furthermore, these results 
indicate that WTI acts upstream of Sry. In addition, WTI remains 
expressed in the developing gonad, and a role of WT I in gonadal 
differentiation can therefore not be excluded (see also 1.4 .2) (Pelletier et a1., 
199Ib). 
19 
Chapter 1 
SF-1 
The gene steroidogenic factor 1 (SF- 1) encodes an orphan nuclear 
receptor, which was found to regulate the expression of steroidogenic 
enzymes in the adrenal and gonads (Lala et aJ., 1992; Morohashi et aJ., 
1992; Honda et aJ., 1993; Ikeda et aJ., 1993). Analysis of the prenatal 
expression pattern revealed that SF-l mRNA is expressed in the 
developing adrenals, gonads, ventromedial hypothalamic nucleus and 
pituitary (Hatano et a1., 1994; Ikeda et aJ., 1994; Ingraham et aJ., 1994). In the 
urogenital ridge, SF-l mRNA expression is found in both sexes during the 
sexually undifferentiated stage (E9-lO) (Figure 1.3). At later developmental 
stages, SF-l mRNA shows a sex dimorphic expression pattern. In the 
developing testes, SF-l mRNA remains expressed at a relatively high level 
in both the interstitial Leydig cells and in Sertoli cells. In the ovary, however, 
expression of SF-l mRNA declines at E12, the time point of morphological 
differentiation (Figures 1.3 and 1.4) (Ikeda et a1., 1994). Due to the temporal 
difference in peak expression of Sry (EI1.5-12) and SF-l mRNA (EI6-18), it 
is most likely that there is no direct transcriptional regulation of SF-1 by Sry. 
Besides its regulatory role in the establishment of the steroidogenic 
pathway, SF-l was shown to regulate expression of AMH mRNA, indicating 
an important role of SF-l in Sertoli cell differentiation (see 1.4.2) (Ingraham 
et a1., 1994; Shen et aJ., 1994; Giuili et a1., 1997). Furthermore, SF-l proved 
to be essential for the development of adrenals and gonads, since SF-l-
deficient mice lack adrenals and gonads (Luo et a1., 1994). Detailed 
analysis of SF-I-deficient fetuses revealed that the initiation of urogenital 
ridge development is not hampered. However, the gonads degenerate due 
to apoptosis around the period of normal testis determination, resulting in a 
complete absence of gonads at E12.5 in both sexes (Luo et a1., 1994). These 
results indicate that SF-l plays an essential role in gonadal development 
before the onset of Sry mRNA expression and, based on the sexual 
dimorphic expression pattern, also has a role in testis differentiation. 
SOX9 
Genes encoding proteins containing an HMG box with more than 60% 
similarity to the Sry HMG box region, are named SOX genes (Sry-re1ated 
HMG box gene) (Wright et aJ., 1993). One of these SOX genes, SOX9, is 
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involved in XY sex reversal. SOX9 contains the HMG box domain and a 
Pro/Glu rich region characteristic for transcription factors (Wright ef a1., 
1995). Mutations in SOX9 in human lead to the severe dwarfism syndrome, 
campomelic dysplasia (CD) (Foster ef al., 1994; Wagner ef aJ., 1994). 
Defects in cartilage and bone development. abnormalities of the olfactory 
system, central nervous system, heart and kidney were observed. In 
addition, in 75% of the XY CD patients sex reversal occurs. The gonads of 
CD sex reversed patients display a range of phenotypes, varying from 
some testicular differentiation to ovary-like gonads with some primary 
follicles (Foster ef a1., 1994; Wagner ef aJ., 1994). 
In the mouse, Sox9 mRNA is expressed at all sites of chondrogenesis, 
in line with the skeletal abnormalities in CD patients <Wright ef aJ., 1995). 
Furthermore, Sox9 mRNA expression was found in genital ridges of both 
XX and XY fetuses at EIO.5 (Figure 1.3) (Kent ef a1., 1996; Morais da Silva et 
a1., 1996). At this time point the ridges are indistinguishable and male 
fetuses just start to express Sry mRNA, suggesting that the initiation of Sox9 
mRNA expression requires other factors than Sry. At EII.5, Sox9 mRNA is 
abundantly expressed in the genital ridge of male fetuses and expression 
remains high in the developing testis, whereas, from ElLS onwards, 
expression declines in the fetal ovary and is absent in the adult ovary 
(Figure 1.3) (Kent ef a1., 1996; Morais da Silva et al., 1996). These 
observations indicate that Sry may be required for sex-specific expression 
of Sox9. In the developing and adult testis, Sox9 mRNA expression is 
restricted to Sertoli cells and is independent of the presence of germ cells 
(Kent et al., 1996; Morais da Silva ef aJ., 1996), suggesting a role of Sox9 in 
Sertoli cell differentiation and in maintenance of Sertoli cell function. The 
sex reversal in CD patients is consistent with a failure in Sertoli cell 
differentiation. All CD patients identified so far are heterozygous for the 
mutations, indicating that one copy of SOX9 is insufficient for testis 
differentiation (Foster ef al., 1994; Wagner ef al., 1994). 
One can conclude that Sertoli cell differentiation is controlled by a 
precise balance between several genes, including Sry, SF-I, Sox9 and 
Dax-l. 
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Oax-1 
Duplication of a defined segment of the short arm of the X chromosome 
causes sex reversal in XY individuals (Bernstein et a1., 1980). The 
presumptive gene at this locus has been termed DSS (dosage-sensitive sex 
reversal), and is suggested to play a female-specific function (Bardoni et 
a1., 1994). In males, DSS would be negatively down-regulated by SRY, 
whereas this repression fails when DSS is present in a double dose. In 
contrast, XY individuals with deletions of the DSS region remain 
phenotypically male. This suggests that DSS is not involved in testicular 
differentiation, but that a double dose will interfere. 
From the DSS region, the gene DAX-1 has been identified, which 
encodes an unusual member of the nuclear hormone receptor family. 
Mutations of this gene have been found in patients with adrenal hypoplasia 
congenita (AHC) (Muscatelli et a1., 1994; Zanaria et a1., 1994). DAX-l (DSS-
AHC critical region on X) contains a ligand-binding domain similar to other 
family members, but lacks the characteristic zinc fingers. Instead, three 
repeats and a fourth incomplete repeat at the N-terminus encode a new 
struciural motif with a DNA-binding function (Zanaria et a1., 1994; Lalli et a1., 
1997). Deletions or mutations in DAX-l cause AHC as well as 
hypogonadotropic hypogonadism (HHG). AHC-HHG is characterized by 
impaired adrenal differentiation and arrested development of the gonads 
(Muscatelli et a1., 1994). 
In the mouse, Dax-l mRNA is expressed in the same tissues as SF-I, 
such as the adrenals, genital ridges, gonads, hypothalamus and pituitary 
(Guo et a1., 1995; Swain et aJ., 1996). In the urogenital ridge, the timing and 
localization of Dax-l mRNA expression corresponds to those of SF-I, 
although the earliest time point of SF-l mRNA expression precedes Dax-I, 
indicating that SF-l might function upstream of Dax-l (Figure 1.3) (Guo et 
a1., 1995; Ikeda et a1., 1996; Swain et a1., 1996). In contrast to SF-l mRNA 
expression, Dax-I mRNA remains expressed in the fetal ovary and 
expression declines in the fetal testes. Furthermore, DAX-1 mutations in 
human do not interfere with the initial stages of gonadal differentiation, in 
contrast to the effect of SF-I deficiency, and a normal mRNA expression 
pattern of Dax-Iis found in SF-I-deficient mice. Taken together, these 
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obserrations suggest that Dax-l mRNA expression is regulated 
independently of SF-l (Ikeda e/ ai., 1996). 
DAX-l has been proposed to be responsible for dosage-sensitive sex 
reversal. In a recent study, Swain e/ al. (1998) showed that Xi mice 
carrying extra copies of Dax-l have delayed testis development. while 
complete sex reversal occurs in Dax-l transgenic mice with weak alleles of 
Sry. These results strongly suggest that Dax-l is responsible for dosage-
sensitive sex reversal, and that there is a rather direct interplay with Sry. 
Furthermore, the level and timing of Dax-l mRNA expression are critical in 
sex determination and differentiation. 
1.4 Anti·Mullerian hormone 
In fetal rabbit castration experiments, lost demonstrated that testosterone 
alone was not sufficient for normal male reproductive development. An 
additional factor proved to be necessary for Mullerian duct regression in 
male fetuses (Jost. 1947; lost. 1953). This factor is known as anti-Mullerian 
hormone (AMH) or Mullerian-inhibiting substance (MIS) (Josso e/ ai., 1993; 
Lee and Donahoe, 1993). Isolation and characterization of the human AMH 
gene revealed that the gene contains five exons and maps to chromosome 
19p13 (Cate e/ ai., 1986; Picard e/ al., 1986; Cohen-Haguenauer ef aJ.. 1987). 
Furthermore, sequence similarity between the C-terminal region of AMH 
and members of the TGFp superfamily of growih and differentiation factors 
was found (Cate e/ al., 1986; Massague, 1990). AMH is synthesized as a 
precursor protein that requires proteolytic cleavage to generate the 
bioactive C-terminal domain, like other members of the TGFp superfamily 
(see Chapter 2) (Pepinsky e/ al., 1988). Members of the TGFp superfamily 
mediate their actions through a heteromeric receptor complex composed 
of type I and type II transmembrane serine/threonine kinase receptors (see 
Chapter 2). A receptor for AMH was cloned which has structural 
characteristics of a type II serine/threonine kinase receptor (Baarends e/ 
al" 1994; Di Clemente e/ al., 1994b; Grootegoed ef 01., 1994). 
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1.4.1 Expression of AMH and its receptor 
AMH is one of the earliest products known to be secreted by the fetal 
Sertoli cells (Tran et al" 1977; Tran and josso, 1982; Vigier et ai., 1983; 
Hayashi et al" 1984). Expression of AMH mRNA is detected in the fetal testis 
before the seminiferous tubules are morphologically apparent (EI2.5) 
(Munsterberg and Lovell-Badge, 1991). During later developmental stages 
AMH mRNA expression is restricted to Sertoli cells, and a high expression 
level is maintained during the period of Mullerian duct regression (Figure 
1.3; see also 1.4.3.1) (Munsterberg and Lovell-Badge, 1991). The fetal Sertoli 
cells also express the AMH type II receptor (AMHRII) (Baarends et al., 1994; 
Di Clemente et ai., 1994b). Furthermore, mRNA expression of AMHRII is 
found in the target cells of AMH, the mesenchymal cells surrounding the 
Mullerian ducts (Baarends et ai., 1994; Di Clemente et ai., 1994b). In male 
rat fetuses, mRNA expression is detected at E 13 and disappears during 
later developmental stages, correlating with regression of the Mullerian 
ducts. Expression of AMHRII mRNA remains high in the Mullerian duct cells 
of female fetuses (Baarends et ai., 1994; Di Clemente et ai., 1994b). 
After birth, AMH mRNA expression strongly decreases and becomes 
hardly detectable in the Sertoli cells (Munsterberg and Lovell-Badge, 1991; 
Baarends et ai., 1995a). Afthough expression of AMH mRNA is low in the 
adult testis, the mRNA expression pattern was found to be stage-dependent 
during the rat spermatogenic cycle: a maximum level of AMH mRNA was 
found at stage VII of the spermatogenic cycle, whereas this expression is 
much lower at other stages of this cycle (Baarends et ai., 19950). In contrast 
to AMH, Sertoli cells of postnatal rat testis express a high level of AMHRII 
mRNA, although in the rabbit a low level of mRNA expression was found 
(Baarends et ai., 1994; Di Clemente et al" 1994b). In the rat, it was observed 
that AMHRII mRNA expression markedly increases during postnatal testis 
development coinciding with the initiation of spermatogenesis. In parallel 
with AMH, AMHRII shows a stage-dependent mRNA expression pattern 
during the spermatogenic cycle: expression increases from stage XIII, 
becomes maximal during the stages VI and VII and declines to 
undetectable levels at stages IX-XII (Baarends et al., 1995a). 
Fetal ovaries express AMHRII mRNA (Baarends et ai., 1994), while 
AMH mRNA expression is absent. Obviously, this inhibition of fetal ovarian 
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AMH gene expression is essential to prevent Mullerian duct regression in 
the female. Surprisingly, after birth, ovarian expression of AMH mRNA is 
detected in granulosa cells, first in preantral follicles in the peripheral area 
(Munsterberg and Lovell-Badge, 1991; Baarends et 01., 1995b). After 
initiation of follicular growth, expression becomes also evident in preantral 
and small antral follicles. AMH mRNA expression is low or absent in large 
antral follicles, corpora lutea and atretic follicles (Ueno et 01., 1989a; Ueno 
et aI., 1989b; Hirobe et 01., 1992; Hirobe et 01., 1994; Baarends et 01., 1995b). 
During the estrous cycle no evident change in the mRNA expression 
pattern of AMH in follicles of the same size classes was observed, except at 
estrous when mRNA expression in the large preantral follicles was 
decreased (Baarends et 01., 1995b). AMHRlI mRNA is expressed at a higher 
level than AMH, and in all small follicles. From day 15 of postnatal 
development in the rat, AMHRII mRNA expression colocallzes with AMH in 
the granulosa cells of preantral and small antral follicles (Baarends et 01., 
1995b). 
1.4.2 Regulation of AMH expression 
The spatial and sex-specific expression pattern of AMH mRNA during fetal 
development suggests that AMH might be a target gene for one of the 
genes involved in sex determination and differentiation. AMH mRNA 
expression is initiated in the fetal Sertoll cells 20 hours after onset of Sry 
mRNA expression (Figure 1.4A) (Hacker et 01., 1995). Transfection studies 
using a cell line derived from differentiating gonadal ridges of male rat 
fetuses, showed that Sry expression causes an increase in AMH promoter 
activity (Haqq et 01., 1994). In addition, using DNA footprinting, a 24 bp Sry 
binding region was identified in the AMH promoter, which contains 6 bp 
with strong resemblance to a consensus Sry binding sequence. Mutation of 
this footprint region reduced binding of Sry to this mutated sequence but 
had no effect on the Sry-induced transcriptional regulation of the AMH 
promoter (Haqq et 01., 1994), suggesting that the Sry dependent activation 
of AMH is indirect. Moreover, other factors may be important, since 
postnatally, AMH mRNA is also expressed in the ovary. 
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Figure 1.4. Regulation of AMH mRNA expression. 
A. Relative mRNA expression levels of Sry, SF-I and AMH during mouse gonadal 
development. These levels are depicted taking EIl.5 Sry, EI8 SF-I and E20 AMH as 
100% of signal (E: days post coilum). AMH mRNA expression starts 24 hrs after the 
peak expression of Sry mRNA, and the mRNA expression pattern runs parallel with 
that of SF-I in the male gonad. In the fetal ovary, SF-I mRNA expression declines 
and AMH mRNA is not expressed [data adopted from (Shen et aJ., 1994; Hacker et 
al., 1995)]. 
Sequences within 2 kb of the AMH promoter region are sufficient for 
SertoH cell- and granulosa cell-specific expression (Peschon et aI., 1992). 
Deletion analysis revealed that regulatory sequences are contained within 
the most proximal 180 bp of the AMH 5'-f1anking region (Shen et al., 1994). 
Besides the element with homology to the consensus binding site for Sry, a 
second putative element was identified. This 20 bp AMH-RE-I contains a 
motif that resembles the half site for a number of nuclear hormone 
receptors (Shen et aI., 1994). The orphan nuclear receptor SF-I shows a 
similar spatial and sex-specific mRNA expression profile to that of AMH 
(Figure 1.4A). Indeed, SF-I was shown to bind the AMH-RE-I and mutation 
of AMH-RE-I abolished binding of SF-I to this region. Furthermore, the SF-I 
binding site turned out to be essential for sex- and cell-specific AMH 
promoter activity in transgenic mice (Giuili et aI., 1997). However, in vitro 
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B. Model for the regulation of AMH mRNA expression. SF-I regulates the AMH 
promoter activity through binding to the AMH-RE-l. WTI association with SF-I 
results in a synergistic activation of the AMH promoter. This association is specific 
for the AMH promoter. In the presence of Dax-I, the synergism between Wfl and 
SF-I is abrogated [model adapted from (Nachtigal et ai., 1998)]. 
studies revealed that SF-I by itself is unable to activate the AMH gene, but 
a truncated SF-I that lacks the putative ligand binding of SF-I does result 
in AMH induction (Shen et al., 1994). This suggests that an additional factor 
is required for AMH activation by SF-I. Furthermore, since SF-I is 
expressed in both sexes at earlier stages, SF-I alone cannot account for 
the testis-specific activation of the AMH gene. 
Pelletier et a1. (l99Ib) have suggested that WTI might be involved in 
modulation of AMH mRNA expression. Indeed, WTI mutations are often 
associated with persistent Mullerian duct structures (Little and Wells, 1997). 
In cotransfection studies, WTl associates with SF-I, resulting in a 
synergistic action between WTl and SF-Ion AMH activation (Figure I.4B) 
(Nachtigal et al., 1998). Furthermore, it was shown that the synergistic 
activation of the AMH promoter by WTI only occurs in the presence of the 
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conserved AMH-RE-l, as WTI fails to synergize with SF-I to induce the 
promoter of the gene encoding the steroidogenic enzyme P450-21-
hydroxylase, although this promoter contains a canonical SF-I response 
element. In addition, mutated WTl protein fails to synergize with SF-I 
(Nachtigal e/ al., 1998). The synergism between WTl and SF-Ion the AMH 
promoter is antagonized by coexpression of DAX-l, the candidate dosage-
sensitive sex reversal gene (Figure I.4B) (Nachtigal e/ al., 1998). These 
results suggest that the ratio of expression levels of factors, that are 
involved in Sertoli cell differentiation, are important in regulation of AMH 
mRNA expression. 
Postnatally, SF-I, WTl and DAX-I may also be involved in regulation of 
AMH mRNA expression, since all these factors are expressed in testicular 
Sertoli cells and ovarian granulosa cells. During the spermatogenic cycle, 
the Dax-l mRNA expression level is low at stages VI-VII, whereas the AMH 
mRNA expression level is highest at these stages (Baarends e/ aJ., 1995a; 
Tarnai e/ ai., 1996). In the ovary, WT-l mRNA is expressed in small follicles, 
thereby overlapping with AMH mRNA expression (Baarends e/ aJ., 1995b; 
Hsu e/ aJ., 1995). However, the precise regulation of AMH mRNA expression 
in the adult gonads has not been elucidated thus far. 
1.4.3 Functions of AMH 
1.4.3.1 Mullerian duct regression 
The Mullerian ducts, which form the anlagen of the female reproductive 
tract, disappear during early embryonic development in the male fetuses. 
In the above mentioned rabbit experiments, Jost demonstrated that in the 
absence of the fetal testis but with androgen substitution, the Mullerian 
ducts remained present in the male (Jost, 1947; Jost, 1953). Purified AMH 
was shown to induce regression of the Mullerian ducts in cultured female 
rat urogenital ridges (Picon, 1969). 
Regression of the Mullerian ducts is morphologically characterized by 
a whorl of condensed mesenchymal cells surrounding the Mullerian duct 
(Dyche, 1979). Breakdown of the basement membrane allows direct 
contacts between epithelial and mesenchymal cells (Trelstad e/ ai., 1982). 
Incorporation of ['HI-thymidine in separately cultured epithelial and 
mesenchymal ductal cells showed that, in the presence of AMH, DNA 
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synthesis in epithelial cells was not changed; however, the labeling index 
was significantly reduced in the mesenchymal cells (Tsuji e/ ai., 1992). This 
suggests that the effect of AMH on the epithelial cells of the Mullerian ducts 
is via the surrounding mesenchymal cells. The expression of AMHRll mRNA 
in the mesenchymal cells supports this finding (Baarends e/ al., 1994; Di 
Clemente e/ al., 1994b). 
With fluorescent labeling techniques and with the use of chick/quail 
chimeras, it was demonstrated that the epithelial cells migrate out of the 
Mullerian ducts during regression and are incorporated in the 
mesonephric tubules (Hutson et al., 1984; Austin, 1995). However, it has also 
been argued that programmed cell death (apoptosis) is involved in 
Mullerian duct regression. The observation of macrophage-infiltration and 
apoptotic cells in the regressing duct sustained this argument (Price et ai., 
1977; Catlin et ai., 1997). 
Regression of the Mullerian ducts is triggered by AMH only during a 
critical time window of sensitivity (Tsuji et a1., 1992). This sensitive time 
window was defined by exposing female urogenital ridges isolated from rat 
embryos of different ages to AMH, and was found to be located between 
E14 and E15, which would compare to E13-E14 in mouse. Exposure of the 
Mullerian ducts to AMH after this period does not cause Mullerian duct 
regression (Tsuji et ai., 1992). 
The role of AMH in Mullerian duct regression has further been 
demonstrated in gain of function and loss of function experiments. Female 
transgenic mice with ectopic expression of AMH lack uterus and oviducts 
(Behringer et al., 1990). AMH-deficient male mice develop, in addition to a 
normally differentiated Wolffian duct system, Mullerian duct derivatives 
(Behringer et al., 1994). Absence of Mullerian duct regression in male 
fetuses was also observed in AMHRII-deficient male mice (Mishina et al., 
1996). Loss of AMH function in the human causes a rare form of male 
pseudohermaphroditism, known as persistent Mullerian duct syndrome 
(PMDS). PMDS is characterized by the presence of uterus and oviducts in 
otherwise normally virilized males (Josso et al., 1997). Mutations in the 
human AMH gene have been found, that result in bio-inactive AMH or 
absent AMH secretion (Knebelmann et al., 1991; Carre-Eusebe et aJ., 1992; 
Imbeaud et ai., 1994). Mutations have also been found in the AMHRII gene 
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of PMDS patients (Imbeaud et a1., 1995; 1mbeaud et 01" 1996). However, in a 
small group of PMDS patients no mutations were detected in either the 
AMH gene or the AMHRIJ gene, reflecting false-negatives in the PCR-SSCP 
analysis or indicating mutations in downstream genes. 
1.4.3.2 Gonadal function 
Testis 
Although fetal testes and adult gonads express AMH, the role of AMH in 
gonadal function is not clear. AMH has been suggested to play a role in 
gonadal cell differentiation during embryonic development. Fetal ovaries 
exposed to AMH become morphologically masculinized. This may explain 
why in the bovine freemartin, in which the female fetus is exposed to 
hormones of the male twin by choriallantoic anastomoses, Mullerian ducts 
regress and, in addition, ovaries develop testis cord-like structures (Jost et 
01., 1972). Exposure of fetal rat ovaries to purified AMH result in a similar 
sex reversed phenotype (Vigier et 01" 1987). Mammalian endocrine sex 
differentiation is characterized by production of testosterone by the testis 
and estradiol by the ovary (George and Wilson, 1978; Wilson et 01., 198Ib). 
Indeed, AMH exposure affects the pattern of fetal gonadal hormone 
secretion; AMH inhibits aromatase activity, the enzyme that converts 
testosterone to estradiol (Figure 1.5), and as a result, AMH-exposed fetal 
ovaries produce testosterone rather than estradiol (Vigier et 01., 1989). 
Endocrine sex reversal is also observed in vivo in female transgenic mice, 
which ectopically express AMH (Di Clemente et 01., 1992). However, AMH 
does not seem to be essential for normal Sertoli cell differentiation, as 
PMDS patients showed normal testis development and the infertility in 
some PMDS patients may be explained by maldescent of the testis caused 
by the presence of female Mullerian duct derivatives (Hutson and Donahoe, 
1986). The abnormal descent of the testis in PMDS boys has led to the 
suggestion that AMH is involved in the process of testis descent, although 
this role is still under debate since abnormal testis descent is not observed 
in other species with PMDS (Tran et 01., 1986; Meyers-Wallen et 01., 1993; 
Hutson et aI., 1997). Furthermore, AMH has been suggested to cause 
mitotic arrest of male germ cells (Cate, 1993). A correlation was found 
between the arrest of germ cell at the prespermatogonia stage and the 
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Figure 1.5. Schematic representation of the Inhibitory effect of AMH on the FSH-
induced aromatase promoter activity. 
AMH signals through a type I/type II receptor complex to inhibit aromatase activity. 
Aromatase converts testosterone (T) to estradiol (E). In the adult ovary, FSH and 
estradiol may be involved in downregulation of AMH and AMHRII mRNA 
expression. 
initiation of AMH production in ovotestis of B6YDOM mice (Taketo et al., 1991). 
AMH mRNA is highly expressed at the time of perinatal mitotic arrest, and 
is switched off after birth in rat and mouse coinciding with the first wave of 
spermatogenesis (Kuroda et aI., 1990; Mi'msterberg and Lovell-Badge, 
1991). In contrast, tissue culture experiments of neonatal mouse testes 
suggest that AMH is required for the maturation of gonocytes to type A 
spermatogonia (Zhou et al., 1993). However, such an action of AMH does 
not seem to be essential for spermatogenesis. Male AMH-deficient mice 
are found to be infertile, but these mice do produce functional sperm and 
the infertility appears to be caused by the presence of the female 
reproductive organs that blocks sperm transfer (Behringer et al., 1994). 
The development of loss and gain of function models for AMH revealed 
a role for AMH in Leydig cell proliferation. Several AMH-deficient male 
mice incidentally develop Leydig cell hyperplasia (Behringer et al., 1994). In 
contrast, strong overexpression of AMH causes feminization of external 
genitalia and impaired Wolffian duct differentiation in transgenic male 
mice, and it was shown that AMH blocks the differentiation of Leydig cell 
precursors (Behringer et aI., 1990; Racine et aI., 1998). In addition, a low 
31 
Chapter 1 
serum concentration of testosterone is measured in transgenic males that 
overexpress AMH (Lyet et al., 1995). 
An inverse relationship between the levels of testosterone and AMH is 
also observed at puberty in human (Hey et al., 1993). In normal boys, the 
testosterone level increases at puberty, whereas the AMH level decreases. 
Also in patients with a high testosterone level, resulting in the onset of 
puberty at an early age, the AMH level drops to postpubertal values (Hey et 
aI., 1993). However, in patients with androgen-insensitivity syndrome (AlS), 
due to an inactivating mutation of the androgen receptor, the AMH 
concentration remains elevated after the onset of puberty (Hey et aI., 1994), 
revealing an inverse relationship between testosterone and AMH, 
regulated via the androgen receptor protein. 
OV81}1 
The specific expression patterns of AMH and AMHHII mHNAs in preantral 
and small antral follicles suggest that AMH functions during follicle 
development (Baarends et aI., 1995b). In cultured granulosa cells, AMH 
decreases aromatase activity and the LH receptor number (Di Clemente et 
al., 1994a). Furthermore, AMH inhibits the epidermal growih factor (EGF)-
induced proliferation and progesterone synthesis of cultured human 
granulosalluteal cells (Kim et aI., 1992; Seifer et aI., 1993). During the 
process of folliculogenesis, many follicles at the small antral stage become 
atretic. It is suggested that the follicle-stimulating hormone (FSH) surge at 
estrus is essential for survival of those small antral follicles that have been 
selected to ovulate (Hsueh et al., 1994). In this respect, the downregulation 
of AMH at estrus is of interest (Baarends et aI., 1995b). In addition, 
treatment of prepubertal rats with FSH, which induces aromatase activity, 
causes downregulation of AMH and AMHRII mRNA expression in some 
preantral and small antral follicles (Figure 1.5) (Baarends et aI., 1995b). 
Therefore, it was suggested by Baarends et a1. (l995b) that AMH functions 
to prevent follicle maturation. However, AMH does not seem to play a 
dominant role in the ovary, as AMH-deficient mice are fertile, and thus far 
no gross abnormalities of the ovary have been reported (Behringer et aI., 
1994); and unpublished observations). 
32 
Introduction 
1.5 The role of estrogens in sex differentiation 
In reptiles and birds. aromatase activity, which causes the conversion of 
testosterone to estradiol. plays an important role in sex differentiation. In 
the turtle, aromatase activity increases in the female fetus during the 
temperature sensitive sex-determination period (Desvages and Pieau, 
1992). In addition, estrogen administration to male fetuses leads to sex 
reversal (Dorizzi et a1., 1991). In birds, estrogen is important for ovarian 
development. Inhibition of aromatase activity at the stage when gonads are 
bipotential, causes genetic females to develop a male phenotype with 
testes capable of spermatogenesis (Elbrecht and Smith, 1992). In 
mammals, however, the role of estrogens in sex differentiation is less clear. 
Estrogens are considered to play a critical role in the development of 
female secondary sex characteristics, the reproductive cycle, and the 
maintenance of pregnancy. Furthermore, an essential role in fetal 
development has been suggested (George and Wilson, 1994). At the age 
that the fetal testes in rats and mice start to produce testosterone, the fetal 
ovaries are capable of synthesizing estradiol, even before morphological 
differentiation has occurred (Greco et a1., 1993; Weniger, 1993). It is 
suggested that estrogens, in part, mediate cellular organization of the 
ovary. Immunohistochemical analysis revealed the presence of the 
estrogen receptor a (ERa) in the developing mouse fetus (Greco et a1., 
1991; Greco et a1., 1992). At E15, a similar level of ERa was detected in the 
reproductive tract of both male and female fetuses. At later developmental 
stages, an increase in ERa was observed in the mesenchymal cells 
surrounding the female tract, whereas in the male fetus, a faint 
immunohistochemical signal remained present in the gonads and ducts 
(Greco et al., 1991; Greco et a1., 1992). Nevertheless, the role of estrogens in 
sex differentiation is considered controversial. Jost demonstrated that in the 
absence of gonads, rabbit male and female fetuses developed as 
phenotypic females, implicating that gonadal steroid hormones are not 
necessary for female differentiation (Jost, 1947; Jost, 1953). However, a role 
of maternal estrogens in fetal development was not excluded in this 
experimen t. 
To elucidate a possible role of estrogens, an animal model lacking a 
functional ERa was created (Lubahn et aJ.. 1993). Unexpected, both male 
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and female ERa knockout (ERKO) mice are viable, showing normal 
external phenotypes; however, both sexeS are infertile (Lubahn et al., 1993; 
Eddy et aJ., 1996). The female knockout mice show hemorrhagic cystic 
ovaries, due to excessive stimulation by gonadotropins because of the lack 
of the negative feedback on the pituitary that is normally exerted by 
estrogens through ERa. Follicle development arrests prior to formation of 
the ovulatory follicles (Lubahn et al., 1993). Infertility of the ERKO male is 
related to a lower concentration of epididymidal sperm, due to a defect in 
the reabsorption of luminal fluid in the head of the epididymides (Hess et 
al., 1997). This aberrant phenotype most likely reflects a postnatal defect, 
since disruption of spermatogenesis and degeneration of the seminiferous 
tubules become evident after 10 weeks of age (Eddy et al., 1996). 
Morphologically, the extragonadal reproductive tracts of male and female 
ERKO mice develop normally in the absence of an estrogen response 
(Lubahn et al., 1993; Eddy et aJ., 1996). Therefore, estrogens do not seem to 
play a crucial role during sex differentiation. 
The results of the studies on the ERKO mice have been placed in a 
different perspective, however, with the identification of another estrogen 
receptor (ER~) (Kuiper et aJ., 1996). The detection of about 5% of normal 
estradiol binding in uteri of ERKO mice (Lubahn et al., 1993), can be 
explained by the presence of ER~. In addition, other estrogen responses 
may be mediated through ER~. ER~ is more abundantly expressed than 
ERa during fetal development, especially in the prostate and the fetal ovary 
and testis (Brandenberger et al., 1997). The generation of ER{3 knockout 
mice and ERa/ER{3 double-knockout mice, will answer questions that still 
remain about the role of estrogens in fetal sex differentiation. 
The presence of estrogen receptors a and ~ in the reproductive tracts 
of male and female fetuses indicates that these tracts are potential targets 
for estrogens (Greco et aJ., 1991; Greco et aI., 1992). Therefore, excess of 
estrogens during differentiation can cause abnormalities. A case in point is 
the administration of the synthetic estrogen diethylstilbestrol (DES) to 
pregnant women, which has led to an increase in genital carcinoma in the 
daughters (Bornstein et al., 1988). Abnormalities of the reproductive tract, 
such as the presence of Mullerian duct remnants, were also observed in 
boys exposed to DES in utero, and in male offspring of mice exposed to 
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DES (McLachlan et ai., 1975; Gill et ai., 1976; Whitehead and Leiter, 1981). 
Organ culture of male reproductive tracts of the mouse demonstrated that 
Mullerian ducts exposed to DES in vivo do not regress, even in the 
presence of control testes, while nonexposed Mullerian ducts regress 
normally (Newbold et ai., 1984). Therefore, it was hypothesized that 
prenatal DES exposure may change the sensitivity of the Mullerian ducts to 
AMH. In birds, such an inhibitory action of estrogens on AMH occurs 
naturally. The right side of a female chicken is masculinized, characterized 
by the presence of an ovotestis and absence of the Mullerian duct, whereas 
the left side contains an ovary and a differentiated Mullerian duct. During 
fetal development of chicken, both male and female gonads produce AMH 
(Hutson et ai., 1981). The failure of the left Mullerian duct to regress in the 
female, despite the presence of AMH, can be explained by a protective role 
of estrogens produced by the fetal ovary. This hypothesis is further 
supported by an increased ERa concentration in the left Mullerian duct 
(Maclaughlin et aJ., 1983). Whether a similar protective mechanism can be 
activated in mammals, which could explain the presence of Mullerian duct 
remnants in the so-called DES-sons, remains to be studied (see Chapter 5). 
1.6 Aim and scope of this thesis 
AMH is a member of the TGFp superfamily of growth and differentiation 
factors. AMH functions during sex differentiation to induce regression of the 
Mullerian ducts in the male fetus. Postnatally, the action of AMH is 
restricted to the gonads. This thesis focuses on the molecular mechanism 
and developmental aspects of AMH action. 
The members of the TGFp family exert their actions via a type I and a 
type II receptor complex. The family members, their receptors, and the 
signaling pathway are described in Chapter 2. 
The candidate AMHRII was cloned from rat (Baarends et ai., 1994; 
Grootegoed et ai., 1994) and rabbit (Di Clemente et ai., 1994b). Chapter 3 
describes the development of transgenic mice containing a cDNA construct 
encoding a dominant negative AMHRII, in order to study the role of this 
receptor in AMH signaling. 
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Chapter 4 describes the isolation and characterization of the human 
gene encoding AMHRII, in order to evaluate possible mutations in the 
AMHRII gene in PMDS patients. 
The action of AMH in Mullerian duct regression is inhibited due to 
prenatal exposure to estrogens, such as the synthetic estrogen 
diethylstilbestrol (DES). However, the mechanism involved in this inhibitory 
effect of DES is not known. The influence of prenatal DES exposure on 
Mullerian duct development, and on the mRNA expression of AMH and 
AMHRII at several time points during male fetal mouse development, are 
described in Chapter 5. 
Due to the fact that it is difficult to develop a good binding assay for 
AMH, the known inhibitory effect of AMH on FSH-induced aromatase 
activity in Sertoli and granulosa cells, was used to develop an in vitro 
model to study the molecular mechanism of AMH action. With this model, 
ALK2 (activin receptor-like kinase 2) was identified as a candidate AMH 
type I receptor. The mRNA expression of ALK2 in the target tissues of AMH 
was studied (Chapter 6). 
AMH may induce apoptosis through an AMHRl/AMHRII complex, as a 
mechanism of Mullerian duct regression. Indeed, apoptotic cells were 
detected in the regressing MuIlerian ducts in male mice, and a 
constitutively active ALK2 was found to induce apoptosis in cultured cells 
(Chapter 7). 
In the General Discussion (Chapter 8) the possible role of AMH in the 
origin of Mullerian duct abnormalities in the female is discussed. 
Furthermore, the implications of the identification of ALK2 in AMH signaling 
are discussed. Finally, some directions for future research are given. 
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Transforming growth factor P family of peptide growth and 
differentiation factors, and their receptors 
in part submitted 
TGFjl family and receptors 
2.1 Introduction 
The transforming growth factor ~ (TGF~) superfamily consists of a large 
group of related peptide growth and differentiation factors, which includes 
the TGF~s, the bone morphogenetic proteins (BMPs), activins and anti-
Mullerian hormone (AMH) (Figure 2.1A) (Massague, 1990). This chapter 
describes structural and functional aspects of the members of the TGF~ 
family and their receptors. The identification of factors that function 
downstream in the TGF~ signaling pathway and the fact that these 
downstream factors can interact wtth the signaling cascade of other growth 
factors may give insight in the diverse biological responses evoked by the 
TGF~ family members. 
2.2 Biological responses 
Members of the TGF~ superfamily have a broad range of functions in 
mesenchymal-epithelial interactions, cell growth, extracellular matrix 
production and tissue remodeling. The development of several knockout 
models in mice has given much information about the range of activities in 
vivo. However, many of the activities are masked by functional redundancy 
among TGF~ family members, which contributes to the complexity of the 
interpretation of the results. Several mouse knockout models are described 
below. 
Knockout experiments have demonstrated a role for TGF~1 in 
immunogenesis (Shull et aI., 1992; Kulkarni et aI., 1993), whereas TGF~3 is 
important in craniofacial development and pulmonary maturation 
(Kaartinen et al., 1995; Proetzel et aI., 1995). Analysis of the phenotype of 
TGF~2-deficient mice revealed that TGF~2 has a more wtdespread function: 
TGF~2-deficiency leads to defects in heart, lung, limb, eye, urogenital and 
craniofacial development (Sanford et al., 1997). Inhibin and possibly also 
activins are involved in regulation of the secretion of follicle-stimulating 
hormone (FSH) from the pituitary gland (Ling et aI., 1986a; Ling et aI., 
1986b; Petraglia et aJ., 1989). Furthermore, activins are involved in 
craniofacial development and dorsal mesoderm induction (Smith et aI., 
1990; Van den Eijnden-van Raaij et aI., 1990; Matzuk et aI., 1995). Inhibin 
has been suggested to function as a tumor-suppressor gene, since inhibin-
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deficient mice developed gonadal somatic cell tumors (Matzuk et a1., 1992; 
Matzuk et al., 1994). Although one might argue, that the tumors arise due to 
the high activin level that is found in inhibin-deficient mice, and that inhibin 
functions to suppress activin action rather than acting directly as a tumor-
suppressor. BMPs, also known as osteogenic proteins, have a broad 
expression pattern and knockout experiments revealed functional 
redundancy. Nevertheless, it was shown that BMPs play a role in bone and 
cartilage formation, neuronal differentiation, kidney development, 
spermatogenesis and ventral mesoderm induction (Wozney et a1., 1988; 
Koster et al., 1991; Sampath et a1., 1992; Dudley et al., 1995; Zhao et al., 
1996). The expression patterns of AMH and growth/differentiation factor-9 
(GDF-9) are more restricted than that of other family members. GDF-9 
expression is specific for oocytes, and, indeed, in GDF-9-deficient mice 
oocyte differentiation and folliculogenesis are blocked in the absence of 
any other phenotypic expression of the loss-of-function mutation (Dong et 
a1., 1996). AMH is expressed by fetal and adult testes, and induces 
Mullerian duct regression in male fetuses. AMH-deficient male mice show 
persistence of Mullerian ducts and develop Leydig cell hyperplasia. The 
latter effect points to a role of AMH in the regulation of Leydig cell 
proliferation through an autocrine action on Sertoli cells. AMH is also 
produced by the adult ovary, but thus far no abnormalities of AMH-deficient 
ovaries have been reported (Behringer et a1., 1994). 
2.3 General structure 
The TGFp family members are synthesized as large precursor proteins, 
which form homo- or heterodimers. Cleavage at mono- or dibasic cleavage 
sites releases the biologically active C-terminal part of the dimeric protein 
(mature protein) (Figure 2.1B). The dimeric N-terminal fragment plays a role 
in proper folding and secretion of the dimeric C-terminal fragment. 
Furthermore, the N-terminal fragment is involved in regulation of the 
biological activity of the C-terminal fragment. Association of the N-terminal 
fragment with the C-terminal fragment after cleavage, keeps the protein in 
an inactive state (Gentry and Nash, 1990). In contrast to other family 
members, full biological activity of the mature AMH protein is only obtained 
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Figure 2.1. The TGF~ family of growth and differentiation factors. 
A. Similarity between members of the TGF~ family. All factors listed are 
mammalian, except DPP, 60A and Screw from Drosophila; VG 1, Xnr and TGF~5 
from Xenopus; and Dorsalin from chicken. The percentage identity refers to the 
amino acid sequences of the bioactive Cterminal domain (modified from 
Massague and Weis-Garcia (1996)]. 
B. Schematic representation of the proteolytic processing of TGFp related proteins. 
The proteins are synthesized as precursor molecules with a pro-domain (N-terminal 
fragment) and a C-terminal mature region. A dibasic cleavage site (RXXR) is found 
near the junction of the pro and mature domains in most of the family members. 
AMH contains a monobasic cleavage site (RAGR) at this position. The mature 
domain contains the seven conseIVed cysteine residues. Proteolytic cleavage 
releases the mature protein. 
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when the N-terminal fragment remains associated with the C-terminal 
fragment (Wilson et a1., 1993). Although the C-terminal fragment of AMH is 
bioactive, as demonstrated by its ability to induce Mullerian duct 
regression in vitro, its activity is augmented in the presence of the N-
terminal fragment (Wilson et a1., 1993). Nevertheless, cleavage of AMH is a 
prerequisite to obtain bioactivity. Mutation of the monobasic site RAGR, 
which is recognized by members of the proprotein convertase family, into 
RAGA, abolished cleavage and as a consequence bioactivity (Nachtigal 
and Ingraham, 1996). 
The TGFj) superfamily is characterized by a conserved spacing of 
seven cysteine residues in the C-terminal fragment (Figure 2.IB). The three-
dimensional structure of TGFj), determined by crystallography, revealed 
that the dimeric protein consist of two pairs of antiparallel j) strands, held 
together by a disulfide bond formed by one pair of the cysteine residues. 
The remaining six cysteines form a conserved arrangement of disulfide 
bridges, known as the "cysteine knot", involved in intrachain folding 
(Daopin et aJ., 1992; Schlunegger and Gruller, 1992). The similarity between 
the different family members ranges from 25-90%, based on the amino acid 
sequence of the C-terminal domain (Figure 2.IA). 
2.4 Serine/threonine kinase receptors 
2.4.1 General structure 
Members of the TGFj) superfamily exert their actions by binding to 
transmembrane serine/threonine (S/I) kinase receptors. In binding studies, 
receptors for TGFj)s were identified and termed type I and type II receptors, 
based upon their respective relative molecular weights of 55 kDa and 80 
kDa (Cheifetz et a1., 1987; Massague, 1990). By expression cloning, the 
genes encoding the TGFj) type II receptor and the activin type II receptor 
were identified [Lin et a1., 1992; Mathews and Vale, 199!). Other S/I kinase 
receptors, including the type I receptors named octivin receptor-like 
kinases (ALK) 1-7, were identified by PCR using primers based on 
conserved residues of the kinase domain of the type II receptors (Attisano 
et oJ., 1993; Ebner et a1., 1993b; Franzen et a1., 1993; He et 01., 1993; 
Matsuzaki et a1., 1993; Ten Dijke et aJ., 1993; Ryden et aJ., 1996). With 
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the cloning and characterization of the new receptors, it became clear that 
the SIT kinase receptor family could be subdivided into two subfamilies, 
based on the structure of the different members (Figure 2.2A and B). 
The members of the SIT kinase receptor family share the following 
overall structure: an N-terminal signal sequence, a short cysteine-rich 
extracellular region, a single hydrophobic membrane-spanning domain 
and a cytoplasmic region containing the kinase domain. The extracellular 
domain of both receptor type I and type II contains a characteristic cluster 
of cysteine residues, the "cysteine box" (Childs et aI., 1993). This cluster is 
preceded by a conserved pattern of seven cysteine residues in type I 
receptors, and a variable set of cysteines in type II receptors. The catalytic 
domain of the SIT kinase domain can be divided into 12 subdomains, which 
contain stretches of conserved amino acids (Ten Dijke et aI., 1994a). The 
type I receptors contain a highly conserved 30 amino acid sequence in the 
juxtamembrane region. This conserved region contains a characteristic 
GSGSG motif, known as the "GS box", and plays a crucial role in signal 
transduciion (see 2.4.2) NVrana et aI., 1994). A unique characteristic of the 
TGF~ receptor family is the presence of two short inserts in the kinase 
domain between subdomains VI-A and VI-B and between subdomains X 
and XI (Ten Dijke et aI., 1994a). Furthermore, the type II receptors have a 
serine/threonine rich C-terminal tail, which is absent in type I receptors 
(Figure 2.2B). 
Sequence comparison of the receptors revealed that the extracellular 
domain shows little sequence homology. However, different receptors with 
affinity for the same ligand are more similar (Ten Dijke et aI., 1994a). 
Comparison of the cytoplasmic kinase domain of the different receptors 
revealed a 30-40% amino acid identity, while comparison within the type I 
and type II receptor subfamilies results in a sequence identity of 60-80% 
(Figure 2.2A) (Kingsley, 1994; Wrana et aI., 1994). 
2.4.2 Mechanism of receptor activation 
The mechanism of receptor activation by TGFp has been well 
characterized. From studies in TGF~ resistant cell lines, which lack binding 
of TGF~ to either type I (R mutant) or type II receptors (DR mutant), it 
became evident that TGF~ has to interact with two receptors, one from 
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each subfamily (Boyd and Massague, 1989; Laiho e/ ai., 1990). TGFp 
signaling is lost in R and DR mutants, but a somatic cell hybrid of the R 
mutant and DR mutant cell lines restores full receptor function (Laiho e/ ai., 
1991). In addition, expression of either wild type TGFp type II receptor 
(TPRII) in the R mutant or wild type TGFp type I receptor (TPR!) in the DR 
mutant cell lines restored all TGFp responsiveness (Wrana e/ al., 1992; 
Franzen e/ ai., 1993; Bassing e/ al., 1994; Ten Dijke e/ al., 1994b). Evidence 
that both receptor types are engaged in physical association in a 
heteromeric receptor complex, was shown by coprecipitation of both 
receptors using antibodies against either receptor (Wrana e/ al., 1992; 
Ebner e/ ai., 1993a; Franzen e/ al., 1993). From these studies, it was 
concluded that the type II receptor can bind ligand in the absence of the 
type I receptor, whereas the type I receptor itself is unable to bind the 
ligand in the absence of the type II receptor. Upon ligand binding by the 
type II receptor, the type I receptor is recruited into the complex (Wrana e/ 
al., 1994). Formation of the heteromeric receptor complex, besides being 
triggered upon ligand binding, may also be stabilized by interaction 
between the cytoplasmic parts of the receptors (Feng and Derynck, 1996). 
Several lines of evidence indicate that the type I and II receptors may 
in fact form a heterotetrameric complex. In cross-linking experiments, it 
was demonstrated that, in the absence of ligand, the type II receptors are 
present in a homomeric complex (Chen and Derynck, 1994; Vivien e/ ai., 
1995). Since TPRI does not bind TGFp in the absence of TpRII, it has been 
difficult to study homodimerization of TpRI in the absence of TPRII. 
Therefore, chimeric receptors with the extracellular domain of the 
erythropoietin (Epo) receptor and the cytoplasmic domain of the TPRI (E-
RI), or TPRII (E-RI!) were constructed. Homodimerization of the extracellular 
domain of the wild type EpoR is necessary for receptor aciivation. Epo 
induced the formation of an active heteromeric complex between chimeric 
E-RI/E-RII. However, a chimeric E-RI, with a constitutively active cytoplasmic 
kinase domain of TPRI (see below), cannot signal in the absence of Epo. 
Epo-induced homodimerization of E-RI is necessary for receptor activity 
(Luo and Lodish, 1996). In addition, kinase-defective and activation-
defective TPRIs can complement each other, suggesting that at least two 
type I receptors are needed (Weis-Garcia and Massague, 1996). In the 
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current model, it is suggested that the signaling complex is formed as a 
heterotetramer, consisting of two type I and two type II receptors (Figure 
2.3). 
cytoplasm 
Figure 2.3. Mechanism of TGFp receptor activation. 
The type II receptor is the primary TGFf3 receptor, which is a constitutively active 
serine/threonine kinase that recruits the type I receptor upon ligand binding.· 
Subsequent phosphorylation of the GS box by the type II receptor activates the type 
I receptor to signal to dovmstream substrates (Wrana et a1., 1994). 
From studies on the mechanism of receptor activation, it was shown 
that the TPRII is highly phosphorylated in the absence of ligand and that 
exposure to TGFp did not alter the phosphorylation level or the kinase 
activity. Tryptic phosphopeptide mapping revealed that TpRII is 
phosphorylated on multiple serine and threonine residues, due to ligand-
independent autophosphorylation and possibly also through 
phosphorylation by other cytoplasmic kinases 0/Vrana et a1., 1994; Chen 
and Weinberg, 1995). Autophosphorylation of serine residues in TPRlI plays 
a role in the regulation of TPRII signaling. It was shown that 
phosphorylation of Ser213 and Ser409 are essential for TPRII signaling, 
while phosphorylation of Ser416 inhibits receptor function, since mutation 
of Ser416 to an alanine residue yielded a hyperactive receptor with 
constitutive activity (Figure 2.2B) (Luo and Lodish, 1997). In addition, in a 
recent paper by Lawler et a1. (1997), it was shown byanti-phosphotyrosine 
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Western blotting that T~RII kinase can also autophosphOIylate on tyrosine 
residues. Furthermore, the kinase activity of T~RII can be inhibited by a 
tyrosine kinase inhibitor or by replacement of three tyrosine 
phosphorylation sites by phenylalanine residues (Lawler el ai., 1997). 
However, phosphorylation of serine/threonine residues in the C-terminal 
tail of T~RII is not essential for signaling, since a mutant T~RII, which lacks 
this tail, showed undiminished signaling activity (Wieser el ai., 1993). 
An important event in TGF~ receptor activation is transphosphorylation 
of the type I receptor by the type II receptor after ligand-induced receptor 
complex formation (Ventura el al., 1994; Wrana el al., 1994). The type I 
receptor becomes phosphorylated at five clustered serine/threonine 
residues in the GS box, which are essential for signaling (Figure 2.2B and 
2.3). Mutation of anyone residue, or two or three residues, results in no loss 
or partial loss in signaling, respectively. However, mutation of four of the 
five residues completely inactivates the receptor \Wrana el al., 1994; 
Franzen el a1., 1995; Wieser el ai., 1995). The crucial role of 
transphosphorylation of the T~RI by T~RII in signaling, was further 
demonstrated by the use of kinase-defective type II receptors. The T~RII­
(K277R), which carries a single amino acid substitution in the nucleotide 
binding fold of the kinase domain, binds ligand and forms a receptor 
complex to a similar extent as the wild type receptor. However, 
autophosphorylation of the T~RII-(K277R) is abolished and the receptor is 
also unable to phosphorylate the type I receptor (Wrana el ai., 1994). For 
the mutant T~RII-(P525L), autophosphoryation was found to be normal. 
Nevertheless, the catalytically active T~RII-(P525L) is unable to 
phosphorylate the type I receptor, suggesting that T~R-(P525L) cannot 
recognize T~RI as a substrate (Carcamo el al., 1995). Transphosphorylation 
of the type I receptor by the type II receptor does not depend on the kinase 
activity of the type I receptor, since mutations that disrupt the kinase activity 
of T~RI do not prevent phosphorylation of T~RI by T~RII. However, 
disruption of the kinase activity of T~RI prevents signaling \Wrana el al., 
1994). This suggests that the type I receptor SelVeS as substrate for the type 
II receptor, and that the kinase activity of the type I receptor is required to 
phosphorylate downstream factors \Wrana el al., 1994). The downstream 
function of T~RI was confirmed by identification of a constitutively active 
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Tpm (Wieser et ai., 1995). In addition to phosphorylation of the residues in 
the GS box, phosphorylation of two additional threonines located near the 
start of the kinase domain plays a role in receptor activation. Mutation of 
these threonines to valine residues inhibits receptor phosphorylation and 
signaling activity (Wieser et aI., 1995). However, replacement of Thr204 with 
an aspartic acid residue results in a type I receptor with elevated kinase 
activity that signals in the absence of ligand and TpmI (Wieser et a1., 1995). 
This suggest that the type I receptor determines the onset of downstream 
signals. Using chimeras between Tpm and one of the other type I receptors 
(ALK2), it was shown that the juxtamembrane domain, including the GS 
box, and most regions in the kinase domain could functionally substitute for 
each other. However, a nine amino acid sequence between subdomains N 
and V of the Tpm, which varies between the different type I receptors, is 
important in determining specific TGFp signals. Replacement of this 
sequence in Tpm by the corresponding sequence of ALK2, which is unable 
to transduce TGFp responses, inactivated TGFp signaling, whereas 
reciprocal introduction of the corresponding Tpm sequence into ALK2 
realizes TGFp signaling (Feng and Derynck, 1997). In addition, serine and 
threonine phosphorylation sites in the cytoplasmic juxtamembrane region 
play a role in the determination of TGFp signals. Mutational analysis 
revealed that phosphorylation of Serl65 modulates TGFp signaling. A 
stronger effect on growih inhibition was observed, whereas the apoptotic 
signal was lost (Souchelnytskyi et a1., 1996). Furthermore, mutation of 
Ser 172 or Thr 176 showed that these residues are dispensable for 
extracellular matrix protein production, but are essential for growih 
inhibition by TGFp (Saitoh et aI., 1996). 
The mechanism of receptor activation by TGFp may serve as a model 
for other family members. Signaling of activins and BMPs is also mediated 
by a type I and type II receptor complex (Attisano et aI., 1996). However, 
variations on this model have been described. BMPs can bind to type I or 
type II receptors individually with low affinity, but high affinity binding is 
achieved when both receptor types are present (Uu et a1" 1995; Nohno et 
a1., 1995). In addition, receptor complex formation by activins and BMPs 
show other variable aspects. Both activins and BMPs can bind to two 
different type IT receptors that, in addition, can interact with more than one 
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type I receptor. Furthermore, some type I receptors, such as ALK2, can 
serve more than one ligand. An overview of the ligand/receptor 
combinations and their downstream factors are presented in Figure 2.4. 
Ligand Tlll:!e II ~ Smad Effects 
recel:!tor recel:!tor 
DPP Thick veins Dorsal closure 
Dorsal pattern 
BMP 
ALK2 ? 
ALK6 Bone fonnation, ventral mesoderm, 
ALK3 apoptosls 
Activin ALK2 ? 
ALK4 Dorsal mesoderm, growth inhibition 
TGFp ALK5 Growth Inhibition, ECM 
AMH ? MOllerian duct regression 
Figure 2.4. Llgand·receptor combtnations and their known effects. 
2.4.3 Downstream signaling molecules 
2.4.3.1 Smad proteins 
Genetic analysis of Drosophila and C. elegans mutants has led to 
identification of a family of proteins that signal downstream of the srr 
kinase receptors to the nucleus, where transcription of target genes is 
initiated. 
The Drosophila gene dpp (decapentaplegic) encodes a member of the 
TGFp superfamily. In a screen for genes that enhance weak dpp mutants, 
Mothers against dpp (Mad) was identified (Raftery et al., 1995; Sekelsky et 
aI., \995). Homozygous Mad mutants display a similar phenotype as dpp 
mutants. Evidence that Mad functions downstream in the DPP signaling 
pathway came from the finding that transgenic expression of the Mad gene 
rescued the phenotype in dpp mutants (Newfeld et aI., 1996). Furthermore, 
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Mad mutations inhibit signaling of the constitutively active DPP type I 
receptor encoded by Thick veins (Hoodless et al., 1996; Wiersdorff et aI., 
1996). In C. elegans, the genes sma2, sma3, and sma4 were identified in a 
screen for mutants with similar phenotypes as the type IT receptor Daf4 
mutants (Small mutants) (Savage et aI., 1996). These genes are 
homologous to the Mad gene of Drosophila. Recently, at least nine genes 
homologous to Mad and sma have been identified. To simplify the 
nomenclature, the homologues of Mad and sma are designated Smads: 
Smadl (MadrI, XmadI, bspI, Dwf-A, ]C4-1), Smad2 (Madr2, Xmad2, JVI8-
I), Smad3 (hMad3, JVIS-2), Smad4 (DPC4), SmadS (Dwf-C, JV5-I), Smad6 
(]VIS-I), Smad7, Smad8, and Smad9 (MADH6) (Raftery et aI., 1995; 
Sekelsky et aI., 1995; Baker and Harland, 1996; Chen et aI., 1996b; Eppert et 
al., 1996; Graff et aI., 1996; Hahn et aI., 1996; Hoodless et al., 1996; 
Lechleider et aI., 1996; Riggins et aI., 1996; Savage et aI., 1996; Yingling et 
aI., 1996; Imamura et aI., 1997; Nakao et aI., 1997a; Topper et aI., 1997; 
Watanabe et aI., 1997). 
The identified Smads can be divided into three subclasses: pathway-
specific, common-mediator, and inhibitory Smads. These three subclasses, 
and the mechanism of Smad activation and translocation to the nucleus 
will be discussed below. 
Pathway-specific Bmads 
Smadl, Smad2, Smad3, SmadS, Smad8 and Smad9 are designated 
pathway-specific Smads. Smadl, and probably Smad5 and Smad8, 
transduce BMP responses (Graff et aI., 1996; Thomsen, 1996), whereas 
Smad2 and Smad3 display TGF~ and activin specificity (Baker and 
Harland, 1996; Graff et al., 1996). Injection of human or mouse Smadl 
mRNA into Xenopus animal cap cells resulted in induction of ventral 
mesoderm (Liu et aI., 1996), similar to a BMP4 response (Koster et aI., 1991), 
suggesting that the function of Smads is conserved across species. 
The pathway-specific Smads become activated upon phosphorylation 
by the type I receptor at their most C-terminal region (Hoodless et aI., 1996; 
Kretzschmar et aI., 1997b). This region contains a conserved Ser/Ser/X/Ser 
(SSXS) motif (Figure 2.SA). By mutational analysis it has been shown that 
the two most C-terminal serine residues become phosphorylated (Abdollah 
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et a1., 1997; Souchelnytskyi et aJ., 1997). The pathway-specific Smads 
interact directly with the type I receptor, as shown by co-
immunoprecipitation (Macias-Silva et aJ., 1996; Zhang et 01., 1996; Nakao et 
aJ., 1997b). This interaction is transient and can only be detected using a 
kinase inactive form of the type I receptor (Macias-Silva et al., 1996; Nakao 
et aJ., 1997b). 
Common-mediator Smads 
Upon phosphorylation, the pathway-specific Smad is released from the 
type I receptor, upon which this Smad protein forms a hetero-oligomer with 
the common-mediator Smad4 and is then translocated to the nucleus to 
activate target genes (Figure 2.5B) (Hoodless et al., 1996; Lagna ef a1., 1996; 
Liu et aJ., 1996; Wu et aJ., 1997). The common-mediator Smad4 forms a 
complex with Smad2 and Smad3 (Lagna et aJ., 1996; Nakao ef al., 1997b; 
Wu et aJ., 1997), but also with Smadl (Lagna et aJ., 1996; Kretzschmar et aJ., 
1997b), indicating its common role in signal transduction. Indeed, injection 
of Smad4 mRNA into Xenopus animal caps induced both dorsal and 
ventral mesoderm (Lagna et al., 1996; Zhang ef aJ., 1997). Smad4 has a 
similar structure as the pathway-specific Smads. However, Smad4 lacks 
the SSXS motif and does not bind to, and is also not phosphorylated by the 
type I receptor, implicating a different function for Smad4 (Figure 2.5A) 
(Macias-Silva et al., 1996; Zhang et al., 1996; Nakao et aI., 1997b). It was 
suggested that the Drosophila gene medea encodes a Smad4 homologue 
(Raftery et aJ., 1995; Massague et a1., 1997). So far, Smad4 is the only Smad 
protein identified in different species as a common-mediator. 
Inhibitory Smads 
Smad6 and Smad7 form the third subclass of Smads (Hayashi et aJ., 1997; 
Imamura et al., 1997; Nakao et al., 1997a). Smad6 and Smad7 share the C-
terminal domain of the other Smads, but. similar to Smad4, lack the SSXS 
motif. The most important hallmark of the inhibitory Smads, Smad6 and 
Smad7, is found in the N-terminal domain, which does not show any 
homology with the N-terminal domain of the other Smads (Figure 2.5A). 
Inhibitory Smads have also been identified in Drosophila (Dad: daughters 
against dpp) (Tsuneizumi et al., 1997), suggesting a conseIVed function. 
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Figure 2.5. Smads: structure and signaling pathway. 
A. General structure of pathway-specific Smads (Smad2), common-mediator Smad 
(Smad4) and inhibitory Smads (Smad7). The areas of homology between the 
different types of Smad proteins are indicated in black. Furthermore, the MH I 
domain (repressor domain), linker domain containing the four PXSP motifs (ERK 
MAP kinase phosphorylation sites), and the MH2 domain (effector domain) with the 
SSXS phosphorylation site, are indicated. 
B. TGFp downstream signaling model. Upon activation of the type I receptor, 
pathway-specific Smads (Smad2; present in a homotrimeric form) are 
phosphorylated, which leads to heterodimerization with the common-mediator 
Smad (Smad4). The hetew-oligomeric complex translocates to the nucleus where it 
binds directly, or in a complex with other factors, to DNA. The inhibitory Smads 
(Smad7) bind to type I receptor and prevent phosphorylation of pathway-specific 
Smads. 
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Analogous to the pathway-specific Smads, Smad6 and Smad7 interact 
directly with the type I receptor. However, since the C-terminal 
phosphorylation site is absent in the inhibitory Smads, the association with 
the type I receptor is more stable than observed for the pathway-specific 
Smads (Hayashi ef al., 1997; Imamura ef al., 1997; Nakao ef al., 1997a), 
suggesting that Smad6 and Smad7 function by competitive inhibition. By 
binding to the type I receptor, the inhibitory Smads interfere with 
phosphorylation of the pathway-specific Smads, thereby preventing the 
formation of active heteromeric Smad complexes and, subsequently, 
translocation to the nucleus (Figure 2.5B) (Hayashi ef ai., 1997; Imamura ef 
al., 1997; Nakao ef al., 1997a). Overexpression of Smad7 inhibits 
phosphorylation of Smad2 and Smad3 by activated TGFj3 type I receptor, 
and also prevents phosphorylation of Smad I by activated BMP type I 
receptors. Therefore, it is suggested that Smad7 functions as a general 
inhibitor (Nakao ef ai., 1997a). Smad6 may act more specific, by inhibiting 
phosphorylation of Smad2 but not Smad3. Furthermore, phosphorylation of 
Smad I by ALK3, but not by ALK6, is inhibited by Smad6 (Imamura ef al., 
1997). Recently, it was shown that, in addition to interaction with type I 
receptors, Smad6 can associate with Smadl, thereby preventing the 
formation of an active Smadl-Smad4 complex (Hata ef ai., 1998). In 
general, the inhibitory Smads may act as an autoregulatory negative 
feedback system in signal transduction. 
In the pathway-specific and common-mediator Smad proteins, two regions 
of homology are present, the N-terminal and C-terminal domains, termed 
the Mad-homology domains MHI and MHZ, respectively. These domains 
are separated by a proline-rich linker sequence. In the inhibitory Smads 
only the linker region and the MHZ domain can be distinguished (Figure 
2.5A). Within the MHI and MHZ domains, specific residues are highly 
conserved, and it has been shown that these conserved residues are 
targets for mutations. A recent paper by Massague ef al. (1997) has given 
insight in the functional role of the Smad domains. The MHZ domain of the 
pathway-specific Smads functions as the effector domain, since it is fully 
active in the absence of the MHI domain (Baker and Harland, 1996). The 
MH2 domain was shown to contain the ability to induce a transcriptional 
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response when fused to a GAL4 DNA-binding domain (Liu et aI., 1996). 
Furthermore, the MH2 domain of pathway-specific Smads plays a role in 
the interaction with Smad4 (Meersseman et aI., 1997). Non-stimulated wild 
type Smad protein is localed in the cytoplasm, and upon phosphorylation 
translocates to the nucleus. In the absence of the MH I domain, the protein 
is predominantly located in the nucleus, even in non-stimulated cells (Baker 
and Harland, 1996). The MHI domain may function as a negative regulator 
by interaction with the MH2 domain, thereby preventing hetero-oligomer 
formation and keeping the Smad protein in an inactive state (Hala et aI., 
1997). Phosphorylation of the SSXS motif releases the interaction between 
the MH I and the MH2 domains, thereby activating the protein. 
How Smad proteins propagate the signal from the ligand to target 
genes, is still under investigation. In a GAL4 fusion experiment, it was 
shown that Smads mediate transcriptional responses (Liu et aI., 1996). 
However, it is unclear whether Smads interact directly with target genes or 
whether other factors are involved. The response elements of several target 
genes have been identified and may serve to identify interacting 
transcription factors. The Mix-2 gene contains an activin response element 
(ARE) (Chen et al., 1996a), and studies on the activation of Mix-2 have 
shown that besides Smad2 and Smad4, another factor is involved. This 
factor, FAST!, is a member of the winged-helix transcription factor family, 
and forms the major DNA-binding component. A C-terminal domain of 
FAST!, termed the Smad-interaction domain, is involved in binding of 
Smad2 and Smad4. This protein complex interacts directly with the ARE of 
the Mix-2 gene (Chen et aI., 1997a). Whether other target genes of the TGFf) 
family members are activated by Smad proteins either directly or in 
complex with another transcription factor remains to be studied. 
2.4.3.2 Other downstream factors 
In addition to the Smad proteins, other factors have been proposed to 
function downstream in the TGFf) signaling pathway (Figure 2.6). The 
involvement of guanine-nucleotide binding proteins (G proteins) and the 
involvement of mitogen-activated protein kinases (MAPKs) in transducing 
the mitogenic signal of polypeptide growth factors, have been suggested, 
and will be discussed next. 
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G proteins can be divided into several classes, such as the 
heterotrimeric signal transducing G proteins and the small G proteins 
(Gilman, 1987; Bourne et aJ., 1990). The heterotrimeric signal transducing G 
proteins, G, and G" modulate the activity of adenylyl cyclase (Gilman, 
1987), and their function can be altered by bacterial exotoxins. Pertussis 
toxin (PT) inhibits receptor interaction of G" resulting in an attenuated 
inhibition of adenylyl cyclase, while cholera toxin (Cf) inhibits the GTPase 
activation of G, (Gilman, 1987). PT and Cf also affect some of the biological 
actions of TGF~, such as stimulation of protooncogene expression (Howe 
and Leof, 1989). Stable transfection of G,", in NIH 3T3 fibroblasts, a cell line 
with little responsiveness to TGF~, restores TGF~ responsiveness to a 
normal level (Kataoka et aJ., 1993). Furthermore, the stimulation of GTPase 
activity and GTPyS binding is induced by TGF~, suggesting an involvement 
of G protein action in TGF~ signaling (Howe et aJ., 1989; Kataoka et al., 
1993). In this respect, the presence of a consensus G protein activating 
sequence in the TGF~ type II receptor is of particular interest (Kataoka et 
aJ., 1993). To determine which G protein or whether f1. or ~y subunits 
mediate the effects of TGF~ requires more studies. 
Many studies have shown a central role of small G proteins (Ras, Rac, 
Rho and Cdc42) in the downstream signaling of tyrosine kinase receptors. 
The association between Ras and tyrosine kinase receptors is made by 
protein intermediates, such as Grb2 (McCormick, 1993). Grb2 binds to 
phosphotyrosine and a guanine nucleotide exchange factor, Sos. Next, Sos 
interacts with and activates membrane-bound Ras, leading to the 
activation of the MAPK family (Figure 2.6) (Egan and Weinberg, 1993; 
McCormick, 1993; Montminy, 1993; Hallberg et al., 1994). 
Three related MAPK cascades have been identified, which include the 
extracellular signal-regulated kinases (ERKs) (Avruch et al., 1994), p38-
MAPK (Han et aJ., 1994), and the c-)un N-terminal kinases (JNKs), also 
known as the stress-activated protein kinases (SAPKs) (Derijard et aJ., 1994; 
Kyriakis et aJ., 1994). The ERKs are central elements in mitogenic signal 
transduction downstream of Ras (Avruch et al., 1994). P38-MAPKs and 
)NKs/SAPKs participate in the pathway of pro-inflammatory cytokines and 
environmental stress, and, in addition, )NKs/SAPKs respond to apoptotic 
signals (Derijard et al., 1994; Han et al., 1994; Kyriakis et al., 1994; Chen et 
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a1" 1996c; Kyriakis and Avruch, 1996; Meyer et a1., 1996). The ERK, 
JNK/SAPK, and p38-MAKP cascades include a role for the MAPKKKs, 
MAPKKs, and MAPKs (Figure 2.6) (Davis, 1993; Cowley et ai., 1994; Minden 
et ai., 1994; Derijard et ai., 1995; Raingeaud et ai., 1995). 
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Figure 2.6. The mammalian MAPK-dependent signal transduction pathways. 
The components of the ERKs, JNK/SAPKs and p38-MAPK pothways are indicated. 
Homologous kinases are indicated within boxes at equivalent sites in the pathways. 
The interaction of TGFp with the MAPK pothways through Ras or TAKI is shown. 
The stippled arrows indicate that the mechanism of activation, and the identity of 
the possible upstream components, are tmknown. 
Recent studies suggest that the small G proteins and the MAPK 
cascade are also included in the signaling pathway of SIT kinase 
receptors. Using a TGF~ sensitive cell line, Mulder and Morris (1992) 
demonstrated activation of small G proteins by TGFI3. TGFI3 stimulation 
resulted in a rapid increase in GTPyS bound to Ras (Mulder and Morris, 
1992). Furthermore, constitutively active small G proteins stimulate 
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transcription of the TGFp reporter construct p3TPlux, while in the presence 
of dominant-negative G proteins this TGFp response was inhibited (Atfi ef 
01., 1997b). The involvement of G proteins, in particular Ras, in downstream 
signaling of S(f kinase receptors, was also demonstrated in the Xenopus 
animal cap assay. When animal caps dissected from blastula stage 
embryos are maintained in vitro, addition of activins or BMPs leads to 
mesoderm formation (Green and Smith, 1990). Expression of dominant-
negative Ras mutants can prevent this mesoderm-inducing effect of activin, 
suggesting that activin utilizes the Ras signal transduction pathway 
(Whitman and Melton, 1992). Similar experiments have been performed in 
the presence of BMP4. BMP4 was shown to increase the activity of API, a 
heterodimer of cFos and dun (Xu ef 01., 1996). Phosphorylation of dun is 
critical for API activity (Whitmarsh and Davis, 1996). Since dun is one of the 
targets of the jNK/SAPK and p38-MAPK cascades, the involvement of Ras, 
Raf, and dun in the BMP4 signaling pathway has been studied. Indeed, 
dominant-negative mutants of Ras, Raf, and cjun inhibit the BMP4-induced 
increase in API activity (Xu et a1., 1996). Collectively, these results suggest 
that signal transduction induced by members of the TGFp family can make 
use of the small G proteins and the MAPK cascade. Indeed, TGFp has been 
shown to activate all three MAPK cascades (Frey and Mulder, 1997a). In an 
intestinal epithelial cell line and a breast cancer cell line, TGFp treatment 
of the cells resulted in growth inhibition and, in addition, rapid activation of 
ERKI or ERK2 was observed (Hartsough and Mulder, 1995; Frey and 
Mulder, 1997a; Frey and Mulder, 1997b). Furthermore, transfection of 
dominant negative ERKI into TGFp-responsive NIH 3T3 fibroblasts, 
abolished stimulation of plasminogen activator inhibitor-I (PAI-I) promoter 
activity by TGFp (Mucsi et 01., 1996). 
The activation of the jNK/SAPK cascade by TGFp has become more 
evident wtth the cloning of Takl (TGFp-activated kinase I) (Figure 2.6) 
(Yamaguchi ef 01., 1995). Takl was identified in a functional expression 
screen for MAPKKK cDNAs that counteract defects of the MAPK pathway, 
and was shown to induce the TGFp-responsive PAI-l promoter in vitro 
(Yamaguchi et 01., 1995). In addition, a kinase-inactive TAKI mutant 
inhibited the TGFp response on the PAI-l promoter. Furthermore, dose-
dependent activation of TAKI was specific for TGFp and could not be 
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induced by EGF (Yamaguchi et a1., 1995). The upstream TAICI binding 
protein (TAB!), that activates TAlC I, was shown to be important in TGF~ 
signaling in a mammalian cell line (Shibuya et a1., 1996). TAICI can activate 
p38-MAPK through SEKI (Yamaguchi et a1., 1995; Moriguchi et a1., 1996). 
Since SEKI is also an activator of jNK/SAPK, the involvement of TAICI in the 
jNK/SAPK pathway was studied. Indeed, a dominant-negative TAICI mutant 
blocked jNK/SAPK activation, indicating a role for TAlCI in jNK/SAPK 
mediated pathways (Wang et a1., 1997). In addition, transfection of 
dominant-negative jNK/SAPK blocked the TGF~-induced p3TPlux 
activation, thereby further demonstrating a role for the jNK/SAPK cascade 
in TGF~ signaling (Figure 2.6) (Atfi et a1., 1997b). 
The factors, which directly mediate the transduction of the signal form 
the TGF~ receptors, to activate the MAPK cascade have not been identified 
yet. In addition to the Smad proteins, schnurri {shn} has been identified in 
Drosophila (Arora et a1., 1995; Staehling-Hampton et a1., 1995). Shn 
encodes a zinc finger transcription factor, homologous to the human major 
histocompatibility complex-binding proteins. The strikingly similar 
phenotypes of mutations in SHN and in the DPP receptors suggests, that 
SHN plays a role downstream of DPP signaling (Arora et a1., 1995; 
Staehling-Hampton et a1., 1995), although it is unclear in which signaling 
cascade and at what position. 
In a recent study by Atfi et a1. (l997b) it was demonstrated that the 
MAPK cascade and the Smad signaling pathway might interact. In the 
presence of dominant-negative dun, the Smad3/Smad4-induced 3TPlux 
activity was inhibited, suggesting a requirement of the jNK/SAPK cascade 
for functioning of the Smad proteins (Atfi et a1., 1997a). Whether integration 
of the actions of Smad proteins and the MAPK cascades is a general 
feature in TGF~ signaling, remains to be studied. Nevertheless, the 
involvement of several downstream signaling pathways in response to 
TGF~ family members suggests that the specificity of the response to the 
ligand is determined, not by specific actions of a given type I/type II 
receptor complex, but rather by the combination of downstream factors 
which is present in the cell. This might explain the apparent contradictory 
responses of TGF~ in different cell types, such as growth inhibition versus 
growth stimulation. 
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2.5 Crosstalk between signaling pathways 
Inductive interaction is a widely observed mechanism during 
embryogenesis. The induction of mesoderm and mesenchymal-epithelial 
interactions are important processes in various aspects of organogenesis. 
Many of these processes are regulated by members of the TGFp family. 
However, also factors that propagate their signal by tyrosine kinase 
receptors, such as fibroblast growth factor (FGF') and epidermal growth 
factor (EGF'), are involved in proper organogenesis. Several studies have 
indicated that the signaling pathways of s;r kinase receptors and tyrosine 
kinase receptors may cooperate. 
TGFp and bFGF together exert a myogenic promoting activity on 
cultured chick paraxial mesoderm, while this effect was not seen when the 
factors were added alone (Stern et al., 1997). Synergistic interaction was 
also observed between FGF4 and the TGFp family member BMP2, for 
induction of cardiogenesis in chick mesoderm explants (Lough et aI., 1996). 
In addition, experiments wtth dominant-negative receptors have 
demonstrated that both bFGF and activin are required for proper 
mesoderm induction in Xenopus embryos (Amaya et al., 1991; Hemmati-
Brivanlou and Melton, 1992). 
Besides synergistic effects, antagonistic effects between members of 
the TGFp family and FGF or EGF have also been described. FGF4 and 
BMPs are both involved in regulation of mouse limb outgrowth. FGF4 
opposes the antiproliferative effect of BMPZ during limb bud outgrowth, and 
prevents the ability of BMP4 to induce interdigital membrane apoptosis 
(Niswander and Martin, 1993a; Niswander and Martin, 1993b; Ganan e/ al., 
1996). Furthermore, in mandibular arches of mouse embryos, BMP2 and 
BMP4 prevent the induction by FGF8 of Pax9, a marker for prospective tooth 
mesenchyme (Neubuser et al., 1997). 
The mechanism by which the synergistic or antagonistic interactions 
are regulated, is unknown. However, in a recent study using cultured mink 
lung epithelial cells, it was shown that the signaling pathways of EGF and 
BMP interact functionally (Kretzschmar e/ al. 1997a). BMP stimulates the 
phosphorylation of Smad 1 at the C-terminal domain and induces nuclear 
accumulation of Smadl, whereas EGF signaling is mediated by the ERK 
family of MAPKs. In the presence of EGF, Smadl became phosphorylated 
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at specific serine residues wtthin the linker region, thereby preventing 
nuclear accumulation of Smadl (Figure 2.6) (Kretzschmar et al., 1997a). 
Mutational analysis of the linker region of Smad 1 demonstrated that four 
repeated PXSP motifs become phosphorylated in the presence of EGF 
(Kretzschmar et al., 1997a). These PXSP motifs are consensus substrate 
sites for MAP kinases (Hill and Treisman, 1995), and are also found in other 
pathway-specific Smads. Thus, regulation of Smad proteins by MAP 
kinases may be a general mechanism for crosstalk between the signaling 
activity of TGF~ family members and other growth factors. The inhibition of 
autophosphorylation of the EGF receptor in a human vulvar tumor cell line, 
and the inhibition of EGF-induced proliferation and progesterone 
production of human granulosa-luteal cells, by recombinant human AMH 
(Kim et al., 1992; Maggard et al., 1996), suggests that the antagonistic 
interactions between TGF~ family members and mitogenic growth factors 
may function in a reciprocal manner. 
Members of the TGF~ superfamily acting through Srr kinase receptors, 
and mitogenic growth factors acting through tyrosine kinase receptors, are 
both involved in control of many aspects of growth and differentiation. 
Crosstalk between the different signaling pathways, which are activated by 
these receptor systems, may serve as a tool to balance the specific signals, 
to achieve coordinated control of developmental processes. 
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Abstract 
Anti-Mullerian hormone (AMH) induces regression of the Mullerian ducts in 
male fetuses. AMH is produced sex-specifically only by the fetal testis, but 
postnatally AMH mRNA is expressed both in testis and ovary. Furthermore, 
the AMH type II receptor (AMHRIl) mRNA is expressed in the mesenchymal 
cells of the fetal Mullerian ducts, and also in fetal and postnatal testis and 
ovary. This expression poses the question whether AMH might have some 
role in development and maintenance of gonadal functions. To study the 
role of AMH during fetal and postnatal development, transgenic mice, 
expressing a dominant-negative AMHRII (MMHRlI) under the control of the 
inducible mouse metallothionein-l (MT-l) promoter, were generated. Five 
founder mice were obtained and were found to express MMHRlI mRNA in 
several tissues including the Mullerian ducts and the gonads. However, 
both without and with the induction of MMHRII mRNA expression, no 
aberrant phenotype was observed. It is concluded that a dominant-
negative effect of the transgene may require a high expression level of the 
transgene. 
Introduction 
In mammals, differentiation of the male reproductive tract is regulated by 
two testicular hormones: testosterone and anti-Mullerian hormone (AMH) 
(Jost, 1953). The fetal SertoH cells produce AMH, also known as Mullerian-
inhibiting substance (MIS). AMH induces the regression of the fetal male 
Mullerian ducts, which form the anlagen of the oviducts, uterus and upper 
part of the vagina (Josso et a1., 1993). The fetal Leydig cells start to produce 
testosterone, which causes the differentiation of the Wolffian ducts into 
vasa deferentia, epididymides and seminal vesicles. The differentiation of 
the female reproductive tract is considered to follow a default pathway: in 
the absence of gonadal hormones the Mullerian ducts differentiate, 
whereas the Wolffian ducts degenerate. Failure of AMH action during male 
fetal development, as a result of a gene mutation leading to inactive AMH, 
causes persistent Mullerian duct syndrome (PMDS), a rare form of male 
pseudohermaphroditism (Carre-Eusebe et a1., 1992; Imbeaud et a1., 1994; 
Imbeaud et a1., 1995). PMDS is characterized by the presence of oviducts 
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and uterus in otherwise normally virilized males. Also in male mice that 
lack AMH, Milllerian ducts do not regress (Behringer ef a1., 1994). These 
mice have morphologically normal testes and can produce functional 
sperm. However, they often become infertile due to obstruction of the 
genital tract caused by the presence of Milllerian duct derivatives. In 
addition, several mice develop Leydig cell hyperplasia at adulthood, 
suggesting that AMH might be involved in maintenance of normal Leydig 
cell function (Behringer ef aJ" 1994). An inhibitory effect of AMH on Leydig 
cell function is observed in testes of transgenic mice that chronically 
express a high level of AMH; these mice develop Leydig cell hypoplasia 
(Behringer ef aJ" 1990). In female rats, AMH mRNA is expressed after birth 
in the granulosa cells of preantral and small antral follicles, suggesting that 
AMH might play a role during follicle development (Baarends ef aJ., 1995b). 
In transgenic female mice that overexpress AMH also during fetal life, 
ovarian aromatase activity is decreased and the ovaries develop cord 
structures resembling testicular cords (Behringer ef a1., 1990). Inhibition of 
aromatase activity was also observed in cultured fetal ovaries exposed to 
AMH (Vigier ef aJ" 1989; Di Clemente ef a1., 1992). 
During folliculogenesis in adult rats and mice, many small antral 
follicles become atretic. The follicle-stimulating hormone (FSH) surge at 
estrus is suggested to be essential for the survival of those small follicles 
that are selected to ovulate (Hsueh ef a1., 1994). At estrus, the ovarian 
expression of AMH mRNA is downregulated, and in addition, treatment of 
prepubertal rats with FSH causes a downregulation of AMH expression in 
some preantral and small antral follicles (Baarends ef aJ., 1995b). 
Therefore, it was suggested that AMH may exert an inhibitory effect on 
follicle maturation (Baarends ef a1., 1995b). However, AMH-deficient female 
mice appeared to be fertile, and no gross abnormalities have been 
observed thus far in the ovaries of these mice (Behringer ef a1., 1994). 
AMH is a member of the transforming growth factor P (TGFP) family of 
growth and differentiation factors (Massague, 1990). These factors signal 
through a serine/threonine kinase receptor complex, consisting of a type I 
and a type II receptor. Upon ligand binding by the type II receptor, the type 
I receptor is recruited into the complex. Phosphorylation of the type I 
receptor by the type II receptor is essential for signaling f'Nrana ef aJ., 
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1994), and kinase-deficient type II receptors were shown to function as a 
dominant-negative receptor in TGF~-, activin-, and BMP-signaling, both in 
vitro .and in vivo (Hemmati-Brivanlou and Melton, 1992; Ishikawa e/ a1., 
1995; Tsuchida e/ aJ., 1995; Attisano e/ aJ., 1996). 
Previously, an AMH receptor was identified that has the general 
structure of a type II receptor (Baarends et aJ., 1994; Di Clemente et aJ., 
1994b; Grootegoed e/ a1., 1994). Expression of mRNA for this novel type II 
receptor was found in defined and putative target cells of AMH, i.e. the 
mesenchymal cells surrounding the Mullerian ducts, the Sertoli cells of 
fetal and adult testes, and the granulosa cells of fetal and adult ovaries 
(Baarends e/ al., 1994; Di Clemente et a1., 1994b; Baarends e/ a1" 1995a; 
Baarends et a1., 1995b). Therefore, it was suggested that the novel type II 
receptor represents an AMH type II (AMHRII) receptor. Conclusive 
evidence for this hypothesis was obtained by analysis of AMHRII knockout 
mice (Mishina et a1., 1996), and the finding of mutations in the human 
AMHRII gene in PMDS patients (Imbeaud et a1., 1995; Imbeaud e/ aJ., 1996). 
To study developmental aspects of the role of AMHRII in AMH signal 
transduction, transgenic mice were generated that express a dominant-
negative AMHRII (MMHRII) under the control of the inducible 
metallothionein-I promoter (MT-l). Upon zinc induction, a high expression 
level of the MMHRII transgene is expected, and induction of the transgene 
should evoke abrogation of AMH signaling at specific time points. 
Furthermore, since in AMH-deficient mice testicular function in adult mice 
is disturbed due to the presence of Mullerian duct remnants, an inducible 
MMHRII may be required to permit normal male fetal development. in 
order to study AMH function in the adult testis. 
Materials and Methods 
Construction of the MT-!JAMHRII transgene 
The endogenous CMV promoter of the pcDNAI vector was removed by 
MluI/BamHI digestion and replaced by a 260 bp BglI-BglII fragment of the 
mouse MT-I (mMT-I) promoter from the pMK' plasmid (Stuart et a1., 1984). 
A 740 bp EcoRI-StuI fragment of the rat AMHRII cDNA, encoding the 
65 
Chapter 3 
extracellular and transmembrane domains, was subcloned into EcoRl/XhoI 
sites of pcDNA-MT-l to generate the construct pMT-MMHRlI (Figure 3.1). 
Nrul Seal 
L/mMT.11 MMHRII SV40pA j-J 
Figure 3.1. Schematic representation of the MT-MMHRII construct. 
A 260 bp mouse metallothionein-l (mMT-l) promoter was fused to the truncated rat 
MMHRII eDNA. encoding the extracellular and transmembrane domains. A 700 bp 
fragment containing the Simian virus 40 (SV40) 3' untranslated region and 
polyadenylation signal was placed downstream of MMHRII. A 1.8 kb NrullScaI 
linear DNA fragment containing the MT-MMHRII transgene was used for 
microinjection of fertilized mouse eggs. 
A 1.8 kb NruI-ScaI pMT-MMHRII linear fragment was isolated and 
used for microinjection into the pronucleus of fertilized eggs generated 
from inbred FVB mice. Microinjected eggs were transferred to the oviducts 
of pseudopregnant foster mothers. Tail genomic DNA was isolated and 
tested either by Southern blotting (founder mice) or by PCR analysis 
(subsequent homozygous generations). All transgenic founder and Fl mice 
were intercrossed with wild type or transgenic littermates at 6 weeks of 
age. The activity of the MT-l promoter was induced by maintaining animals 
on drinking water containing 25 mM ZnSO,. Animals were kept under 
standard animal housing conditions in accordance with the NIH Guidelines 
for the Care and Use of Experimental Animals. 
RNA analysis 
RNA was isolated from mouse tissues using the tiCl/urea method (Auffray 
and Rougeon, 1980). A 310 bp EcoRl-KpnI rat AMHRlI cDNA fragment 
encoding the extracellular domain, was subcloned in pBluescript KS and 
used to generate [32Pl-UTP-labeled anti-sense probe. The control 
glyceraldehyde-3-phosphate dehydrogenase (GAPD) RNA probe was 
synthesized using a construct containing 163 bp Accl-Sau3AI fragment of 
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the rat GAPD cDNA. RNase protection assay of \0 I1g total RNA with these 
probes was performed as described by Baarends et 01. (1994). 
Morphology and histological analysis 
Transgenic and zinc·exposed transgenic mice of lines 14 and 79 were 
analyzed at 1 month of age for general functional and morphological 
abnormalities. For histological analysis, fetuses were isolated from 
pregnant control and transgenic mice at E13, E15, El7 and E19. Vaginal 
plug detection was considered day 0 (EO) and pregnant mice were given 
drinking water with or without 25 mM ZnSO, from EO onwards. Fetuses 
were fixed overnight in Bouin's fixative, embedded in paraffin, sectioned 
transversally at 7 11m and stained with hematoxylin/eosin. 
Results 
Generation of MT-!JAMHRII transgenic mice and analysis of expression 
The MT-AAMHRII transgene, encoding the extracellular and 
transmembrane domains of the rat AMHRII, was expressed under the 
control of a mouse MT-l promoter (Figure 3.1). This promoter has been 
shown to yield a high expression level of the transgene upon zinc induction 
in a variety of fetal and adult tissues (Palmiter et 01., 1983). Based on the 
high sequence conservation of transmembrane serine/threonine kinase 
receptors between species (Ten Dijke et 01., 1994a), it is anticipated that the 
rat AAMHRlI transgene encodes a functional protein that can compete with 
the endogenous AMHRII for AMH binding. 
Five founder transgenic mice were generated by pronuclear injection 
of fertilized mouse eggs (Figure 3.2). All founder mice were males, of which 
line 82 was infertile. Upon closer examination of founder 82, no anatomical 
abnormalities were observed, and sperm was found in the epididymides. 
However, no vaginal plugs were found in females that were mated with 
founder 82. 
peR and Southern blot analysis of genomic DNA from offspring from 
the other four founder mice demonstrated that all four lines transmitted the 
transgene. However, with breeding of lines 81 and 92 the transgene was 
transmitted only to male offspring, suggesting that the transgene had 
67 
Chapter 3 
integrated on the Y chromosome. As expected, the integrated transgene 
copy number was different between the various transgenic mouse lines: 
line 79 had the highest copy number and line 82 the lowest, although the 
exact copy numbers were not determined (Figure 3.2). 
14 79 81 82 83 92 
Figure 3.2. Southern blot analysis of transgenic DNA. 
Transgenic mice were identified by Southern blot analysis using the 1.8 kb 
transgene as probe. The approximate order of mouse lines with respect of the 
number of transgene copies, is as follows: line 79 ~ line 14;?; line 81 ;::: line 92;?; line 
82. Number 83 represents a non-transgenic littermate. 
RNase protection assay was performed to analyze the expression of 
the MT-AAMHRII transgene in both reproduclive and nonreproductive 
tissues of lines 14 and 79. In both mouse lines, the transgene is expressed 
in several tissues. In line 14, zinc-induced mRNA expression was observed 
in ovary, uterus1 prostate, colon and muscle, whereas testis expressed a 
substantial level of the MT-AAMHRII transgene mRNA without zinc 
induction (Figure 3.3). Also in the testis of line 79, a high expression level of 
the transgene, which could not be increased upon zinc induction, was 
found. Zinc-induced expression of the Iransgene was found in the ovary 
and kidney of line 79 (Figure 3.3). 
Morphological and histological analysis of MT-dAMHRII transgenic mice 
In AMH or AMHRII knockout mice, disruption of the AMH signal leads to 
persistence of Mullerian duct derivatives in males (Behringer et aI., 1994; 
Mishina et aI., 1996). However, upon macroscopic inspection, adult 
transgenic mice of lines 14 and 79 did not display anatomically abnormal 
urogenital and gonadal development. Furthermore, no derivatives of 
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A. Tissue distribution of MT-AAlv1HRII transgene expression (line 79) in the absence 
(-J or presence (+ J of ZnSO, in the drinking water. 
B. Testicular expression of MT-MMHRII (line 14) was not increased upon zinc 
induction. 
Mullerian origin were observed in any of the male transgenic mice. In 
addition, the transgenic male mice that were exposed to zinc, starting 
prenatally at EO, developed normally, and no Mullerian duct remnants were 
observed after birth. 
Male fetuses were examined in more detail during the critical period of 
Mullerian duct regression at El3 and E15. However, histological 
examination of sections did not reveal any difference in Mullerian duct 
regression between control and zinc-exposed transgenic animals (Figure 
3.4A-D), and no Mullerian duct remnants were found at El9 (Figure 3.4EjF'). 
The testes and ovaries of zinc-exposed transgenic mice, and the gonad-
associated structures, did not show any anatomical abnormalities (results 
not shown). 
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Figure 3.4. Histology of Miillerian duct regression In MT-AAMHRII transgenic 
male fetuses 
Miillerian duct regression was studied in the absence (left panel) or presence (right 
panel) of ZnS04 in tile drinking water of the mothers during pregnancy. No 
difference in MUllerian duct regression was observed between control and zinc-
exposed transgenic fetuses at El3 (A and B) and at EI5 (C and D). The expression 
of MT-MMHRII did not result in the presence of Miillerian duct remnants at El9 (E 
and F). 
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Discussion 
Members of the TGF~ family are believed to exert their actions through a 
serine/threonine receptor complex consisting of a type I and a type II 
receptor. The type I receptor induces the downstream signaling, which was 
demonstrated with the use of a constitutively active type I receptor that can 
signal in the absence of ligand and type II receptor (Wieser et aJ., 1995). 
However, normally the kinase activities of both receptors are important for 
signal transduction. A kinase-deficient type I receptor can be 
phosphorylated by the type II receptor but is unable to activate 
downstream factors. The kinase activity of the type II receptor is not 
required for ligand binding or receptor complex formation, but it is 
essential for activation of the type I receptor (Wrana et al., 1994), indicating 
a primary role for the type II receptor in signal transduction. 
Overexpression of kinase-deficient activin type II (ActRI!) receptors or TGF~ 
type II (T~RIl) receptors inhibits ligand-induced 3TPlux activity (Tsuchida et 
a/., 1995; Attisano et al., 1996). Furthermore, a truncated T~RII that lacks the 
serine/threonine kinase domain acts as a dominant-negative receptor, 
since it blocks TGF~ signaling in neonatal cardiac myocytes (Brand et al., 
1993; Filvaroff et aJ., 1994). Truncated type II receptors also function as a 
dominant-negative receptor in vivo. Expression of truncated bone 
morphogenetic protein type II (BMPRI!) receptors or ActRII in Xenopus 
embryos inhibits mesoderm formation (Hemmati-Brivanlou and Melton, 
1992; Ishikawa et aJ., 1995). In addition, introduction of a dominant-negative 
T~RII under the control of the MT-I promoter in mice inhibits TGF~ 
signaling (Bottinger et al., 1997a; Bottinger et al., 1997b). Primary 
hepatocytes and pancreatic acinar cell cultures generated from these 
transgenic mice have lost growih inhibition in response to TGF~ (Bottinger 
et al., 1997b). 
Although truncated type II receptors, with deficient kinase activity, have 
been shown to function as dominant-negative receptors in vitro as well as 
in vivo, no inhibition of AMH signaling was observed in the MT-MMHRII 
transgenic mice generated in the present study. The absence of an AMH-
deficient phenotype, such as partial PMDS, in MT-MMHRII transgenic 
mice, may be due to a low expression level of the transgene. Exposure to 
zinc resulted in an increased mRNA expression of the transgene in several 
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tissues, but the level of transgenic mRNA expression was lower than the 
mRNA expression of the endogenous AMHRII gene in adult gonads (results 
not shown). The expression of the transgene may be limited by several 
factors. The chromosomal integration site and the copy number of the 
transgene may vary, and as a result, different lines of the same transgene 
can display different levels of expression (Simoni, 1994). Furthermore, it has 
been suggested that expression of a transgene is higher, when the 
construct contains the genomic exon and intron structure (Simoni, 1994), 
although in transgenic experiments that used cDNA sequences, the 
expression of the transgene was not hampered (Murakami et a1., 1993; 
Davis et a1., 1994; Zsigmond et aJ., 1994). In the present study, cDNA 
encoding the truncated rat MMHRII under the control of the mMT-I 
promoter was used to generate the transgenic construct. The mMT-I 
promoter has been used in several transgenic studies, although most 
studies made use of a 1.7 kb mMT-I promoter fragment, whereas we used 
a 260 bp fragment (Wang et a1., 1994; Zsigmond et a1., 1994; Bottinger et aJ., 
1997b; Guo et aJ., 1998). This small fragment contains the five potential zinc 
responsive regulatory elements. However, it cannot be excluded that 
additional 5' regulatory elements might be necessary to obtain a high 
expression level of the transgene (Stuart et a1., 1984). Bottinger et a1. 
0997b) generated i\TGF~RII transgenic mice using the larger 1.7 kb mMT-I 
promoter fragment and 5' and 3' MT locus control regions. These mice 
demonstrated a high mRNA expression level of the transgene also without 
zinc induction (Bottinger et a1., 1997b). 
In the testis of the MT-MMHRII mice, but not in most other tissues, a 
substantial level of mRNA expression of the transgene was measured, and 
this expression was not increased further upon zinc induction. This lack of 
zinc induction of the transgene could be due to a high endogenous zinc 
level in the testis, which may result in maximal stimulation of the transgene. 
Zinc plays an important role in testicular functionl since zinc deficiency 
leads to degeneration of the seminiferous epithelium and spermatogenic 
arrest (Apgar, 1985). Furthermore, it has been reported that the 
endogenous MT-J gene is constitutively transcribed in male germ cells (De 
et a1., 199 I), probably as a result of the high endogenous zinc level. It may 
well be possible that also the MT-I-MMHRII transgene is constitutively 
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transcribed in the testis. Therefore, the use of the MT-I promoter to 
generate an inducible transgene to study testicular function, has to be 
reconsidered. 
An additional reason for the overall low extragonadal expression and 
high testicular expression of the transgene, may be the methylation status 
of the transgene. One of the mechanisms to silence gene expression, is 
methylation of the promoter region of the respective gene (Chomel, 1991). 
In a study by Salehi-Ashtiani et a1. (1993), it was shown that expression of a 
transgene driven by the mouse MT-I promoter was repressed in all 
somatic tissues, even when heavy metals were administered, whereas the 
transgene was transcribed in the testis. Examination of the transgene 
methylation status revealed that expression was inversely correlated with 
hypermethylation of the locus. The promoter region was fully methylated in 
somatic tissues, but was undermethylated in the testis (Salehi-Ashtiani et 
al., 1993). However, whether the methylation status of the MT-illTh1HRII 
transgene plays a role in the regulation of its expression in the present 
experiments, remains to be investigated. 
While the present study was ongoing, AMHRII knockout mice were 
generated (Mishina et a1" 1996). The phenotype of the AMHRII-deficient 
mice appears to be an exact phenocopy of the AMH-deficient mice, 
suggesting that AMHRII is the only type II receptor for AMH (Mishina et a1., 
1996). AMH- and AMHRII-deficient male mice become infertile, but this is 
probably due to obstruction of the genital tract caused by the presence of 
Mullerian duct derivates. Furthermore, the testes of several of the AMH-
and AMHRII-deficient mice developed Leydig cell hyperplasia (Behringer et 
a1., 1994; Mishina et a1., 1996), suggesting a role for AMH in Leydig cell 
function, probably through SertoH cell-Leydig cell interaction. Similar to the 
AMH-deficient mice, thus far no histological abnormalities of the ovaries 
have been found in AMHRII-deficient mice (Mishina et a1" 1996). 
The intrinsically high testicular expression of transgenic MT-I 
constructs interferes with studies on the effect of transgene-encoded 
proteins, using the MT-1 promoter in testis development. Hence, the 
recently developed technique of tissue- and developmental stage-specific 
inactivation of genes (conditional knockout mice), using the Cre-LoxP 
system, may prove to be more suitable (Gu et a1., 1994; Zou et a1" 1994; 
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Porter, 1998). To generate gonadal AMHRII-deficient mice, the promoter of 
the follicle-stimulating hormone receptor could be used to control Cre 
activity. 
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Abstract 
Using the rat anti-MUllerian hormone type II receptor (AMHRlI) eDNA as a 
probe, two overlapping lambda phage clones containing the AMHRlI gene 
were isolated from a human genomic library. Sequence analysis of the exons 
was performed and the exon/intron boundaries were determined. The coding 
region was found to consist of 11 exons, divided over 8 kb. The genomic 
structure resembles that of the related activin type II receptor gene. The 
AMHRlI gene was mapped to human chromosome 12qI2-qI3. The results 
reported are essential for identification of AMHRlI gene alterations in patients 
with persistent Mullerian duct syndrome. 
Introduction 
Anti-Mullerian hormone (AMH) is a member of the TGF~ family of growih and 
differentiation factors (Cate ef aI., 1986). AMH plays a critical role during male 
fetal sex differentiation, by inducing regression of the MUllerian ducts, the 
anlagen of the female urogenital tract Gost, 1947; Josso ef ai., 1993; Lee and 
Donahoe, 1993). During fetal life, AMH is produced only by the testicular 
Sertoli cells, but postnatally this factor is also found in ovarian granulosa cells 
(Hirobe ef aI., 1992). 
Previous studies have shown that members of the TGF~ family exert their 
action via a heteromeric signaling complex that includes a type I and a type II 
receptor rNrana ef aJ., 1994). Both receptors are transmembrane 
serine/threonine kinases. The type I receptors constitute a smaller subfamily, 
that is characterized by a specific cysteine spacing in the extracellular 
domain and a GS-rich juxtamembrane motif (Attisano ef aJ., 1994). 
Recently, the rat (Baarends ef aJ., 1994) and the rabbit (Di Clemente ef al., 
1994b) AMH type II receptor (AMHRII) cDNAs were cloned, as new members 
of the serine/threonine kinase receptor family. AMHRlI mRNA is expressed in 
the mesenchymal cells surrounding the Mullerian ducts, during the period of 
fetal development that the MUllerian ducts respond to AMH (Baarends ef aJ., 
1994). Furthermore, COS cells transfected with AMHRlI eDNA are able to bind 
AMH (Di Clemente ef aJ., 1994b). AMHRlI mRNA was also found in fetal 
gonads, and in Sertoli cells and granulosa cells of adult rats, although the 
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function of AMH in the gonads remains to be established (Baarends et a1., 
I 995a; Baarends et ai., 1995b). 
Failure of AMH action leads to the Persistent Mullerian Duct Syndrome 
(PMDS), a rare form of male pseudohermaphroditism characterized by the 
presence of uterus and fallopian tubes in otherwise normally virilized males 
(Josso et al., 1991). In some cases, this phenotype is caused by a mutation in 
the AMH gene (Knebelmann et al., 1991). However, the presence of bioactive 
AMH in other PMDS patients (Guerrier et al" 1989) indicaies resistance of the 
Mullerian ducts to AMH, possibly as a result of alterations in the AMHRlI 
gene. A mutation in the AMHRlI gene that may result in alternative splicing 
has recently been reported (lmbeaud e/ a1., 1995). 
Herein, we present the genomic structure of the human AMHRlI gene 
and its chromosomallocaiization. 
Materials and Methods 
Library screening 
Approximaiely 1.7 x 106 plaques of a phage lambda EMBL3 human eMLO 
(chronic myeloid leukemia cell line) genomic DNA library were transferred in 
duplicaie to Hybond-N+ nylon filters (Amersham International pIc, Uttle 
Chalfont, UK), and screened with the full length 1.9 kb rat AMHRlI cDNA as a 
probe (Baarends e/ al., 1994). The probe was labeled with [32Pl-dA1P 
(Amersham) by random-priming. Hybridization was done o/n at 42 e in 50% 
formamide, 5xSee, 5xDenhardt's, 1% SDS, 50 mM Na,HPOJNaH,PO, (pH6.8) 
and 100 ~g/ml denatured herring sperm DNA. The filters were washed in 2x 
sec and 0.1 % SDS at 42 e for 10 minutes prior to autoradiography. 
Positive phage lambda clones 
Four positive clones were identified on initial screening of the genomic library. 
These clones were purified to homogeneity by secondary and tertiary 
screening using the rat AMHRlI cDNA probe. Phage DNA of 2 positive clones 
was isolated, digested with several restriction enzymes and analyzed by gel 
electrophoresis to orient the genomic DNA with respect 10 the lambda arms. 
The DNA was transferred to Hybond-N+ filters (Amersham) and probed with 
fragments of the rai AMHRll cDNA to determine the positions of the 5' and 3' 
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ends of the gene, the overlap, and the coding regions. Fragments of the 
coding regions were subcloned into the appropriate sites of the vector 
pBluescript KS( +) (Stratagene, La Jolla, CA, U.S.A.) for sequence analysis. 
DNA sequence analysis 
DNA sequencing was performed on plasmid DNA by the dideoxy chain 
termination method, using Ml3 and human AMHRll primers. Sequence 
alignments were performed using the sequence analysis program DNAMAN 
(Lynnon Biosoft, Vaudrieul, Quebec, Canada) and Clustal V. 
In situ hybridization to metaphase chromosomes 
Phage DNA was labeled with biotin-14-dATP using the bio-NICK system (Life 
Technologies, Gaithersburg, MD, U.S.A.). The labeled DNA was precipitated 
with ethanol in the presence of herring sperm DNA. Precipitated DNA was 
dissolved and denatured ai 80 C for 10 min followed by incubation for 30 min 
at 37 C, and added to heat-denaiured chromosome spreads where 
hybridization was carried out oln in a moist chamber at 37 C. After 
posthybridization washing (50% formamide, 2 x SSC, at 42 C) and blocking 
with nonfat dry milk powder, the hybridized probe was detected using avidin-
mc (Vector Laboratories, Burlingame, CA, U.S.A.) with two amplification 
steps using rabbit-anti-mC (Dako, Glostrup, Denmark) and mouse-anti-
rabbit mc (Jackson Immunoresearch, West Grove, U.S.A.). Chromosome 
spreads were mounted in antifade solution with blue dye DAPI. 
Results and Discussion 
Isolation and characterization of the human AMHRII gene 
A human CMLO genomic library was screened with the rai AMHRll cDNA as 
a probe. Four positive clones were identified and two of these clones were 
used to construct a restriction enzyme map of the human AMHRll gene. 
Restriction enzyme mapping, Southern blot analysis using specific regions of 
the rat AMHRll cDNA as a probe, and DNA sequencing revealed that the 
AMHRll gene consists of 11 exons and 10 introns, and spans approximately 8 
kb (Figure 4.1). 
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Figure 4.1. Structure of the human AMHRII gene. 
The overlapping phage lambda clones 3.1 and 7.1 are shown with the unique 
restriction enzymes that were used to construct a linear map. The relative length 
and localization of the exons (boxes) and introns are shown underneath (dravm to 
scale). E: EcoRI; H: Hindlll; K: KpnJ; S: Sail. The Sail sites are contained in the 
lambda EMBL3 arms and do not occur in the human AMHRII gene. 
All eleven exons of the human AMHRII gene, and the intron/exon 
boundaries were sequenced. The DNA and protein sequences of the 
deduced open reading frame and the DNA sequences of the intron-exon 
boundaries are shown in Figure 4.2. Exons 2-10 vary in length from 78 bp to 
234 bp, and the coding regions of Ihe first (exon I) and last (exon II) exons 
are 49 bp and 297 bp, respectively. These lenglhs are consistent with the 
observation that the length of coding exons usually does not exceed 300 bp 
(Robberson et a1., 1990). Introns 4 and 10 are relatively long, 3 kb and I kb, 
respectively, and contribute to approximately half of the gene. The other 
introns are much shorter, varying from 120 bp to 425 bp. All of the intrans start 
with GT and end with AG, consistent with the donor/acceptor splice rule 
(Balvay et ai., 1993). 
Comparison of the deduced human AMHRII amino acid sequence to the 
sequences of the rat and rabbit receptors, revealed well-conserved 
sequences with few amino acid changes (Figure 4.3). The amino acid identity 
is approximately 80 %. In the AMH receptor the Ser'" in the sequence HRDLS 
is conserved in the three mammalian species investigated (Figure 4.3; see 
also Grootegoed et a1., 1994). This feature distinguishes the AMH type II 
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exon 1 <> exon 2 
GGCTTA'l'GC'l'CTTCTCCT'I'CTGC'l'GCTGCCATCC'l'CCAGCAAGATGCTAGGGTC'l"l"roGGGCCATTACTTCCCl\CAGCTGTGGAAGCACCCCCMACAGGCGAACC'l'G'l'GTGTT 120 
M L G S L G L W ALL PTA V E A P P N R R T C V F26 
C'l"l'TGAGGCCCCTGGAGTGCGGGGAAGCACAAAGACACTGGGAGAGCTGCTAGATACAGGaCAGAGCTCCCCAGAGCTATCCGC'l'GCCTC'I'ACAGCCGC'l'GCTGCT'I"TC'l"GGAA 240 
F E A P G V R G S T K T L GEL L D T GTE L P R A IRe L Y S R C C F G I W N66 
exon :2 <> exon 3 
CCTGACCCAAGACCGGGCACAGGTGGAAATGCAAGGATGCCGAGACAGTGA'l'GAGCCAGGC'l'G'l'GAGTCCCTCCACTGTGACCCAAGTCCCCGAGCCCACCCCAGCCC'l'GGCTCCACTC'I' 360 
L T Q D R A Q V E M Q G C R D S 0 E P GeE S L H C D P S P R A H P S P G S T L 106 
exon3 <> exon4 
C'l'TCACCTGCTCCTG'l'GGCAC'l'GAC'l'TCTGCAATGCCAATTACAGCCATCTGCCTCCTCCAGGGAGCCCT'GGGACTCCTGGCTCCCAGGGTCCCCAGGCTGCCCCAGGTGAGTCCATCTG 480 
FTC S C G T D FeN ANY S HLP P P G S P G T P G S Q G P Q A A P G E S I W 146 
exon 4 <> exon 5 
GATGGCACTGGTGC'tGCTGGGGC'tGTTCC'l'CCTCCTCCTGC'l'CG'I"GCTGGGCAGCATCATC'l"l'3GCCCTGCTACAGCGAAAGAACTACAGAGTGCGJ>.GGTGAGCCAG'rGCCAGAGCCAAG 600 
MAL V L L G L F L L L L L V L G S I I L ALL Q R K N Y R V R G E P V PEP R 186 
exon 5 <> exon 6 GCCAGACTCAGGCAGGGACTGGAGTG'l'GGAGCTGCAGGAGC'l'GCC1'GAGrc.ro=ro',r'~';;:'CTCCCAGGTAATCCGGGAAGGAGGTCATGCAGTGGTI"I'GGGCCGGGCAGCt'GCAAGGAAAACT 720 
P 0 S G R D W S VEL Q E L PEL C F S Q V IRE G G H A V V WAG Q L Q G K L 226 
GGTTGCCA'l'CAAGGCC'l"l'CCCACCGAGGTCTGTGGC'I'CAGTl'CCAAGCTGAGAGAGCA'l"l'G'l"ACGAACTTCCAGGCCTACAGCACGACCACA'l"l'GTCCGAT'I'l'ATCACTGCCAGCCGGGG 840 
V A. I K A F P P R S V A Q F Q A ERA LYE LPG L Q H D H I V R FIT A $ R G266 
exon 6 <> exon 7 
GGGTCCTGGCCGCC'l"GCTCTC'l'GGGCCCC'l'GC'l'GGTAC'IGGAACTGCATCCCAAGGGCTCCCTGTGCCACTAC'l"TGACCCAGTACACCAG'I'GACTGGGGAAGTTCCCTGCGGATGGCACT 960 
G P G R L L S G P L L V L E L H P K G $ L C H Y L T Q Y T $ D W G $ S L R MAL 306 
exon 7 <> exon 8 
GTCCCTCGCCCAGGGCC'I'GGCA'I'TTCTCCATGAGGAGCGC'I'GGCAGAA'I'GGCCAATATAAACC1\GGTATTGCCCACCGAGATC'l'GAGCAGCCAGAA'l'G'l'GCTCATTCGGGAAGATGGATC 1080 
S L A Q G L A F L H E E R W Q N G Q Y K P G I A H R D L $ $ Q N V L IRE D G $346 
exon 8 <> exon 9 
GTGTGCCA'l'TGGAGACCTGGGCC'l"l'GCTGCTCCC'l'GGCCTCACTCAGCCCCC'l'GCCTGGACCCCTACTCAACC'l'CAAGGCCCAGCTGCCATCA.TGGAAGC'I'GGCACCCAGAGGTA 1200 
C A I G D L G L A L V LPG L T Q P PAW T P T Q P Q G P A A I MEA G T Q R Y 386 
CA'I'GGCACCAGAGCTC'l"IGGACAAGACTC'I'GGACCTACAGGA'l"l'GGGGCkTGGCCC'l'CCGACGAGC'l'G1I.TA'l'TI'ACTC1."'l'"'l'GCTC'l"GCTCC'l'GTGGGAGATAC'l'GAGCCGCTGCCCAGA 1320 
MAP ELL D K T L D L Q D W G MAL R R A DIY $ L A L ~ L WEI L S R C P D 426 
exon 9 <> exon 10 
TTTGAGGCCTGACAGCAGTCCACCACCCTTOCAACTGGCCTATGAGGCAGAACTGQGCAATACCCCTACCTCTGATGAGCTA1GGGCCTTGGCAaTGCAGGAGAGGAGGCGTCCCTACAT 1440 
L R P D SSP P P F Q LAY E A E L G N T P T S DEL W A L A V Q ERR R P Y I 
exon 10 <> exon 11 
CCCATCCACCTGGCGCTGC'!"l'"l'GCCACAGACCC'I'GA'I"GGGCTGAGGGAGCTCCTAGAAGACTG'l"l'GGGATGCAGACCCAGAAGCACGGC'I'GACAGCTGAGTGTGTACAGCAGCGCC'I'GGC 
PST W R C FAT D P D G L R ELL E D C W DAD PEA R L T A E C V Q Q R L A 
TGCCTl"GGCCCATCCTCAAGAGAGCCACCCC'M"I'CCAGAGAGC'l'GTCCACG'l"CGCTGCCCACCTCTCTGCCCAGAAGACTGTACTTCAATTCCTGCCCCTACCATTCTCCCCTGTAGGCC 
A L A H P Q E S H P F PES CPR G C P P L C P E D C T SIP APT I L P C R P 
TCAGCGGAGTGCCTGCCACTTCAGCG'l"l'CAGCAAGGCCC'l'TGTTCCAGGAATCCTCAGCCTGCCTGTACCC'l'TI'C'I'CC'I'G'l'GTAAA'l"ATGCAG'l'TI'ATATCAGTTC'I'GACCAGTGAC'I'l' 
Q R SAC H F $ V Q Q G P C S R N P Q PAC T L $ P V ~ 
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exon 1 (>49 bp) GTG GM G gtaagt ... in tron 1 (303 bp)._ .tgggcctcag CA eee CCA exon 2 
V E A P P 
exon 2 (183 bp) ATG CAA G gtgaat ... intron 2 (215 bp) ... catccatcag GA Gce eGA exon 3 
M Q G C R 
exon 3 (193 bp) Gce eCA G gtagcc ... intron 3 (264 bp) ..• tgatgtccag GT GAG Tee exon 4 
A P G E S 
exon 4 (78 bp) ATe TTG G gtacta ... intron 4 (212 bp) ... tctgttccag cc eTG eTA exon 5 
I L A L L 
exon 5 (119 bp) TTC Tee CAG gtgccc ... intron 5 (120 bp) ... tccccagcag GTA ATe eGG exon 6 
F S Q V I R 
exon 6 (234 bp) CAT eee AAG gtgagc ... intron 6 (- 3 kb) ... gtttccccag GGe Tee eTG exon 7 
H P K G S L 
exon 7 (115 bp) CAG AAT G gtgggt ... in tron 7 (425 bp) ..• tcccccacag GC CAA TAT exon 8 
Q N G Q y 
exon 8 (178 bp) ATe ATG GAA gtgagt. .. intron 8 (204 bp) .•. tgctctccag GCT GGe Ace exon 9 
I M E A G T 
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exon 10 (137 bp) TTT Gce ACA gtaaga ... intron 10 (- 1 kb) ... ttccccccag GAC CCT GAT exon 11 
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exon 11 (>297 bp) 
Figure 4.2. Human AMHRII gene 
A. Nucleotide and amino acid sequence of the deduced open reading frame. The arrowheads indicate the beginning (» and 
end «) of the respective exon. 
B. Intron/exon boundaries in the humcm AMHRlI gene. The nucleotide sequence for each intron/exon boundary and the size 
of each exon and intron are shown. The consensus acceptor/donor sequences are shown in bold. 
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human AMHRII gene 
receptor from the other members of the TGF~ receptor family, which contain 
a lysine residue at that position. Another conspicuous characteristic of the 
AMHRII is the cysteine spacing in the extracellular ligand binding domain, 
which may reflect the evolutionary distance of the AMH-AMHRII pair to the 
other ligand-serine/threonine kinase receptor pairs. 
Similar to the activin type II receptor (ActRII) (Mafzuk and Bradley, 1992) 
and the bone morphogenetic protein 2/4 type I receptor (BMPRI) (Mishina et 
aI., 1995) gene, the human AMHRII gene contains II exons. However, the 
AMHRII gene is remarkably small: 8 kb compared to >60 kb for the ActRII 
gene and 38.2 kb for the BMPRI gene. The different exons encode separate 
functional domains in the AMHRII protein molecule. The signal sequence is 
encoded by exon I, the extracellular ligand binding domain by exons 2 and 3, 
and the transmembrane domain is encoded by exon 4. The remaining exons 
5-11 contain the sequence information for the kinase domain. When the gene 
structure of the receptors of the TGF~ family is compared, the spacing of the 
exons and even the division of the functional protein domains into different 
numbers of exons indicate that the receptors show distant evolutionary 
relationship. Thus, this comparison provides no information on similarities in 
mechanism of action of the different serine/threonine kinase receptors. 
Chromosama//acalizatian af the AMHRII gene 
F1uorescent in situ hybridizaiion to metaphase chromosomes using the two 
isolated lambda phages, showed fluorescent signals at 12q12-13 (Figure 4.4). 
One of the clones (clone 3.1) also showed a signal at 9q, but this was not 
observed with clone 7.1 (not shown). Other genes in the 12q12/13 region 
include the Wingless-type MMTV integraiion site I gene (Wnt!), the Keratin 3 
gene (Krt3), the retinoic acid receptor-y gene (Rarg) and the Homeobox C 
cluster genes (Hoxc) (Online Mendalian Inheritance in Man). In the mouse, we 
mapped the mouse AMHRII gene to chromosome 15F (result not shown). TIlls 
region (lSF(50-58)) is syntenic with the human chromosome 12, and contains 
mouse homologues of the genes mentioned above (Mouse Genome, 1994). 
In conclusion, we have cloned and sequenced the human gene encoding 
the AMHRII. The AMHRII is well conserved between mammalian species. This 
information is essential to identify possible gene alterations in diseases 
involving the MUllerian ducts. 
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Figure 4.3. Comparison of the human (hAMHRII), the rabbit (ocAMHRII) and the rat (rAMHRII) AMHRII amino acid 
sequences. Reversed script is used to highlight amino acid residues that are found at the senne position in at least two of the 
three receptors. 
o 
". 
'" :2. 
!l 
... 
..... tt 
.. 
human AMHRII gene 
Figure 4.4. Chromosomal localization of the human AMHRII gene. 
The photomicrograph shows localization of the AMHRII probe on 12q12-q13 using 
fluorescence in situ hybridization {left panel}. The identification of individual 
chromosomes was deduced from converted DAPI banding patterns (right panel). 
The hybridization sites are marked by arrows. 
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Abstract 
The clinical use of diethylstilbestrol (DES) by pregnant women has resulted 
in an increased incidence of genital carcinoma in the daughters born from 
these pregnancies. Also in the so-called DES-sons abnormalities were 
found, mainly the presence of Mullerian duct remnants, which indicates 
that fetal exposure to DES may have an effect on male sex differentiation. 
Fetal regression of the Mullerian ducts is under testicular control through 
anti-Mullerian hormone (AMH). In male mice, treated in utero with DES, the 
Mullerian ducts do not regress completely, although DES-exposed testes 
do produce AMH. We hypothesized that incomplete regression in DES-
exposed males is caused by a diminished sensitivity of the Mullerian ducts 
to AMH. Therefore, the effect of DES on temporal aspects of Mullerian duct 
regression and AMH type II receptor (AMHRlI) mRNA expression in male 
mouse fetuses was studied. 
It was observed that Mullerian duct regression was incomplete at E 19 
(19 days post coitum), upon DES administration during pregnancy from E9 
through E16. Furthermore, analysis of earlier time points of fetal 
development revealed that the DES treatment had clearly delayed the 
onset of Mullerian duct formation by approximately two days; in untreated 
fetuses Mullerian duct formation was complete by E13, whereas fully 
formed Mullerian ducts were not observed in DES-treated male fetuses 
until E15. 
Using in situ hybridization, no change in the localization of AMH and 
AMHRlI mRNAs expression was observed in DES-exposed male fetuses. 
The mRNA expression was quantified using RNase protection assay, 
showing an increased expression level of AMH and AMHRII mRNAs at El3 
in DES-exposed male fetuses. Furthermore, the mRNA expression levels of 
Hoxa 11 and Steroidogenic Factor I (SF-!) were determined as a marker 
for fetal development. Prenatal DES exposure had no effect on Hoxa 11 
mRNA expression, indicating that DES did not exert an overall effect on the 
rate of fetal development. In DES-exposed male fetuses, SF-l showed a 
similar increase in mRNA expression as AMH, in agreement with the 
observations that the AMH gene promoter requires an intact SF-l DNA 
binding site for time- and cell-specific expression, although an effect of 
DES on SF-l expression in other tissues such as the adrenal and pituitary 
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gland cannot be excluded. However, the increased expression levels of 
AMH and AMHRII mRNAs do not directly explain the decreased sensitivity 
of the Mullerian ducts to AMH. Therefore, it is concluded that prenatal DES 
exposure of male mice delays the onset of Mullerian duct development, 
which may result in an asynchrony in the timing of Mullerian duct formation 
with respect to the critical period of Mullerian duct regression, leading to 
persistence of Mullerian duct remnants in male mice. 
Introduction 
Anti-Mullerian hormone (AMH), a member of the transforming growih 
factor ~ (TGF~)-superfamily of peptide growih and differentiation factors, is 
the earliest protein known to be secreted by the fetal Sertoli cells (Cate et 
al., 1986; Massagu8, 1990). In contrast to other family members, which have 
a broad range of functions, AMH has a very specific role during sex 
differentiation. AMH, which is only produced by the fetal testes and not by 
the ovaries during fetal development, might play a role in gonadal 
differentiation, as indicated by the formation of "ovotestes" in female mice 
overexpressing AMH (Behringer et aI., 1990). Most importantly, in the male 
AMH induces the regression of the Mullerian ducts, which form the anlagen 
of the uterus, oviducis, and upper part of the vagina. It has been shown that 
the timing of AMH action on the Mullerian ducts is very critical. In the rat, 
exposure of female fetuses to AMH after El6 (16 days post coitum) does not 
result in Mullerian duct regression (Munsterberg and Lovell-Badge, 1991; 
Tsuji et aI., 1992). 
The cellular and molecular mechanisms by which AMH induces 
Mullerian duct regression are poorly understood. However, the 
identification and cloning of the AMH type II receptor (AMHRII) has 
contributed to the elucidation of this question (Baarends et aI., 1994; Di 
Clemente et aI., 1994b). AMHRII mRNA is expressed in the fetal gonads 
and in the mesenchymal cells located adjacent to the Mullerian duct 
epithelium, which corresponds to the sites of action of AMH (Baarends et 
al., 1994; Di Clemente et al., 1994b). Recent results have shown that AMH 
elicits its effect on the Mullerian duct epithelium via the surrounding 
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mesenchymal cells, a process which may also involve induction of 
programmed cell death (Tsuji et 01., 1992; Catlin et aI., 1997). 
AMHRII is a member of the transmembrane serine/threonine kinase 
receptor family, to which also the TGF~ and activin receptors belong (Ten 
Dijke et aI., 19940). Members of the TGF~-superfamily exert their action 
through a heteromeric signaling complex, consisting of a type I and a type 
II receptor (Wrana et aI., 1994). Failure in AMH action, as a result of a gene 
mutation leading to either inactive AMH or AMHRII, causes inhibition of 
Mullerian duct regression, resulting in a rare form of 
pseudohermaphroditism in man known as persistent Mullerian duct 
syndrome (PMDS) (Imbeaud et aI., 1994; Imbeaud et aI., 1995). Gene 
knockout experiments in mice have confirmed that in the absence of AMH 
or AMHRII, Mullerian ducts do not regress (Behringer et aI., 1994; Mishina 
et aI., 1996). 
In chickens, unilateral regression of Mullerian ducts occurs in the 
female. The left Mullerian duct is retained whereas the right Mullerian duct 
regresses, due to the fact that, in contrast to mammalian species, AMH is 
also expressed by the fetal ovary (Hutson et aI., 1981). It has been 
suggested that estrogens protect the left duct from regression. This is 
supported by the observation that the concentration of estrogen receptor in 
the left duct is higher than that in the right duct (MacLaughlin et aI., 1983). 
Furthermore, inhibition of estrogen production in female chick fetuses, by 
treatment with an aromatase inhibitor during egg incubation, resulted in 
regression of both ducts (Elbrecht and Smith, 1992). Exposure to estrogen 
during egg incubation prevents Mullerian duct regression in both male and 
female chick fetuses (Hutson et aI., 1982; Doi and Hutson, 1988). 
Although it is a large step from chicken to human, it is of interest to 
compare the data from the experiments with chickens with clinical data. In 
human, intrauterine exposure to diethylstilbestrol (DES), a potent synthetic 
estrogen that has been administrated during pregnancy to prevent 
miscarriages, has led to an increased incidence of reproductive tract 
abnormalities. The effects of prenatal DES exposure in so-called DES-
daughters, such as an increased risk of genital carcinoma, have been well 
documented (Bornstein et aI., 1988). However, also the sons born from DES-
controlled pregnancies have an increased incidence of genital tract 
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abnormalities, including epididymal cysts, cryptorchidism, and the 
presence of Mullerian duct remnants (Gill e/ aJ., 1976; Whitehead and 
Leiter, 198!). This indicates that DES has an effect on male sex 
differentiation. To study the prenatal effects of DES on the developing 
genital tract in an animal model, McLachlan e/ aJ. (1975) injected DES daily 
into pregnant mice during the phase of growth and differentiation of the 
fetal reproductive tract. Observations on the male offspring of these DES-
treated mice indicated that the developing reproductive tract of the fetus is 
sensitive to DES exposure. Hypoplastic testes and Mullerian duct remnants 
were found (McLachlan e/ aJ., 1975; Newbold ef aI., 1987). It is, however, not 
clear how DES mediates its inhibitory effect on reproductive tract 
differentiation. 
In a mouse organ culture system, after in vivo DES treatment, Newbold 
e/ oj. (1984) studied whether the inhibitory effect of DES on Mullerian duct 
regression results from suppression of fetal testicular AMH production or a 
change in responsiveness of the Mullerian ducts to AMH. Control Mullerian 
ducts regressed normally when cultured in the presence of control testes, 
whereas DES-exposed Mullerian ducts in the presence of DES-exposed 
testes did not regress. Combination of control Mullerian ducts and DES-
exposed testes resulted in normal regression. However, in the reciprocal 
combination, DES-exposed ducts and control testes, only partial regression 
of the Mullerian ducts was observed. These results indicate that DES-
exposed testes still produce bioactive AMH, and that the effect of DES is 
mainly due to a decrease in AMH responsiveness of the Mullerian ducts. 
We hypothesized that the change in sensitivity of the Mullerian ducts to 
AMH may result from an effect of DES on the expression of AMHRII. In this 
paper we describe the effects of DES exposure of mouse male fetuses on 
the Mullerian ducts, in particular AMH and AMHRII mRNA expression, 
during the period of reproductive tract differentiation. As a control for 
possible effects of DES exposure on general fetal development (Krumlauf, 
1994; Hsieh-Li ef aJ., 1995), the expression of Hoxa II mRNA was measured. 
The mRNA expression level for Steroidogenic Factor I (SF-I) mRNA, an 
orphan nuclear receptor essential for the development of steroidogenic 
tissues (Luo ef aJ., 1994), was measured as a control for possible effects of 
DES exposure on urogenital ridge development. The results of this study 
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may contribute to our knowledge about the possible involvement of 
exposure to exogenous estrogenic compounds in the postulated increased 
incidence of reproductive tract disorders in wild-life, and perhaps also in 
humans (Sharpe and Skakkebaek, 1993; Guillette and Guillette, 1996). 
Materials and Methods 
Animals and treatment 
FVB mice were kept under standard animal housing conditions in 
accordance with NIH Guidelines for the Care and Use of Experimental 
Animals. Vaginal plug detection was considered day 0 (EO) of pregnancy. 
Pregnant mice were given daily subcutaneous injections with DES (100 
J-lg/kg body weight) Ganssen Chi mica, Beerse, Belgium) dissolved in olive 
oil, or olive oil alone, on days E9 through E 16 of gestation. Pregnant mice 
were sacrificed by cervical dislocation at E13, E14, E15, EI7 or EI9 of 
gestation. Fetuses were isolated and snap frozen in liquid nitrogen and 
stored at -80 C. Total RNA was isolated using the LiCl/urea method (Auffray 
and Rougeon, 1980). In addition, fetuses from the same litter were also 
fixed overnight in 4% paraformaldehyde, embedded in paraffin, and 
sectioned transversally at 7 J-lm. PCR reactions using placental genomic 
DNA (Hogan et ai., 1986) were performed as described by Mitchell et al. 
(1991), using primers for the mouse genes Sbx and Sby (Kay et al., 1991; 
Mitchell et ai., 1991), to determine the sex of the fetuses. 
In situ hybridization 
A Pst! fragment containing bp 1243-1640 of the rat AMHRlI cDNA and an 
NheI fragment containing bp 38-400 of the rat AMH cDNA were subcloned 
in pBluescript KS (Stratagene, Westburg, Leusden, The Netherlands) and 
used to generate sense and antisense [35S1-UTP-Iabeled (Amersham, 's 
Hertogenbosch, The Netherlands) transcripts in vitro. In situ hybridization 
was performed as described by Zeller and Rogers (Zeller and Rogers, 
1991) with some modifications (Baarends et al., 1994). Sections were 
mounted on slides that were coated with 3-aminopropyl-ethoxysaline. AIter 
deparaffinization, sections were treated with 0.2 N HCI (20 min), treated 
with proteinase K (l J-lg/ml in 0.2 M Tris pH 7.5, 2 mM CaCI2; incubation for 
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15 min at 37 C) and postfixed in 4% paraformaldehyde in 0.1 M phosphate-
buffered saline. After treatment with dithiothreitol and blocking of non-
specific binding with 0.1 M triethanolamine, followed by 0.1 M 
triethanolamine and acetic anhydride, sections were incubated with ["Sl-
UTP-Iabeled antisense and sense AMH and AMHRII RNA probes at a final 
concentration of 5x 10' cpmAl!. Hybridization was carried out as described 
previously (Baarends et a1., 1994). Sections were exposed at 4 C for 1 week, 
developed, and counterstained with haematoxylin and mounted. 
RNase protection assay 
A mouse AMHRII DNA template for in vitro transcription was generated by 
RT-PCR. The RT-PCR reaction was carried out on 100-200 ng total RNA, 
extracted from 25-day-old mouse testis, using random hexamers. A sample 
of the reverse transcription reaction product was used in the PCR reaction 
using the primers 5'GCTCCGGAGCTCTTGGACAAG3' (forward primer) 
and 5'CAGGCGCTGCTGCACACACTC3' (reverse primer) corresponding to 
kinase subdomains VIII, IX, and X of the AMHRII gene transcript. A 350 bp 
PCR product was subcloned in pBluescript KS and used to generate ["Pl-
UTP-Iabeled anti-sense probe. The AMH RNA probe was obtained using a 
430 bp Pst! fragment, containing exon I, of mouse genomic DNA. The SF-I 
RNA probe was obtained using a 252 bp HindIII-EcoRI fragment of mouse 
SF-I cDNA (Lala et aJ., 1992). The Hoxa 11 RNA probe was obtained using 
a 300 bp BamHI-Bglll fragment of the mouse Hoxa 11 cDNA (Hsieh-Li et aJ., 
1995). The control glyceraldehyde 3-phosphate dehydrogenase (GAPD) 
RNA probe was synthesized using a construct containing 163 bp Acel-
Sau3AI fragment of the rat GAPD eDNA. RNase protection assays of 50 I1g 
total fetal RNA with these probes were performed as described by 
Baarends et a1. (1994). GAPD was used as a control for RNA loading. The 
relative amount of protected mRNA band was quantified through exposure 
of the gels to a phosphor screen (Molecular Dynamics, B & L Systems, 
Zoetermeer, The Netherlands), followed by a calculation of the relative 
density of the obtained bands using a phospho-imager and Image Quant 
(Molecular Dynamics) as computer analysis software. The arbitrary units 
are expressed as the rations after division by the corresponding GAPD 
values. 
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Results 
Effect of DES exposure on Mullerian duct formation 
The development of the Mullerian duct was studied in male fetuses at E13, 
E15, and E19, at three positions along the axis of the Mullerian ducts 
(Figures 5.1, 5.2, and 5.3). Position I indicates the most cranial part of the 
ducts, at the level of the fetal testes. Position II is at the level where the 
Mullerian and Wolffian ducts cross each other. Position III indicates the 
caudal part of the Mullerian ducts, near the urogenital sinus. 
In control fetuses at E13, no morphological signs of regression could 
be detected along the axis of the Mullerian ducts (Figure 5.IA/D). In DES-
exposed E 13 fetuses, on the other hand, Mullerian ducts were only found at 
position I (Figure 5.lF). Caudally, at positions II and III, the Mullerian ducts 
were not formed, indicating a delay in their formation caused by the DES 
treatment (Figure 5. II, position III). 
At E15, differences in Mullerian duct regression between control and 
DES-exposed fetuses were observed. In EI5 control fetuses, regression of 
the Mullerian ducts had started but was not complete (Figure 5.2A/D). The 
regression of the Mullerian ducts was initiated cranially at position I, and 
concomitantly we observed the characteristic presence of a whorl of 
mesenchymal cells surrounding the Mullerian ducts (Figure 5.2A). No signs 
of Mullerian duct regression could be detected at positions II and III at E15, 
indicating that degeneration of the Mullerian ducts is initiated cranially and 
then progresses caudally (Figure 5.2D). In contrast, regression of the 
Mullerian ducts in the DES-exposed EI5 fetuses was not initiated at all 
three positions, as indicated by the absence of the typical whorl of 
mesenchymal cells (Figure 5.2F/ll. The appearance of the Mullerian ducts 
in DES-exposed fetuses at EI5 corresponds to that of the Mullerian ducts in 
control fetuses at E 13, implicating that the onset of Mullerian duct 
regression is delayed by approximately two days. 
It was observed that regression of the Mullerian ducts in control male 
fetuses resulted in their complete absence at EI9 (Figure 5.3A). In the DES-
exposed male fetuses at E19, regression of the cranial part of the Mullerian 
ducts was complete at positions I and II, as no Mullerian structures could 
be detected (results not shown). However, more caudally, at position III, the 
Mullerian ducts were still present (Figure 5.3B). The epithelial and 
95 
Chapter 5 
-rr"" .·:tl ,·.~:o-ff·-';:'-
96 
DES eifect on MOllenan duct development 
Figure 5.1. Histology of Mullerian ducts and expression of AMH and AMHRII 
mRNAs in control and DES-exposed male mouse fetuses at E13. 
The formation of the MUllerian ducts is represented schematically in the top panel. 
The roman numerals indicate positions It II, and HI, at which sections were taken for 
morphology study and in situ hybridization. The left figures (position I: A, B, C; 
position II: D, E) and the right figures (position I: F, G, H; position II: \, J) are sections 
from control and DES·exposed fetuses, respectively. At position I, the MUllerian 
ducts are present in control fetuses (A) and in DES-exposed (F) fetuses, although 
less differentiated. At position II, the MUllerian ducts are found in control (D) but not 
in DES·exposed fetuses (I). Expression of AMH and AMHRlI mRNAs was 
determined using in situ hybridization. Darkfield views of AMHRII (control: B, E; 
DES-exposed: G, J) and AMH (control: C; DES·exposed: G) mRNAs are shown in 
adjacent sections. No difference between control and DES-exposed fetuses is found 
in the localization of AMH and AMHRII mRNAs expression; AMH mRNA expression 
is found in the testes, and AMHRlI mRNA expression in the testes and the 
mesenchymal cells surrounding the MUllerian ducts. Arrows indicate expression 
sites. T, testis; W, Wolffian duct; M, MUllerian duct. Scale bar represents 100 flm. 
mesenchymal cells of the Mullerian duct remnants, in DES-exposed male 
fetuses at E 19 (Figure 5.3B), were differentiated and had an appearance 
comparable to that found in control female fetuses of the same 
developmental stage (results not shown). 
These results are schematically summarized in the top panels 01 
Figures 5.1, 5.2, and 5.3. 
Expression of AMH and AMHRIf mRNAs 
The expression 01 AMH and AMHRII mRNAs was studied by in situ 
hybridization. AMH mRNA expression was localized in the gonads 01 DES-
exposed male fetuses, similar to controlletuses, although differences in the 
quantitative level 01 expression were detected. The testes of DES-exposed 
letuses at El3 showed a marked increase in AMH mRNA expression 
compared to control testes (figure 5.IC/H). This increase in AMH mRNA 
expression was also present on EI5 (Figure 5.2C/H), while testicular 
expression of AMH mRNA could hardly be detected in both control and 
DES-exposed El91etuses (results not shown). 
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Figure 5.2. Histology of MUllerian ducts and expression of AMH and AMHRII 
mRNAs In control and DES-exposed male mouse fetuses at E15. 
In the top panel, the regression of the MUllerian ducts is represented schematically. 
The stippled lines indicate the regressed Miillerian ducts. The left figures (position I: 
A. B, C; position III: D, E) and the right figures (position I: F, G, H; position III: I, J) are 
sections from control and DES-exposed fetuses, respectively. Regression has 
initiated in control fetuses at position I (A), but not at position II and 1II (D). In DES· 
exposed fetuses the MUllerian ducts are completely present (F, I), although no signs 
of regression are found at position I (F). Note the presence of a whorl of 
mesenchymal cells surrounding the Mullerian duct in control fetuses (A). Expression 
of AMH and AMHRII mRNAs was determined using in situ hybridization. Darkfield 
views of AMHRII (control: B, E; DES·exposed: G, J) and AMH (control: C; DES· 
exposed: H) mRNAs are shown in adjacent sections. AMH and AMHRII mANA 
expression are increased in felal testes of DES fetuses. At position t mesenchymal 
cells of control fetuses do not express AMHRlI mRNA, whereas in DES-exposed 
fetuses a low expression is found. At position III no expression of AMHRII was found. 
Arrows indicate expression sites. T, testis; W, Wolffian duct; M, Mullerian duct. 
Scale bar represents 100 ~m. 
AMHRII mRNA expression was also studied at the three positions 
indicated in Figure 5.1. Expression of AMHRlI mRNA in DES·exposed 
fetuses was found in the same tissues as in control fetuses; the fetal gonads 
and the mesenchymal cells surrounding the Mullerian ducts (Figure 
5.1B/G). It is important to note that, although the formation of the Mullerian 
ducts was not complete by El3 in DES'exposed fetuses, AMHRII mRNA was 
already expressed. More caudally, at positions II and III, the Mullerian 
ducts were absent in DES·exposed fetuses; hence, expression of AMHRII 
mRNA could not be detected at these sites (Figure 5.1D, In control fetuses, 
AMHRII mRNA was expressed along the whole axis of the Mullerian ducts, 
although expression decreased caudally (Figure 5.1B/E). 
In control fetuses at E 15, expression of AMHRlI mRNA could no longer 
be detected in the mesenchymal cells surrounding the Mullerian ducts, at 
all three positions studied (Figure 5.2B/E). The mesenchymal cells of the 
cranial Mullerian ducts in DES·exposed E15 fetuses did still express 
AMHRlI mRNA (Figure 5.2G), although the expression was lower compared 
to that in El3 DES·exposed fetuses. Caudally, at position III, expression 
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Figure 5.3. Histology of MOlierian ducts in control and DES-exposed male 
mouse fetuses at E19. 
In the top panel the regression of the Mullerian ducts is represented schematically. 
At position III, the Milllerian ducts have completely regressed in control fetuses (A), 
whereas in DES-exposed fetuses remnants of MUllerian ducts are clearly visible (B). 
The Mullerian duct remnants show differentiation of epithelial and mesenchymal 
cells. W, WoUBon duct; M, Miillerian duct. Scale bar represents 100 J.1m. 
could not be detected (Figure 5.21). In the testes of control fetuses, AMHRII 
mRNA was only weakly expressed, whereas the testes of DES-exposed 
fetuses at El5 still showed a clear AMHRII mRNA expression (Figure 
5,2B/G). An increase in testicular AMH mRNA expression in DES·exposed 
fetuses compared to control fetuses was still observed at EI5 (Figure 
5.2C/H), 
At E19, testicular AMHRII mRNA expression was equally low, in both 
control and DES·exposed fetuses. AMHRII mRNA expression in the 
mesenchymal cells of the Mullerian ducts could not be detected in control 
and DES·exposed fetuses, although the Mullerian ducts were still present 
in DES·exposed male fetuses near the urogenital sinus (results not shown). 
Expression levels of AMH and AMHRII mRNAs were quantified more 
precisely using an RNase protection assay (Figure 5.4A). Furthermore, the 
expression of SF· I mRNA was included as a marker for urogenital ridge 
development. The results of the RNase protection showed that the 
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Figure 5.4 Quantitative analysis of the expression of AMH, AMHRII, SF-1, and 
Hoxa 11 mRNAs In control and DES-exposed fetuses, studied by RNase 
protection assay. 
Expression in whole fetuses was determined at E13. E14, E15, E17, and E19. A. The 
results of the RNase protection assay. B. Quantitative analysis of the expression 
levels. The mRNA expression level is expressed as the ratio AMH/GAPD, 
AMHRllfGAPD, SFlfGAPD, and HoxallfGAPD. The open bars represent control 
fetuses and filled. bars the DES-exposed fetuses. The bars and error bars represent 
the mean and standard deviation of two fetuses, isolated. from different treatments. 
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expression patterns of AMH and AMHRII mRNAs mimic the expression 
pattern of SF-l mRNA (Figure 5.4B). In DES-exposed male fetuses at El3 
the expression of SF-l mRNA is strongly increased compared to control 
fetuses. A similar increase in AMH mRNA expression was measured in 
DES-exposed male fetuses, as was obseIVed with in situ hybridization. An 
increase of AMHRII mRNA expression was found using RNase protection 
assay in DES-exposed fetuses at E13, although this increase was less 
evident compared to AMH and SF-l mRNAs expression. At El4 and E15, 
DES-exposed fetuses showed a higher expression of SF-I, AMH, and 
AMHRII mRNAs than control fetuses, although less pronounced than at 
E13. From El5 onwards, changes in mRNA expression of SF-I, AMH and 
AMHRII were limited to a sl1ght increase at E19. 
In addition to the expression of SF-l mRNA, the Hoxa 11 mRNA 
expression level was determined, as a control for a possible effect of DES 
treatment on the general rate of fetal development. It was observed that 
DES-treated fetuses were born one day later compared to control fetuses. 
This might indicate that the DES-induced delay in Mullerian duct formation 
would reflect a general delay in fetal development of DES fetuses. 
However, DES-treated and control fetuses did not show a difference in fetal 
Hoxa 11 mRNA expression at all time points studied (Figure 5.4), indicating 
similar rates of general fetal development in the two treatment groups. 
Furthermore, no differences in length, width, or digit differentiation were 
obseIVed between control and DES-treated fetuses during fetal 
development (results not shown). 
Discussion 
This paper describes the effect of prenatal DES exposure on regression of 
the Mullerian ducts of fetal male mice. In agreement with previous studies 
(McLachlan et aI., 1975; Newbold et al., 1987), we found incomplete 
Mullerian duct regression upon DES exposure. In male fetuses from DES-
treated mice, regression had initiated in the cranial part of the Mullerian 
ducts, but did not progress completely caudally, leaving remnants of 
Mullerian ducts at the position of the urogenital sinus. The nonregressed 
parts of the Mullerian ducts showed female-like differentiation, indicating 
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that the Mullerian duct remnants might be responsive to estrogens. In 
female mice, prenatal exposure to DES also causes uterine epithelial cell 
hypertrophy (Wordinger et al., 1991). These findings indicate that the 
Mullerian ducts are a target for DES action in both male and female 
fetuses. 
In addition to the appearance of Mullerian· duct remnants, we 
observed that DES exposure resulted in a delay in Mullerian duct formation 
of approximately two days. In control fetuses, the complete Mullerian ducts 
were present at E13, whereas in DES-exposed fetuses fully formed 
Mullerian ducts were not found before E15. In addition, DES-exposed 
fetuses were born one day later compared to control fetuses. These 
observations suggest that DES causes a delay in general embryonic 
development. Also in rats, exposure to estrogens during pregnancy leads 
to a prolonged gestation (Zimmerman et al., 1991), but this is explained by 
an inhibiting effect of DES on the onset of uterine contraction. Caesarian 
sections, performed to rescue the litter, revealed no difference in size of 
fetuses from control and DES-treated mothers (Zimmerman et a!., 1991). 
Transgenic mice, overexpressing the estrogen receptor a (ERa), have 
similar problems with birth, with gestation lengths prolonged up to four 
days (Davis et aI., 1994). Exposure to DES in neonatal mice results in an 
increase of ERa mRNA expression in uterine cells (Sato et al., 1992), 
suggesting that the longer gestation time in DES-exposed mice may be a 
phenocopy of the change in pregnancy in ERa transgenic mice, and 
reflects a maternal effect rather than a delay in fetal development. No 
differences in body size or digit differentiation were observed between 
control and DES-treated fetuses during fetal development (results not 
shown). Furthermore, the expression of Hoxa II mRNA was studied as a 
marker for general fetal development (Krumlauf, 1994; Hsieh-Li et a!., 1995). 
Hoxa II mRNA is expressed in the limbs, the kidneys, and in the stromal 
cells surrounding the Mullerian and Wolffian ducts, and this expression is 
detected at EIO, several days before reproductive tract differentiation 
(Hsieh-Li et al., 1995). In the present study, no difference in Hoxa II mRNA 
expression between control and DES-exposed fetuses was observed, at all 
embryonic stages studied. This indicates that the rate of general fetal 
development is not affected, but that DES elicits a specific effect on 
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reproductive tract development. The variation in the results with the Hoxa 
II probe is due to the large differences in specific activity of the probe in 
different experiments. 
The anlagen of the reproductive tract, the Wolffian and Mullerian 
ducts, are formed separately. The Wolffian duct is formed as an excretory 
duct of the mesonephros and is recognizable before the gonads are 
formed. At the time of gonad formation, the Mullerian ducts develop in a 
cranial to caudal direction along the Wolffian ducts, which function as a 
guiding structure for early growih of the Mullerian ducts (Byskovand Hoyer, 
1994, and references therein). The genes involved in Mullerian duct 
formation have not been identified yet. It has been suggested that the 
Wolffian ducts release epithelial cells which contribute to the developing 
Mullerian ducts (Dohr and Tarmann, 1984). It has also been suggested that 
the growih of Mullerian ducts is autonomous (Grunwald, 1941). In our 
studies, DES treatment affects the formation of the Mullerian ducts rather 
than formation of the Wolffian ducts, because DES was administered after 
completion of Wolffian duct formation. However, an effect of estrogens on 
Wolffian duct formation cannot be ruled out. It has been observed that the 
Wolffian ducts are affected by exogenous estrogen exposure, resulting in 
several abnormalities, such as seminal vesicle tumors and prostate 
inflammation (Newbold, 1995). Also in female fetuses, the Wolffian ducts 
are a target for DES action. Retention of Wolffian ducts, postnatally, was 
observed in females, both in human and mouse (Newbold et al., 1983; 
Haney et al., 1986). These effects of DES on Wolffian and Mullerian duct 
differentiation may point to a common mechanism in the development of 
these duct systems. Both Wolffian and Mullerian ducts can respond to 
estrogens, since the estrogen receptor ERa is present in both structures 
during development (Greco et ai., 1993). The identification of a novel 
estrogen receptor, ERP (Kuiper et al., 1996), may contribute to our 
understanding of the mechanism of DES action. Recently, it was reported 
that ERa and ERP, when activated by estradiol, signal in opposite ways via 
an API site (paech et al., 1997). DES, therefore, may cause different effects, 
depending on the tissue studied. ERP is highly expressed in prostate and 
ovary, whereas ERa shows a higher expression in the uterus (Kuiper et al., 
1997). Studying the effects of prenatal DES exposure in ERa, ER/3, or 
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double-knockout mice, will reveal which ER type is mainly involved in DES 
action. 
In previous studies it has been proposed that incomplete regression of 
the Mullerian ducts in fetuses exposed to exogenous estrogens, is a result 
of a change in sensitivity of the ducts to AMH (Newbold et aI., 1984). 
Therefore, we have studied the effect of DES on AMHRlI mRNA expression. 
The expression of AMH and AMHRII mRNAs was studied by in situ 
hybridization, and the expression levels in total fetuses were quantified by 
RNase protection. With in situ hybridization, a strong increase in AMH 
mRNA expression in the fetal testes of DES-exposed fetuses was evident. 
Quantification of the expression revealed a two-fold increase of AMH 
mRNA expression in DES-exposed fetuses compared to controls. This 
increase was most significant at E13. Nevertheless, this higher AMH mRNA 
expression did not result in complete Mullerian duct regression. This is in 
agreement with the observations in in vitro studies, that addition of a 
relatively high dose of AMH did not result in full regression of Mullerian 
ducts from DES-exposed fetuses (Newbold, personal communication). The 
DES-induced increase in AMH mRNA expression implies a direct effect of 
estrogens on the regulation of AMH mRNA expression. Indeed, a 13 
basepair palindromic sequence, nearly identical to the estrogen response 
element (ERE), has been identified in the AMH gene promoter (Guerrier et 
aJ., 1990). In footprinting experiments, this site was shown to bind ERa. 
Furthermore, 39 ERE half-sites were identified in the 5' flanking sequences 
of the AMH gene (Dresser et aI., 1995). Clusters of half-sites or degenerate 
palindromic sites can be effective, as was shown in vitro, where several 
ERE half-sites can act synergistically to control expression of the ovalbumin 
gene (Kato et 01., 1992). However, the functionality of the ERE half-sites in 
the AMH gene has not been proven. Recent papers have shown that AMH 
expression is dependent on SF-l (Shen et aJ., 1994; Giuili et aI., 1997). SF-I, 
an orphan nuclear receptor expressed in adrenals, gonads and the 
gonadotrophes of the pituitary gland, was characterized as a transcription 
factor which regulates several genes, such as genes encoding 
steroidogenic enzymes (Lala et 01., 1992). SF-J knockout mice lack gonads 
and adrenals, revealing an essential role for SF-l in sexual differentiation 
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and formation of primary steroidogenic tissues (Luo et aI., 1994). In in vivo 
experiments, it was demonstrated that the proximal AMH gene promoter 
requires an intact binding site for SF-I for time- and cell-specific 
expression (Giuili et aI., 1997). We observed a strong increase in SF-l 
mRNA expression in DES-exposed fetuses, which was most significant at 
El3 and decreased towards E17. The increased expression of AMH mRNA 
in DES-exposed mice was found to have a similar temporal pattern as the 
SF-I mRNA expression, corresponding with the role of SF-l in regulation of 
AMH gene expression. These data suggest that DES has an effect on fetal 
gonadal gene expression. An effect of prenatal exposure to estrogenic 
compounds on SF-I mRNA expression has been reported previously, 
although the described effect was a downregulation of SF-l mRNA 
expression (Majdic et aI., 1997). In that study by Majdie et al. (1997), DES or 
the estrogenic compound 4-octylphenol were injected twice during 
pregnancy (Ell and E15) and expression of SF-l mRNA was measured in 
the fetal testis at E 17 (Majdic et al., 1997). The disagreement between their 
and our results may be explained by the animal model, the experimental 
procedure, and the time points at which expression was determined. 
In the present study, expression of AMHRII mRNA was also found to be 
increased at El3 in DES fetuses, although this increase was less obvious 
and could not be detected by in situ hybridization. In in vitro studies, no 
direct regulation of the AMHRII promoter by estrogens was found (Visser et 
aJ., unpublished results). Therefore, it is likely that DES influences AMHRll 
mRNA expression indirectly. In the DNA sequence of both the human and 
mouse AMHRII gene promoter, an SF-l response element was identified 
(lmbeaud et aJ., 1995, and results not shown). Although regulation of 
AMHRll mRNA expression by SF-l has not been reported, the increased 
AMHRll mRNA expression in DES-exposed fetuses might be a 
consequence of an increased SF-l level. In accordance with 
developmental changes in SF-l and AMH mRNAs expression, the most 
pronounced increase in AMHRll mRNA expression was found at E13, and 
this increase becomes less evident in older fetuses. 
The increased mRNA expression levels of AMH and AMHRll do not 
directly explain the decreased sensitivity of the Mullerian ducts to AMH. 
However, a DES-induced effect on factors downstream of AMHRll, such as 
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a type I receptor or Smad proteins, can not be excluded. One can 
hypothesize that a DES-induced inhibition of downstream signaling factors 
influences a negative feedback loop, resulting in an increased expression 
of AMH and AMHRII mRNA, although the existence of such a feedback 
system for AMH has not been reported yet. Furthermore, whether the 
increase mRNA expression levels result in higher protein levels remains to 
be studied. 
The in situ hybridization demonstrated that AMHRII mRNA expression 
can be detected along the entire axis of the Mullerian ducts in control 
fetuses at E 13, but it decreases in caL\dal direction towards the urogenital 
sinus. At E15, expression of AMHRII mRNA could not be detected in the 
regressed cranial part of the Mullerian ducts. However, also in the caudal 
part of the Mullerian ducts, AMHRII mRNA expression could hardly be 
detected. These observations suggest that the onset of the critical period 
for AMH sensitivity of the Mullerian ducts (EI3), is at the time point when 
Mullerian ducts are completed and express the AMH type II receptor, 
whereas the end of this critical period (EI5) is demarcated by 
disappearance of the receptor. In DES-exposed fetuses at E13, AMHRlI 
mRNA expression was found in the cranial part of the Mullerian ducts. The 
caudal parts have not been formed, and expression could not be detected 
at this site, suggesting that AMHRII mRNA expression is dependent on the 
presence of a formed Mullerian duct. At E15, a time point at which the 
Mullerian ducts have completely formed in the DES-exposed fetuses, 
AMHRII mRNA expression was detectable in the cranial ducts although 
expression was much lower compared to E13. Caudally, expression could 
hardly be detected, comparable to expression in control EI5 fetuses. In 
DES-exposed mice just prior to birth (EI9), the Mullerian duct remnants had 
lost expression of AMHRlI mRNA and, therefore, are unable to respond to 
AMH at this late developmental time point. Although the formation of the 
Mullerian ducts is delayed in DES-treated fetuses, the timing of AMHRII 
mRNA expression is not delayed. This probably leads to a temporal 
asynchrony between the presence of the Mullerian ducts and the onset of 
the critical period of Mullerian duct regression. 
The present observation of a DES-induced delay in Mullerian duct 
formation, contributes to our understanding of the diversity of 
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developmental defects in affected DES-sons. In humans, exposure of 
mothers to DES during early pregnancy results in a two-fold increase in the 
prevalence of malformations in their sons (Wilcox et aI., 1995). The 
formation of the Mullerian ducts is completed before the 11th week of 
gestation, and Mullerian duct regression is initiated at the 11 th week. 
Exposure to DES after this period results in less abnormalities, while 
exposure before the 11 th week results in a higher incidence of Mullerian 
duct remnants in the DES-sons (Wilcox et aI., 1995). This is in concordance 
with the present observations in mice, and we suggest that, also in humans 
administration of DES during early pregnancy causes an asynchrony 
h 
between Mullerian duct formation and the critical period of Mullerian duct 
regression. 
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Abstract 
Anti-Mullerian hormone (AMH) is a member of the transforming growth 
factor ~ (TGF~) family of growth and differentiation factors. In mammalian 
male fetuses, AMH produced by the testes, causes the regression of the 
Mullerian ducts, which otherwise would differentiate into fallopian tubes, 
uterus and upper part of the vagina. In mouse and human, absence of 
AMH action caused by gene defects, results in persistence of the Mullerian 
ducts and development of duct derivatives in the male. In transgenic mice 
that overexpress AMH in many tissues including the ovary, Mullerian duct 
regression is also found in female fetuses. In addition, the ovaries of these 
mice develop testis cord-like structures and have suppressed aromatase 
activity. Inhibition of aromatase activity by AMH is also shown in cultured 
fetal ovaries and postnatal granulosa cells. 
Members of the TGF~ family are believed to exert their actions through 
a receptor complex consisting of a type I and a type II receptor. Although 
the signaling mechanism of many TGF~ family members has been studied 
in much detail, little is know about AMH signaling. The AMH type II receptor 
cDNA was isolated recently, but an AMH type I receptor is unknown. To 
study AMH signaling, we developed an in vitro model based on the 
inhibitory effect of AMH on follicle-stimulating hormone WSH}-induced 
aromatase activity. HEK-293 cells were stably transfected with cDNAs 
encoding the follicle-stimulating hormone (FSH) receptor and the AMH type 
II receptor, resulting in HEK-293FAN cells. Because promiscuity in ligand 
binding by type I receptors has been shown, we hypothesized that one of 
the known type I receptors might function as an AMHRI. Therefore, we 
investigated whether one or more of the six different type I receptors, 
known as activin receptor-like kinases (ALKI-6), could inhibit the FSH 
induction of the aromatase promoter. The HEK-293FAN cells were 
transiently cotransfected with an aromatase promoter-luciferase reporter 
construct, together with constitutively active mutated forms of the different 
ALKs. Only the constitutively active ALK2 and ALK6 were able to repress 
FSH-induced aromatase promoter activity. In addition, both wild type ALK2 
and wild type ALK6 were found to be able to signal in response to AMH, 
although the inhibition found with ALK6 was less than that observed wtth 
ALK2. 
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Expression of an AMH type I receptor is expected at the potential 
target sites of AMH that also express AMHRll receptor, which are the 
mesenchymal cells surrounding the Mullerian ducts and the fetal and adult 
gonads. ALK2 and ALK6 mRNAs are expressed in the urogenital ridge of 
both male and female fetuses. In situ hybridization revealed that ALK2 
mRNA is expressed by the mesenchymal cells of the Mullerian ducts. In 
addition, the fetal gonads express ALK2 mRNA, whereas ALK6 mRNA could 
not be detected. 
Based on the temporal and spatial mRNA expression pattern of ALK2, 
and its ability to inhibit FSH-induced aromatase promoter activity in 
response to AMH, we suggest that ALK2, but not ALK6, can function as an 
AMH type I receptor. 
Introduction 
Anti-Mullerian hormone (AMH), also known as Mullerian-inhibiting 
substance (MIS), is a member of the transforming growth factor ~ (TGF~) 
family of growth and differentiation factors. This family includes the TGF~s, 
activins, and the bone morphogenetic proteins (BMPs; Massague, 1990). In 
contrast to these other family members, which fulfill a broad range of 
functions, AMH has a very specific role during sex differentiation. In male 
fetal mice, AMH is the earliest known protein secreted by the testicular 
Sertoli cells (Munsterberg and Lovell-Badge, 1991). The secreted protein 
acts as a hormonal factor to induce regression of the Mullerian ducts, 
which form the anlagen of the fallopian tubes, the uterus and the upper 
part of the vagina. Failure of AMH action, such as caused by a genetic 
defect, results in absence of Mullerian duct regression and thereby in a 
rare form of male pseudohermaphroditism in human, known as persistent 
Mullerian duct syndrome (PMDS; Carre-Eusebe et aJ., 1992; Imbeaud et aJ., 
1994). Indeed, gene knockout experiments in mice have demonstrated that 
in the absence of AMH, Mullerian ducts do not regress (Behringer et aJ., 
1994). 
In addition to its specific role in sex differentiation, AMH also may play 
a role in the control of germ cell and gonadal development (Taketo et aJ., 
1991). In AMH-deficient mice, no abnormalities in spermatogenesis were 
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observed, but closer examination of AMH-deficient testes revealed the 
occasional presence of Leydig cell hyperplasia, suggesting a role for AMH 
in the control of Leydig cell development and/or function (Behringer et a1., 
1994). This is supported by the finding that transgenic mice, which 
overexpress AMH showed Leydig cell hypoplasia (Behringer et aI., 1990). In 
the ovary, AMH is only expressed in the granulosa cells of pre-antral and 
small antral follicles, and it has been suggested that AMH is involved in a 
negative control of follicle maturation (Baarends et al., 1995). However, in 
the ovaries of AMH knockout mice no obvious abnormalities in follicle 
development have been reported (Behringer et al., 1994). In contrast, 
ovarian differentiation is disturbed in transgenic mice that overexpress 
AMH. At birth, ovaries of these mice had less germ cells than normal and 
showed masculinization, i.e. their somatic cells had differentiated into testis 
cord-like structures. The change of ovarian differentiation into a more 
testis-like phenotype was correlated with a decreased aromatase activity in 
these transgenic ovaries, leading to a higher testosterone level (Behringer 
et al., 1990), since aromatase is the only enzyme that can convert 
testosterone to estradiol. Inhibition of aromatase activity was also shown 
when in vitro cultured fetal ovaries were exposed to AMH, resulting in 
release of testosterone rather than estradiol (Vigier et al., 1989; Di 
Clemente et al., 1992). In addition, suppression of aromatase activity by 
AMH has been shown in an in vitro assay of cultured granulosa cells 
isolated from postnatal ovaries (Di Clemente et al., 1994a). 
The members of the TGF~ family exert their action via a family of 
related serine/threonine kinase receptors, which can be subdivided into the 
type I or activin receptor-like kinases (ALKs) and the type II receptors. The 
six known type I receptors contain a Gly/Ser-rich motif known as the GS 
box, that is located N-terminal of the kinase domain, while the type II 
receptors are characterized by a short Ser/Thr-rich C-terminus, which is 
absent in type I receptors (Ten Dijke et al., 1994a; Massague and Weis-
Garcia, 1996). Upon ligand binding to a type II receptor, a type I receptor is 
recruited into the hetero-dimeric receptor complex. Finally, a tetrameric 
receptor complex is formed, consisting of two type II receptors and two 
type I receptors (Wrana et al., 1994; Luo and Lodish, 1996; Weis-Garcia and 
Massague, 1996). A prerequisite for signaling is the phosphorylation of the 
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type I receptor on serine residues in the GS box by the type II receptor, 
which has constitutive kinase activity (Wrana et al., 1994; Massague and 
Weis-Garcia, 1996). The final signal is generated by the type I receptor 
through its kinase activity. The signaling capacity of type I receptors was 
demonstrated by a mutated TGF~ type I receptor (T~Rl), in which a 
threonine residue located near the kinase domain was replaced by an 
aspartic acid, resulting in a constitutively active receptor that signals in the 
absence of ligand and type II receptor (Wieser et al., 1995). Recently, a 
family of downstream phosphorylation targets of type I receptors was 
identified. These so-called Smad proteins become phosphorylated by type 
I receptors and interact with a common signaling component named 
Smad4. The complex subsequently translocates to the nucleus where it 
regulates gene transcription, either directly after DNA binding or as a 
cofactor in association with DNA-binding proteins (Massague, 1996; Heldin 
et al., 1997). 
Although the signaling mechanism of many members of the TGF~ 
family has been studied in much detail, little is known about AMH 
signaling, also due to the fact that the type I receptor of AMH has not been 
identified yet. The type II receptor for AMH (AMHRll) was cloned and 
identified (Baarends et al., 1994; Di Clemente et al., 1994b; Grootegoed et 
al., 1994), and AMHRII mRNA is expressed in the mesenchymal cells 
surrounding the Mullerian ducts, coinciding with the site of action of AMH 
(Baarends et al., 1994; Di Clemente et al., 1994). Furthermore, AMHRlI 
mRNA is expressed in the granulosa and Sertoli cells of fetal and adult 
gonads (Baarends et al., 1995a; Baarends et al., 1995b). Similar to AMH-
deficient mice, male AMHRII knockout mice possess a female genital tract 
in addition to a complete male reproductive tract (Mishina et al., 1996). 
Furthermore, Leydig cell hyperplasia was also observed in testes of 
AMHRII-deficient mice (Mishina et al., 1996). Since AMHRll-deficient mice 
are an exact phenocopy of the AMH-deficient mice, these in vivo 
experiments proved that AMH is the only and necessary ligand for a single 
type II receptor, the AMHRIl. This conclusion is further supported by the 
identification of mutations in the human AMHRII gene in patients with 
PMDS (lmbeaud et al., 1995; 1mbeaud et al., 1996). 
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To study the signaling mechanism of AMH, the identification of the 
AMH type I receptor is a prerequisite. Binding studies with AMH were not 
conclusive, since radiolabeling of AMH appears to abolish its ability to bind 
to the receptor and decreases its biological activity (Donahoe et aI., 1977). 
Iodinated AMH bound in a dose-dependent manner to cells transfected 
with AMHRII cDNA, but the level of non-specific binding was very high (Di 
Clemente ef aI., 1994b). So far, AMH action can only be studied in an in 
vitro Mullerian duct regression assay, or in a fetal ovary assay in which 
inhibition of aromatase activity is measured. 
Herein, we describe a novel in vitro assay, which is based on the 
ability of AMH to inhibit FSH-induced aromatase activity. Furthermore, we 
describe the functional identification of ALK2 as a candidate AMH type I 
receptor, using this assay. 
Materials and Methods 
DNA constructs 
The expression vector for AMHRII was constructed by cloning an EcoRI-
XhoI fragment encoding the full-length rat AMHRII cDNA (Baarends ef aI., 
1994) into EcoRI-BamHI sites of pSG5 (Green et aI., 1988). The expression 
vectors for rat follicle-stimulating hormone receptor (FSHR), Neo, and the 
wild type and constitutively active ALKI-Q20ID, ALK3-Q233D, ALK4-T206D, 
ALK5-T204D, and ALK6-Q203D, activin type II receptors (ActRIIA and 
ActRIIB), and bone morphogenetic type II receptor (BMPRIl) have been 
described previously (Van Doren ef aI., 1984; Ten Dijke ef aI., 1994c; Wieser 
et al., 1995; Hoodless et aI., 1996; Martens ef aI., 1997; Kraaij ef aI., 1998). 
The wild type ALK2 cDNA was subcloned into the EcoRI site, and the 
constitutively active ALK2-Q204D (J. de Winter, unpublished) was subcloned 
into the BamHI site, of pSG5. The aromatase promoter-Iuciferase reporter 
construct was generated by cloning the HindIlI-XbaI fragment encoding the 
rat aromatase promoter (Fitzpatrick and Richards, 1993) into the SmaI site 
of pGL2-basic (Promega, Leiden, The Netherlands). 
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Transfeclion and luciferase assay 
HEK-293 (human embryonic kidney) cells were maintained in DMEM-Fl2 
(Life Technologies, Breda, The Netherlands) and 10% FCS (SEBAK, 
Aidenbach, Germany) at 37 C in a 5% CO, atmosphere. Transfection was 
conducted using the calctum phosphate method (Chen and Okayama, 
1987) at 35 C and 3% CO,. Stable cell lines, denoted HEK-293FAN cells, 
expressing FSHR and AMHRIl, were generated and selected for neomycin 
resistance, after cotransfection with 5 I1g FSHR, 5 I1g AMHRIl, and 1 I1g 
pKO-Neo. The HEK-293FAN cells were transiently transfected with 10 I1g 
aromatase promoter-luciferase reporter construct or 1 I1g pADne02-C6-
BGL, a vector that contains six cAMP response elements (Himmler et ai., 
1993). In the case of cotransfection with the constitutively active type I 
receptors, 1 I1g of expression plasmid was used. Cotransfection with the 
wild type ALK2 or wild type ALK6 was carried out with 5 I1g of expression 
plasmid. To correct for transfection efficiencies, the ~-galactosidase 
expression plasmid pCH110 (l I1g/75 mm dish; NUNC, Life Technologies) 
was added (Hall et ai., 1983). Following transfection, cells were split into 12 
well plates (NUNC) and allowed to attach overnight. Subsequently, the cells 
were incubated with vehicle, 1 IU/ml recFSH (Organon, Oss, The 
Netherlands), 1 IU/ml recFSH together with 1.8 I1g/ml AMH, or 1.8 I1g/ml 
AMH alone, in DMEM-Fl2 containing 0.1 % (w/v) BSA. AMH was obtained by 
concentrating medium of HEK-293 cells coexpressing AMH and 
prohormone convertase 5 (PC5). PC5 is able to process AMH, and PC5-
cleaved AMH was proven to have full bioactivity in the MUllerian duct 
regression assay (Nachtigal and Ingraham, 1996). 
An additional transfection experiment was conducted in which HEK-
293 cells were cotransfected with the aromatase promoter-luciferase 
reporter construct and 1 I1g of the ActRIIA, ActRIlB, or BmpRIl expression 
plasmids together with 5 I1g of ALK2, or ALK6 expression plasmids. 
Subsequently, cells were incubated with vehicle, 1 IU/ml recFSH, 1 IU/ml 
recFSH together with 20 ng/ml activin, or 100 ng/ml BMP2, or 100 ng/ml 
BMP7, or activin, BMP2, or BMP7 alone. 
After 48 hours, cells were lysed, and luciferase and ~-galactosidase 
activities were measured (Miller, 1972; Blok et ai., 1992). 
116 
Candidate AMH Type I receptor 
RNA isolation 
FVB mice were kept under standard animal housing conditions in 
accordance with the NIH Guidelines for the Care and Use of Experimental 
Animals. Vaginal plug detection was considered day 0 (EO) of pregnancy. 
Pregnant mice were sacrificed by cervical dislocation on E13, 14, 15 or 18. 
Fetal tissues and adult gonads (40 days) were isolated and snap frozen in 
liquid nitrogen and stored at -80 C. Total RNA from fetal tissues was 
isolated using a microscale version of the method described by 
Chomczynski and Sacchi (1987), and total RNA from adult tissues was 
isolated using the LiCl/urea method (Auffray and Rougeon, 1980) In 
addition, fetuses were fixed overnight in Bouin's fixative, embedded in 
paraffin, and sectioned transversally at 811m. PCR reactions using 
placental genomic DNA (Hogan et a1., 1986) were performed as described 
by Mitchell et a1. (1991), using primers for the mouse genes Sbx and Sby 
(Kay et a1., 1991; Mitchell e/ a1., 1991), to determine the sex of the fetuses. 
RNAse protection assay and in situ hybridization 
A mouse AMHRII DNA template for in vitro transcription was generated by 
RT-PCR. The RT-PCR reaction was carried out on 100-200 ng total RNA, 
extracted from 25-day-old mouse testis, using random hexamers. A sample 
of the reverse transcription reaction product was used in the PCR reaction 
using the primers 5'GCTCCGGAGCTCTTGGACAAG3' (forward primer) 
and 5'CAGGCGCTGCTGCACACACTC3' (reverse primer), corresponding 
to the kinase subdomains VIII, IX, and X of the AMHRII gene. A 350 bp PCR 
product was subcloned in pBluescript KS and used to generate [32PI-UTP-
labeled anti-sense RNA probe. The AMH RNA probe was obtained using a 
430 bp mouse genomic DNA Pst! fragment of the AMH gene, containing 
exon l. An EcoRl-HindIII fragment containing bp 1-472 of the mouse ALK2 
eDNA, and a HpaI-ApaI fragment containing bp 79-551 of the mouse ALK6, 
both encoding the extracellular domain, were subcloned in pBluescript KS 
and used to generate [32PI-UTP-labeled anti-sense RNA probes. The control 
glyceraldehyde 3-phosphate dehydrogenase (GAPD) RNA probe was 
synthesized using a construct containing 163 bp Accl-Sau3AI fragment of 
the rat GAPD eDNA. RNase protection assays of 10 I1g of total RNA with 
these probes were performed as described by Baarends et a1. (1994). 
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The EcoRI-HindlII fragment containing bp 1-472 of the mouse ALK2 
eDNA was also used to generate sense and anti-sense [' Sl-UTP-labeled 
transcripts for in situ hybridization. The in situ hybridization procedure was 
performed as described by Zeller and Rogers (1991) with some 
modifications (Baarends et a1., 1994). 
Results 
Development of an AMH in vitro assay 
To study several aspects of the molecular mechanism of AMH action, we 
developed an in vitro assay based on the inhibitory effect of AMH on FSH-
induced aromatase promoter activity (Vigier et a1., 1989; Di Clemente et a1., 
1992; Di Clemente et a1., 1994). Stable HEK-293 cell lines expressing the 
cDNAs encoding the FSHR and AMHRII were generated, and the cell line 
with the highest FSHR and AMHRII mRNA expression level (HEK-29aFAN 
cells) was used in further experiments. 
The aromatase promoter-luciferase reporter construct was transfected 
transiently into the HEK-29aFAN cells. Upon FSH stimulation, a three- to 
four-fold increase in arornatase promoter activity was measured compared 
to nonstimulated cells (Figure 6.1). The main signal transduction pathway 
by FSH is activation of adenylyl cyclase through G,. The FSH-induced rise 
in intracellular cAMP regulates expression of several genes through 
interaction of CREBP (cAMP response element binding protein) with CREs 
(Birnbaumer, 1992; Lalli and Sassone-Corsi, 1994). Using a luciferase 
reporter construct with six cAMP response elements (6xCRE), a four- to five-
fold increase in luciferase was obtained, while basal luciferase activity 
using this reporter construct was much higher (Figure 6.1). These results 
indicate the presence of a functional FSHR and cAMP transduction system 
in the HEK-293FAN cells. 
Identification of type I receptors with inhibitory signaling ability 
To identify type I receptors that are able to signal the inhibition of FSH-
induced aromatase activity, mutant receptors ALKI-ALK6 with constitutive 
kinase activity were cotransfected with the aromatase promoter-Iuciferase 
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Figure 6.1. FSH-response In HEK-293FAN cells. 
HEK-293 cells were stably transfected with cDNAs encoding FSHR and AMHRJI and 
selected for neomycin resistance, resulting in HEK-293FAN cells. The HEK-293FAN 
cells were transiently transfected with either the aromatase promoter-Iuciferase 
reporter construct (AROM) or with a luciferase reporter containing six cAMP 
response elements (6xCRE). Cells were incubated without (open bars) or with 
(black bars) human recFSH (lIU/ml) for 4 hours. Luciferase activity was measured 
in celllysates and given as mean ± SEM (3 independent experiments). 
reporter construct into HEK-293FAN cells. 'These mutant receptors have a 
mutation C-terminal of the GS box, leading to constitutive activity in 
theabsence of ligand and type II receptor (ALKI-Q20 lD, ALK2-Q204D, 
ALK3-Q233D, ALK4-TZ06D, ALK5-T204D, and ALK6-Q203D). 'The presence of 
the control vector pSG5 (results not shown) or wild type ALKs did not affect 
the FSH-induced aromatase promoter activity (Figure 6.2). This was also 
found with the constitutive active mutants of ALKI and ALK4, while ALK3-
Q233D and ALK5-T204D caused a slight increase of basal reporter activity 
(Figure 6.2). In contrast, transfection of the constitutive active ALK2-Q204D 
and ALK6-Q203D caused inhibition of FSH-induced aromatase promoter 
activity (Figure 6.2). In addition, the basal activity of the aromatase 
promoter-luciferase reporter construct was suppressed in the presence of 
constitutive active ALK2-Q204D (Figure 6.2). 
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Figure 6.2. Inhibition of FSH-induced aromatase promoter activity by 
constltullvely active ALKs. 
HEK-Z93FAN cells were transiently cotransfected with the aromatase promoter-
luciferase reporter construct, and with cDNAs encoding the jndicated wild type or 
constitutively active receptors. The expressed receptors are: wild type ALKl-6 and 
mutant receptors ALKI-Q201D, ALK2-Q204D, ALK3-Q233D, ALK4-T20BD, ALK5-T204, 
and ALKB-Q203D. Wild type and mutant receptor are expressed by identical 
vectors. The transfected cells were incubated for 48 hours without (open bars) or 
with (black bars) recFSH (l IV/mI). Luciferase activity was measured in celllysates 
and given as mean ± SEM (3 independent experiments). Data were subjected to 
Student's t-test: *, significcmtly different from non-treated wild type receptor (P < 
0.05); ", significantly different from non-treated wild type receptor (P < 0.005); ", 
significantly dilferent from FSH-treated wild type receptor (P < 0.005); "" 
significantly different from FSH-treated wild type receptor (P < 0.0005). 
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AMH signaling through ALK2 and ALK6 
To study the ability of ALK2 and ALK6 to relay the signal of AMH, HEK-
293FAN cells were cotransfected with the aromatase promoter-Iuciferase 
reporter construct and wild type ALK2 or wild type ALK6. In the presence of 
ALK2 or ALK6, stimulation with FSH alone resulted in an increase of 
aromatase promoter activity (Figure 6.3A). However, incubation of HEK-
293FAN cells expressing ALK2 with both FSH and AMH resulted in 
approximately 50% inhibition of the aromatase promoter activity compared 
to stimulation with FSH alone (Figure 6.3A). Incubation with a higher 
concentration of AMH did not result in a further decrease of aromatase 
promoter activity (results not shown). Incubation of HEK-293FAN cells 
expressing ALK2 with AMH alone decreased the basal activity of the 
aromatase promoter (Figure 6.3A). 
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Figure 6.3. Inhibition of FSH-Induced aromatase promoter activity by AMH. 
A. HEK-Z93FAN cells were transiently cotransfected with the aromatase promoter-
luciferase reporter, together with eDNA encoding the indicated wild type receptor 
or with the pSG5 vector. B. To obtain cells not expressing AMHRlI, HEK293 cells 
were transiently cotransfected with cDNAs encoding FSHR, the aromatase 
promoter-lucilerase reporter and ALK2. The transfected cells were incubated for 48 
hours with recFSH (I IU/ml; light grey bars), recFSH together with AMH (I IU/ml and 
1.8 flg/ml, respectively; black bars), AMH alone (I.8 flg/ml; dark grey bars), or 
vehicle (open bars). Luciferase activity is given as mean ± SEM (3 independent 
experiments). Data were subjected to Student's t-test; 0, significantly different from 
non-treated cells (P < 0.05); " significantly dilferent from FSH-treated cells (P < 
0.05); ", significantly different from FSH-treated cells (P < 0.00 I). 
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Similar results were obtained with HEK-293FAN cells transfected with ALK6 
(Figure 6.3A), but the inhibition of FSH-induced aromatase promoter activity 
was statistically less strong than the inhibition measured in the presence of 
ALK2. In the absence of AMHRll, incubation with AMH did not affect the 
FSH-induced aromatase promoter activity in HEK-293 cells cotransfected 
with FSHR, the aromatase promoter-luciferase reporter construct and ALK2 
(Figure 6.3B), demonstrating that also in HEK-293 cells AMHRII is essential 
for AMH signaling. 
ALK2 and ALK6 may also function as activin and/or BMP type I 
receptors. Therefore, HEK-293 cells were cotransfected with the aromatase 
promoter-luciferase reporter construct and the cDNAs encoding the activin 
type II receptors (ActRIIA or ActRIlB), or BMP type II receptor (BMPRll), 
together with ALK2 or ALK6. Transfected cells were stimulated with recFSH 
alone or with recFSH together with activin, BMP2, or BMP7. However, no 
inhibition of FSH-induced aromatase activity was found with either of these 
combinations (Figure 6.4). These results suggest that the inhibition of FSH-
induced aromatase activity is specific for AMH, signaling through an 
AMHRll/ALK2 receptor complex. 
Expression of ALK2 and ALK6 mRNAs. 
The results with the aromatase promoter assay suggest that ALK2 and 
ALK6 can function as an AMH type I receptor (AMHRl) in vitro. However, to 
fulfill the role of AMHRl in vivo, the type I receptor has to be expressed in 
the target tissues of AMH, which are the mesenchymal cells surrounding 
the Mullerian ducts, the fetal testis and possibly also the adult testis and 
ovary. Using RNase protection assay, the expression of ALK2 and ALK6 
mRNAs was studied in isolated urogenital ridges and gonads at E 13, E 14, 
E1S, and El8 (Figure 6.SA). Both ALK2 and ALK6 mRNAs are expressed in 
the urogenital ridges of male and female fetuses at all ages, although the 
mRNA expression level of ALK2 is higher compared to the level of ALK6. 
Expression of AMHRlI mRNA is lost in the urogenital ridges during male 
fetal development, whereas it remained expressed in the female urogenital 
ridge (Figure 6.SA). The loss of AMHRII mRNA expression is not correlated 
with a comparable loss of ALK2 mRNA expression. Expression of both 
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Figure 6.4. Activln, BMP2, and BMP? do not inhibit FSH-induced aromatase 
promoter activity. 
HEK-293 cens were transiently cotransfected with the aromatase promoter-
lucilerase reporter, together with cDNAs encoding the FSHR, the ActRiI receptors, 
or BMPRII, and the indicated wild type type I receptor. The transfected cells were 
incubated for 48 hours with recFSH (I IU/ml; light grey bars), recFSH (I IU/ml) 
together with activin (20 ng/ml), BMP2 or BMP? (100 ng/ml) (black bars), activin, 
BMP2, or BMP? alone (dark grey bars), or vehicle (open bars). Luciferase activity is 
given as mean ± SEM (2 independent experiments). The ligand used in each 
experiment is indicated at the top. 
AMHRII and ALK2 mRNAs is also found in the fetal gonads of both sexes, 
but mRNA expression of ALK2 was lower in the fetal ovary than in the fetal 
testis (Figure 6.5A). In contrast, ALK6 mRNA expression was not detected in 
the fetal gonads of both sexes, at all time points studied (Figure 6.5A). 
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Figure 6.5. Expression of AMHRII, ALK2, and ALK6 mRNAs in AMH target 
tissues. 
A. Expression in fetal urogenital ridge and fetal gonads. The fetal ages at which the 
tissues were obtained. and the sex of the fetuses are indicated at the top of the 
lanes. 
B. Expression in the adult gonads. ALK6 mRNA expression in testis and ovary was 
measured in separate experiments. T, testis; 0, ovary. AMHRII, ALK2, ALK6, and 
GAPD indicate the position of the respective protected fragments. The GAPD mRNA 
level was included as a control for RNA loading. 
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Postnatally, ALK6 mRNA is only expressed in the adult ovary but not in the 
adult testis, whereas ALK2 mRNA is expressed in the ovary and also, albeit 
at lower. level, in the testis (Figure 6.5B). 
In siiu hybridization was used to study the localization of ALK2 mRNA 
expression in mouse embryos at the AMH sensitive period of Mullerian duct 
regression (EI3). ALK2 mRNA is highly expressed in fetal liver and adrenal, 
tissues in which AMHRII mRNA is not present (Figure 6.6). In addition, ALK2 
mRNA expression was detected in the mesenchymal cells surrounding the 
Mullerian ducts, but not in association with Wolffian ducts (Figure 6.6B). No 
mRNA expression above background could be detected in the fetal testes 
(Figure 6.6B). We were not successful in detecting ALK6 mRNA expression 
using in situ hybridization, possibly caused by the very low mRNA 
expression level of ALK6 (Figure 6.5A). The expression data indicate that in 
all tissues that express AMHRIl, ALK2 is also expressed, allowing a 
possible role of ALK2 as AMHRI. 
Figure 6.6. Expression of ALK2 in mate fetuses at E13, determtned using In situ 
hybridization. 
A. Haematoxylin·eosin stained section. B. Darkfield view of Al.K2 mRNA. a, adrenat; 
1, liver; t, tes~is; m, MUllerian duct; w, Wolffian duct. White arrows indicate the sites 
of expression (the ring structure at the middle-left is an artifact). Scale bar 
represents 100 11m. 
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Discussion 
The molecular signaling mechanism of several members of the TGF~ 
family of peptide growth and differentiation factors, such as TGF~ and 
BMPs, has been studied in detail. However, little is known about the AMH 
signaling cascade. The AMHRII receptor has been identified recently 
(Baarends e/ 01., 1994; Di Clemente e/ 01., 1994; Grootegoed e/ 01., 1994), 
but the identity of the type I receptor of AMH has remained unknown. So 
far, binding studies with AMH have appeared to be difficult, in contrast to 
observations on binding of TGF~s, activins and BMPs. All members of the 
TGF~ family are synthesized as large precursor proteins that contain a 
proteolytic cleavage site. Cleavage at this site generates the C-terminal 
mature growth factor and the N-terminal pro-domain, and the dissociation 
of the two domains is required for bioactivity (Gentry and Nash, 1990). 
However, to obtain full bioactivity of AMH, continuous association of the 
mature growth factor with the pro-domain after proteolytic cleavage is 
necessary (Wilson e/ 01., 1993). The instability of the hormone upon labeling 
(Donahoe e/ 01., 1977) and its size (140 kDa) have precluded binding 
experiments with suffictent specific binding to AMHRII (Di Clemente e/ al., 
1994bO. Therefore, the use of binding experiments for identification of the 
AMH type I receptor may not be feasible. 
AMH has first been identified by its induction of Mullerian duct 
regression in male fetuses (Picon, 1969). However, AMH was also shown to 
be capable of inhibiting FSH-induced aromatase activity in gonadal cells. 
The aromatase activity of cultured fetal ovaries and postnatal granulosa 
cells is suppressed in the presence of AMH (Vigier e/ 01., 1989; Di Clemente 
et 01., 1992; Di Clemente et 01., 1994a). This feature of AMH, the inhibition of 
FSH-induced aromatase activity, was used to study the mechanism of AMH 
action. The stable cell line HEK-293FAN, expressing FSHR and AMHRII, 
was generated. In these cells, the aromatase promoter-luciferase reporter 
construct was transfected transiently. The 641 bp aromatase promoter 
region contains sequences required for cAMP induction (Fitzpatrick and 
Richards, 1993). Indeed, upon FSH or dbcAMP stimulation, a three- to four-
fold increase in aromatase promoter activity was obtained in this assay. 
To study the downstream signaling pathway of AMH, our aim was to 
identify type I receptors that are able to signal the inhibition of FSH-
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induced aromatase activity. Ligand binding to type II receptors is very 
specific, as illustrated by the fact that the TGF~ type II receptor only binds 
TGF~ and the BMP type II receptor (BMPRII) only binds BMPs (Lin e/ al., 
1992; Estevez e/ al., 1993). Also, AMH is the exclusive ligand for the AMHRII, 
since AMHRII knockout mice are an exact phenocopy of AMH knockout 
mice (Behringer e/ al" 1994; Mishina e/ al., 1996). However, ligand binding 
to type [ receptors shows a high degree of promiscuity. ALK5 was shown to 
be a functional TGF~ type [ receptor, and ALK3 and ALK6 both function as 
BMP type [ receptors (FranzEm e/ al., 1993; Suzuki e/ al., 1994; Ten Dijke e/ 
al., 1994a; Ten Dijke e/ al., 1994c). ALKI can bind TGF~ and activin, 
although no biological responses are known (Attisano e/ al., 1993). ALK4 
signals in response to activin, whereas ALK2 can bind TGF~, activin, BMP2 
and BMP7, but not BMP4 (Attisano e/ al., 1993; Ebner e/ al., 1993; Tsuchida 
e/ al., 1993; Carcamo e/ al., 1994; Ten Dijke e/ al" 1994c). However, with 
respect to the signaling capacity of ALK2 in response to these ligands, 
conflicting data have been reported. Activin can induce fibronectin and 
PAl-I, but these responses could not be relayed by ALK2 (Carcamo e/ al., 
1994). Activin can use ALK2 to stimulate 3TPlux, a reporter construct 
containing the plasminogen activator inhibitor-I (PAl-I) promoter. However, 
a kinase deficient ALK2 was unable to exert a dominant negative effect on 
the activin-induced 3TPlux response (Tsuchida e/ al., 1993; Carcamo e/ aI., 
1994). A 3TPlux response to BMP2 or BMP7 was also observed when celts 
were cotransfected with BMPRII and ALK2 (Liu e/ al., 1995). In addition, 
incubation with BMP2 or expression of constitutively active ALK2 in 
Xenopus animal cap explants resulted in similar phenotypes, i.e. ventral 
mesoderm markers but no dorsal markers were induced (Suzuki e/ al., 
1997). Furthermore, a low level of ALK2 was found to overrule the 
dorzalizing effect of ALK4 when constitutively active ALK2 and constitutively 
active ALK4 were cotransfected (Armes and Smith, 1997). Although ALK2 
seems to bind activin as well as BMP2 and BMP7, ALK2 only transduces 
BMP signals but not activin signals, in the context of Xenopus embryos. The 
ubiquitous tissue expression pattern of several type I receptors (Dewulf e/ 
al., 1995; Verschueren e/ al., 1995) suggests that they might be shared with 
other members of the TGF~ family. For these reasons, we have studied 
whether the type [receptors identified so far (ALKI-ALK6) might function as 
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an AMH type I receptor, instead of attempting to clone new type I 
receptors. 
The ability to inhibit FSH-induced aromatase promoter activity was 
studied using constitutively active type I receptors. Of the six type I 
receptors studied, only constitutively active ALK2-Q2040 and ALK6-Q2030 
were able to inhibit FSH-induced aromatase promoter activity. In addition, 
wild type ALK2 and wild type ALK6 were able to relay the AMH signal in the 
presence of AMHRII, with ALK2 signaling resulting in a significantly 
stronger inhibition of aromatase promoter activity than ALK6 signaling. In 
agreement with the observed AMH-induced inhibition of basal aromatase 
activity in cultured granulosa cells (Oi Clemente ef a1., 1994a), the 
constitutively active ALK2-Q2040 and ALK6-Q2030, and also wild type ALK2 
and ALK6 upon AMH incubation, suppress basal aromatase promoter 
activity. The amount of AMH used to suppress FSH-induced aromatase (1.8 
l1g/ml) corresponds to the concentration of AMH used in previously 
reported sludies on aromatase inhibition, such as 2.25-3 l1g/ml for cultured 
fetal ovaries and 0.2-7.5 ~lg/ml for cultured postnatal granulosa cells (Vigier 
ef a1., 1989; Oi Clemente ef a1., 1994a). 
The inhibition of FSH-induced aromatase activity was dependent on 
the presence of AMHRII and was specific for AMH. The constitutively active 
forms of BMP or activin type I receptors, ALK3 and ALK4 respectively, were 
unable to suppress FSH-induced aromatase promoter activity. 
Furthermore, activin signaling through an ActRII/ALK2 complex or BMP 
signaling through ActRII/ALK2, ActRII/ALK6, BMPRII/ALK2, or BMPRII/ALK6 
complexes, also did not inhibit FSH-induced aromatase promoter activity. 
This lack of inhibition was not the result of inactive ligands, since activin 
and BMPs were able to induce the 3TPlux reporter with the proper type I 
and type II receptors (results nol shown). These results suggest that activin, 
BMP2 and BMP7 are unable to signal through ALK2 in the aromatase 
promoter assay. 
An essential requirement for an AMHRl, is its correct spatial and 
temporal expression in the target sites of AMH, I.e. the Mullerian ducts, and 
the fetal and adult gonads. ALK2 and ALK6 mRNAs were expressed in the 
genital ridges of both male and female fetuses at all time points studied, 
although mRNA expression of ALK6 was much lower compared to ALK2 
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mRNA expression. In contrast to AMHRII mRNA expression, which is lost 
during male fetal development (Baarends et a1., 1994), mRNA expression of 
both ALK2 and ALK6 remained present in male urogenital ridges. This may 
point to additional functions for ALK2 and ALK6. 
Mullerian duct regression involves a change in mesenchymal-
epithelial interaction, resulting in destruction of the epithelial structure 
(Trelstad et a1., 1982). Incorporation of [3HJ-thymidine into separately 
cultured epithelial and mesenchymal ductal cells in the presence of AMH 
showed that DNA synthesis in epithelial cells was not changed, whereas 
the labeling index was significantly reduced in the mesenchymal cells. This 
suggests that the effect of AMH on the epithelial cells of the Mullerian ducts 
is via the surrounding mesenchymal cells (Tsuji et a1., 1992). This 
suggestion was supported by the localization of AMHRII mRNA expression 
in the mesenchymal cells (Baarends et a1., 1994; Di Clemente et a1., 1994b). 
Therefore, expression of an AMH type I receptor in the mesenchymal cells 
of the Mullerian ducts is a prerequisite for proper AMH signaling. Using in 
situ hybridization, ALK2 mRNA expression in the urogenital ridge was 
shown to be present in the mesenchymal cells surrounding the Mullerian 
ducts but not in the cells near to the Wolffian ducts. In contrast, ALK6 mRNA 
expression in the urogenital ridge has been located in the epithelial cells, 
of both Mullerian and Wolffian ducts (Dewulf et a1., 1995). Thus, ALK2 is the 
type I receptor that fulfills all requirements of an AMHRI: it functions as 
AMHRI in vitro, and it is expressed in the urogenital ridge at the right time 
in the right cells. 
Although the role of AMH in the gonads is less clear, some effects have 
been described. The phenotype of AMH or AMHRII knockout mice included 
the presence of Leydig cell hyperplasia, whereas transgenic mice 
overexpressing AMH developed Leydig cell hypoplasia (Behringer e/ a1., 
1990; Behringer et a1., 1994; Mishina et a1., \996). Fetal ovaries do not 
produce AMH, but AMHRII mRNA is expressed in these ovaries. Ovaries of 
transgenic mice overexpressing AMH develop testis cord-like structures 
and have decreased aromatase activity (Behringer et a1., 1990; Baarends et 
a1., 1994; Di Clemente et aJ., 1994b), indicating the presence of a functional 
AMH receptor complex. Therefore, the candidate AMH type I receptor is 
expected to be expressed in both fetal testis and ovaries. Indeed, ALK2 
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mRNA expression was found in the fetal gonads of both sexes, at all time 
points studied during development. In contrast, ALK6 mRNA expression 
could not be detected in the fetal gonads. Postnatally, ALK6 mRNA 
expression was found only in the ovary but not in the testis, whereas ALK2 
mRNA is expressed in gonads of both sexes. The fetal gonadal expression 
of ALK2 mRNA further supports our conclusion that ALK2, but not ALK6, is 
an AMH type I receptor. Ultimate proof that ALK2 can function as an AMH 
type I receptor may come from conditional knockout experiments, in which 
ALK2 function is specifically abrogated in the target sites of AMH. 
The identification of ALK2 as a functional candidate AMH type I 
receptor, will enable us to study the downstream components of AMH. In 
this respect, a recently identified member of the Smad family, Smad8, is of 
interest (Chen et al., 1997b). Smad8 is specifically phosphorylated by a 
constitutively active ALK2. Furthermore, Smad8 is able to rescue the 
expression of genes blocked by a dominant-negative ALK2. These results 
suggest that Smad8 may function as a downstream factor of ALK2 (Chen et 
al., 1997b). 
The expression pattern of ALK2 mRNA is not restricted to the target 
sites of AMH, which suggests that ALK2 may also function as a type I 
receptor for other ligands. A relatively high level of ALK2 mRNA was 
observed in fetal liver and adrenal. Since ALK2 has been suggested to 
serve as an activin type I receptor, ALK2 may be involved in the anti-
proliferative effects of activin on hepatocytes and fetal adrenal cells 
(Spencer et al., 1992; Hully et al., 1994; Coerver et al., 1996; Mesiano and 
Jaffe, 1997). In addition, ALK2 has been suggested to function as a BMP 
type I receptor, and several BMPs are expressed in the fetal liver and 
adrenal, in which they are suggested to play a role in growih and 
differentiation (Ozkaynak et al., 1992; King et al., 1994; Song et al., 1995; 
Knittel et al., 1997). Recent data suggest that, in Xenopus embryos, ALK2 
may indeed act as a BMP type I receptor (Armes and Smith, 1997). 
Downstream factors in the BMP Signaling pathway may, therefore, also be 
of interest for AMH signaling. Smad I and Smad5 were shown to act 
downstream of BMP2 (Yamamoto et a1., 1997). Interestingly, Smad5 
expression was detected in the urogenital ridge (Meersseman et a1., 1997). 
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It will be of interest to study, which of the Smads acts downstream of ALK2 
in response to AMH. 
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AMH acUon Involves apoptosls 
Abstract 
Anti-Mullerian hormone (AMH), a member of the transforming growth 
factor ~ (TGF~) family, induces Mullerian duct regression in mammalian 
male fetuses. AMH elicits its effect on the epithelial cells of the Mullerian 
ducts via the surrounding mesenchymal cells. However, the molecular 
mechanism by which AMH induces Mullerian duct regression is not known, 
although it has been suggested that induction of apoptotic cell death is 
involved. Since members of the TGF~ family are able to induce apoptosis 
in various other cell systems, we investigated whether Mullerian duct 
regression is associated wtth this mechanism of programmed cell death. 
Indeed, using the TUNEL assay, apoptotic nuclear bodies were only 
detected in the Mullerian ducts of male fetuses during the critical period of 
Mullerian duct regression, but not in the Mullerian ducts of female fetuses. 
In addition, apoptotic bodies were absent from the Mullerian ducts of AMH-
deficient male fetuses. 
The AMH type II receptor and ALK2, recently identified as a strong 
candidate AMH type I receptor, are both expressed by the mesenchymal 
cells surrounding the Mullerian ducts. We investigated whether AMH is 
capable of inducing apoptosis through signaling by an AMHRll/ALK2 
complex, in cultured cells. To this end, HEK-293 cells were cotransfected 
with AMHRII and ALK2. These transfected cells did not undergo apoptosis 
upon AMH exposure. In view of limited biological activity of AMH in 
different cell/tissue culture systems, an additional experiment was carried 
out. Transfection of ALK2 carrying a mutation that renders the type I 
receptor constitutively active resulted in a markedly increase in apoptotic 
cells. Cotransfection of green fluorescent protein showed that the apoptotic 
nuclei were only present in transfected cells. 
The results described in this paper show that AMH action on Mullerian 
duct regression may involve induction of apoptosis, and that in cultured 
cells, the constitutively active candidate AMHRl is capable of induction of 
the apoptotic pathway. However, additional experiments are necessary to 
elucidate the exact molecular mechanism of Mullerian duct regression. 
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Introduction 
Anti-Mullerian hormone (AMH) is a member of the transforming growth 
factor P (TGFP) family of growth and differentiation factors (Massague, 
1990). In contrast to other family members, which have a broad range of 
effects, the biological function of AMH is very restricted. AMH mRNA is 
expressed by preantral and small antral follicles in the adult ovary and 
may play a role in ovarian folliculogenesis (Baarends et a1., 1995b). 
Furthermore, the fetal and adult testes express AMH mRNA (Baarends et 
a1., 1995a), where AMH seems to be involved in the regulation of Leydig cell 
function, since AMH-deficient mice develop Leydig cell hyperplasia, and 
transgenic mice, which overexpress AMH develop Leydig cell hypoplasia 
(Behringer et aJ., 1990; Behringer et aJ., 1994). ·In the AMH-overexpressing 
mice and in cultured fetal ovaries, AMH was also shown to decrease 
aromatase activity (Behringer et aJ., 1990). Nevertheless, AMH is best 
known for its specific role during sex differentiation. In the male fetus, AMH 
induces the regression of the Mullerian ducts, the anlagen of the female 
urogenital tract that, in female fetuses in the absence of AMBo wtll 
differentiate into the uterus, oviducts and upper part of the vagina 
(Munsterberg and Lovell-Badge, 1991). Regression of the Mullerian ducts 
occurs during a critical period of sensitivity to AMH, in the mouse around 
E13-15 (days post coitum). In the rat, exposure of female fetuses to AMH 
after EI6 does not result in Mullerian duct regression (Tsuji et a1., 1992). 
Morphologically, regression of the Mullerian ducts is characterized by a 
whorl of condensed mesenchymal cells surrounding the Mullerian duct 
(Dyche, 1979). Electron microscopy demonstrated the dissolution of the 
basement membrane prior and during Mullerian duct regression, allowtng 
direct contact between epithelial and mesenchymal cells and the 
possibility of the epithelial cells to enter the mesenchymal cell population 
(Trelstad et aJ., 1982). Based on the observation that macrophages and 
apoptotic cells are present in the regressing ducts, it was suggested that 
apoptosis (programmed cell death) plays a role in Mullerian duct 
regression (Price et a1., 1977; Catlin et a1., 1997). However, wtth fluorescent 
labeling techniques in male alligator fetuses, and wtth the use of 
chick/quail chimeras, it was demonstrated that the epithelial cells migrated 
out of the Mullerian duct and were· incorporated into the mesonephric 
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tubules (Hutson et al., 1984; Austin, (995). Nevertheless, since Mullerian 
duct regression may involve both apoptosis and cell migration, the results 
from these studies do not necessarily exclude one another. 
From in vitro experiments it became clear that AMH elicits its effect on 
the epithelial cells of the Mullerian ducts via the surrounding mesenchymal 
cells (Tsuji et al., 1992). Accordingly, the mesenchymal cells are also the 
cells that express the AMH type II receptor (AMHRII) mRNA during the 
period that the Mullerian ducts respond to AMH (Baarends et aJ., 1994; Di 
Clemente et al., 1994b). However, the molecular mechanism by which AMH 
induces Mullerian duct regression is not known yet. 
AMHRII is a member of the transmembrane serine/threonine kinase 
receptor family through which the members of the TGFp superfamily exert 
their actions. Based on their structure, this receptor family can be 
subdivided into type I and type II receptors. The type I receptors, also 
known as activin receptor-like kinases (ALKs), are characterized by a 
glycine/serine-rich motif (GS box) that is located N-terminal of the kinase 
domain, whereas the type II receptors contain a longer serine-rich C-
terminus (Ten Dijke et aJ., 1994a; Massague and Weis-Garcia, 1996). Upon 
ligand binding by the type II receptor, the type I receptor is recruited into 
the complex, and serine residues in the GS box become phosphorylated by 
the type II receptor (Wrana et aJ., 1994). Replacement of these serines in 
the GS box by valine residues rendered the receptor unable to transduce 
signals. In addition to phosphorylation of residues in the GS box, two 
additional phosphorylated threonines, located near the start of the kinase 
domain, play a role in receptor activation. Replacement of Thr204 with 
aspartic acid results in a TGFp type I receptor with constitutive activity that 
signals in the absence of ligand and type II receptor (Wrana et al., 1994). 
Although the signaling mechanism of several members of the TGFp 
family has been well studied, little is known about AMH signaling, also 
because the type I receptor for AMH had not been identified. Binding 
studies with AMH proved to be difficult, since radiolabeling of AMH seems 
to abolish its ability to bind to the receptor (Donahoe et al., 1977; Di 
Clemente et al., 1994b). To avoid difficulties in binding assays with 
radiolabeled AMH, we have developed a cell culture system based on the 
inhibitory action of AMH on the FSH-induced aromatase promoter activity. 
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Using this in vitro model, it was shown that inhibition of FSH-induced 
aromatase activity by AMH was transduced through an AMHRII/ALK2 
receptor complex. Furthermore, ALK2 mRNA expression was found in the 
mesenchymal cells surrounding the Mullerian ducts, colocalizing with 
AMHRII at the site where AMH elicits its effects. Therefore, it was proposed 
that ALK2 is a strong candidate AMH type I receptor (Visser et aI., 
submitted) . 
The present experiments concern the mechanism of AMH action and 
the role of ALK2 in MUllerian duct regression. We have investigated 
whether apoptotic cells are present in the Mullerian duct during the period 
of Mullerian duct regression. Furthermore, it was studied whether a 
constitutively active ALK2 can induce apoptosis in vitro. The results 
described herein may contribute to the understanding of molecular and 
cellular aspects of the mechanism of AMH signaling. 
Materials and Methods 
TUNELassay 
Apoptotic cells were detected in situ using the terminal deoxynucleotidyl 
transferase (TdT)-mediated dUTP nick end labeling (TUNEL) method 
(Gavrieli et a1., 1992). FVB mice were kept under standard animal housing 
conditions in accordance with NIH Guidelines for the Care and Use of 
Experimental Animals. Vaginal plug detection was considered day 0 (EO) of 
pregnancy. Control and AMH-deficient (Behringer et aI., 1994) pregnant 
mice were sacrificed by cervical dislocation at El3 and El5 of gestation. To 
determine the sex of the fetuses, PCR reactions using placental genomic 
DNA (Hogan et a1., 1986) were performed as described by Mitchell e/ a1. 
(1991), using primers for the mouse genes Sbx and Sby (Kay et a1., 1991; 
Mitchell et a1., 1991). Fetuses were isolated, fixed overnight in 4% neutral 
buffered formalin, embedded in paraffin and sectioned transversally at 5 
/lm. 
Tissue sections were rehydrated and incubated with proteinase K (7.5 
/lg/ml) in PBS for 15 min at room temperature, rinsed in distilled water, and 
incubated with 3% (v/v) H,O, in PBS for 5 min to block endogenous 
peroxidase activity. Sections were pretreated with terminal 
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deoxynucleotidyl transferase (TdT) buffer (0.1 M sodium-cacodylate, I mM 
COC!z, I mM DTT, 5% (w/v) BSA) for 5 min before incubation with TdT-buffer 
containing 0.0 I mM Biotin-16-dUTP (Boehringer Mannheim, Almere, The 
Netherlands) and 0.3 U/~l TdT-enzyme (Promega, Leiden, The Netherlands) 
for at least 30 min at 37 C. Enzyme reactions were terminated in TB-buffer 
(300 mM NaC!, 30 mM sodiumcitrate) for 15 rriin. Before and after 
incubation in PBS containing 2% (w/v) BSA, slides were rinsed in water and 
PBS for 5 min each. Next, slides were incubated with streptavidin-
biotinylated horseradish-peroxidase complex (I :200, DAKO; Glostrup, 
Denmark) for 30 min. After rinsing in water and PBS, sections were stained 
with 0.075% DAB (3,3'-diaminobenzidine; Fluka, Buchs, Switzerland) in PBS 
for 5 min. Finally, sections were rinsed in water and counter-stained with 
hematoxylin. 
Transfections 
cDNAs encoding wild type mouse ALK2 and the constitutively active mouse 
ALK2-Q204D (J. de Winter, unpublished) were subcloned into the EcoRi and 
the BamHI site of pSG5, respectively (Green e/ aI., 1988). HEK-293 (human 
embryonic kidney) cells were maintained in DMEM-Fl2 (Life Technologies, 
Breda, The Netherlands) and 10% fetal calf serum (SEBAK, Aidenbach, 
Germany) at 37 C in a 5% CO, in air atmosphere. Cells were split into 6 well 
plates and transiently transfected overnight with I ~g of control expression 
vector, wild type ALK2 or ALK2-Q204D, using the calcium phosphate 
method (Chen and Okayama, 1987) at 35 C and 3% CO"~ In some 
experiments, cells were cotransfected with I ~g AMHRII and I ~g ALK2. In 
addition, the ~-galactosidase expression plasmid pCH 110 (I ~g/ml 
precipitate; Hall e/ aJ., 1983) was added to measure the number of 
transfeded cells in time, or a vector expressing enhanced green 
fluorescent protein (pEGFP; I Ilg/ml precipitate; Clontech, Westburg, 
Leusden, The Netherlands) was added to visualize transfected cells. Cells 
transfected with AMHRII and ALK2 were incubated with vehicle, or with 1.8 
~g/ml AMH obtained from a HEK-293 cell line that constitutively expresses 
rat AMH (Nachtigal and Ingraham, 1996). Cells were lysed and ~­
galactosidase activity was measured (Blok et aJ., 1992) I, 12,24 or 36 h after 
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transfection. At the same time points cells were studied for the presence of 
apoptotic nuclei. 
To visualize apoptosis in unfixed monolayers, cells were incubated for 
30 min with the fluorescent DNA binding dyes Hoechst 33342 and 
propidium iodide (PI) at a final concentration of I ~g/ml and 3.5 ~g/ml, 
respectively. Hoechst freely crosses the intact and damaged plasma 
membranes, and leads to a blue staining of the DNA, whereas PI can only 
penetrate cells with damaged membranes, resulting in pink nuclear 
staining. 
Results 
Detection of apoptosis during Mill/erian duct regression 
To determine whether the AMH-induced regression of the Mullerian ducts 
might be associated with apoptosis, urogenital ridges of EI3 and El5 
fetuses were studied for the presence of apoptotic cells. The TUNEL assay 
was used as an in situ apoptosis detection method. With this assay, cells in 
which DNA fragmentation has occurred are labeled using incorporation of 
Biotin-16-dUTP with terminal deoxynucleotidyl transferase, and the labeled 
cells are visualized with streptavidin-biotinylated horseradish-peroxidase 
complex. 
Apoptotic cells were observed in the urogenital ridges of both male 
and female fetuses at EI3 and El5 (Figures 7.1 and 7.2). In male fetuses, 
apoptotic cells were specifically located in the epithelial compartment of 
the regressing Mullerian ducts (Figure 7.IA and B, Figure 7.2A and B), 
whereas in female fetuses apoptotic cells were present in the epithelial 
part of the Wolffian ducts. The latter result is in agreement with 
degeneration of the Wolffian ducts in female fetuses, due to absence of 
testosterone (Figure 7.IC and D). In female fetuses and in male AMH-
deficient fetuses no AMH is present. Accordingly, hardly any or no 
apoptotic bodies were found in the Mullerian ducts of these fetuses (Figure 
7.IC-F). 
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Cranial Caudal 
Figure 7.1. Detection of apoptosis In the reproductive tract of control fetuses 
and AMH·deficient male fetuses at E13 using the TUNEL assay. 
Apoptotic cells were detected along the whole cranial-to-caudal axis of the 
Mullerian duct of male fetuses, before regression of the duct is morphologically 
visible (A and B). In female fetuses, little or no apoptotic cells were detected in the 
Mullerian duct but apoptotic cells were present in the degenerating Wolffian duct 
(C and D). In AMH·deficient male fetuses (AMH·KO), in which the Mullerian ducts 
do not regress due to the absence of AMH, little or no apoptotic bodies were 
detected along the whole axis of the Mullerian ducts (E and f). Apoptotic bodies are 
indicated with small arrowheads. MUllerian duct (M) and Wolffian duct (W) are 
indicated with large arrows; in the caudal sections both left and right ducts are 
present. Scale bar represents 50 ~m. 
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It has been obseIVed that, morphologically, Mullerian duct regression 
progresses in a cranial to caudal direction (Visser et aI., 1998). At E13, the 
cranial parts of the MUllerian ducts in male fetuses are narrowed and a 
whorl of mesenchymal cells is visible, but these morphological features of 
Mullerian duct regression are not present in the caudal part of the male 
Mullerian ducts, at the same stage of development. However, apoptotic 
cells were present in both the cranial and caudal regions of the MUllerian 
ducts of male fetuses at El3 (Figure 7.1A and 0), suggesting that the 
apoptotic process of Mullerian duct regression precedes the 
morphological characteristics. At E15, the morphological features of 
Mullerian duct regression are found along the axis of the Mullerian ducts of 
male fetuses (Figure 7.2A and B), and at this time point an increase in 
apoptotic cells is found compared to the number found at E13. In female 
fetuses at £15, apoptotic bodies are found at the midline of the caudal part 
of the Mullerian ducts (Figure 7.20). This is of interest, because the caudal 
part of the left and right Mullerian ducts fuse to form the upper part of the 
vagina. The presence of apoptotic bodies at the midline of the Mullerian 
ducts may reflect this fusion process. 
Constitutively active ALK2 induces apoptosis in vitro 
In a previous study, ALK2 was identified as a candidate AMH type I 
receptor (Visser et a1., submitted). Therefore, we studied the ability of ALK2 
to induce apoptosis in vitro, using a constitutively active ALK2 mutant 
(ALK2-Q2040). HEK-293 cells were transiently transfected with ALK2 or 
ALK2·Q2040, together with either pEGFP or pCH lID, and the transfected 
cells were studied subsequently for the presence of apoptotic nuclei at 
different time points after transfection. 
To detect intact cells, cells undergoing apoptosis, or dead cells 
resulting from apoptotic and/or necrotic processes in the same sample at 
the same time, cells were stained with Hoechst and PI. Normal cells are 
characterized by a faint blue staining of the intact nucleus, whereas 
apoptotic cells stain bright blue due to nuclear fragmentation and 
condensation. Dead cells are red fluorescent due to the uptake of PI. Green 
staining can be obseIVed in cells that express the green fluorescent 
protein. 
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Cranial Caudal 
Figure 7.2. Detection of apoptosls In the reproductive tract of control fetuses at 
E15 using the TUNEL assay. 
In male fetuses, many apoptotic cells are detected in the regressing MUllerian duct, 
but only few in the Wolffian duct (A and B). In the female fetuses. the WoUfian duct 
has degenerated (C and D). Apoptotic cells are found in the midline of the caudal 
region of the Millierian ducts (D) Apoptotic bodies are indicated with small 
arrowheads. Milllerian duct (M) and Wolffian duct rNl are indicated with large 
arrows; in the caudal sections both left and right ducts are present. Scale bar 
represents 50 ~m. 
No apoptotic nuclei were observed in cells transfected with the wild 
type ALK2 at any time point up to and including 30 h after transfection 
(Figure 7.3A-C). Cells transfected with the control vector gave similar 
results. For HEK-293 cells transfected with ALK2-Q2040, the first apoptotic 
cells were observed 24 h after transfection (Figure 7.30). Apoptosis is 
characterized by nuclear fragmentation, and apoptotic cells were found to 
round up and detach from the dish (Figure 7.30, F). The apoptotic effect of 
the constitutively active ALK2 was probably a cell-autonomous effect, since 
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apoptosis was only observed in cells that expressed pEGFP, as indicated 
by the green staining (Figure 7.3E). At 30 h after transfection, the number of 
apoptotic nuclei in ALK2-Q204D transfeeled cells had increased, and 
apoptosis was also observed in cells that did not express pEGFP (results 
not shown). This latter effect may be explained by the loss of GFP from 
leaky apoptotic cells, since in late apoptotic cells GFP staining was less 
bright. 
To obtain a quantitative estimation of cell death, we determined the ~­
galaelosidase activity in cells transfeeled with ALK2 or its constitutively 
aelive counterpart (Figure 7.4). With time after transfeelion, a similar 
increase in ~-galaelosidase aelivity was measured in cells transfeeled with 
either the control veelor or wild type ALK2. However, for cells transfeeled 
with ALK2-Q204D, the ~-galactosidase activity at 24 and 30 h after 
transfection was much lower, compared to cells transfeeled with wild type 
ALK2 (Figure 7.4). 
In an in vitro system based on the inhibitory aelion of AMH on FSH-
induced aromatase aelivity, ALK2 was identified as a candidate AMH type I 
receptor (Visser et a1., in preparation). Therefore, HEK-293 cells were 
transiently transfeeled with ALK2 and AMHRIl, and incubated with or 
without AMH, to study the ability of ALK2 to relay the apoptotic signal of 
AMH. Unexpeeledly, apoptotic cells were not observed upon AMH 
stimulation (results not shown). 
Since ALK2 may also funelion as a type I receptor for other ligands 
(Attisano et a1., 1993; Armes and Smith, 1997), induction of apoptosis in 
response to bone morphogenetic protein (BMP) 2, BMP7 or activin was 
studied in the present cell culture system. HEK-293 cells were transfected 
with the activin type II receptors (ActRIlA or ActRIIB) or bone 
morphogenetic protein type II receptor (BMPRlI), together with ALK2, and 
transfected cells were incubated with activin, BMP2, or BMP7. However, no 
induction of apoptosis was observed with all receptor combinations (results 
not shown). 
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ALK2 ALK2·Q204D 
Figure 7.3. Constitutively active ALK2 Induces apoplosls In vitro. 
HEK-293 cells were transfecled with ALK2 (A-C), or the constitutively active ALK2-
Q204D (D-n together with pEGfP. Nuclei were stained 30 h after transfection with 
Hoechst/propidium iodide, and observed using a fluorescent microscope (A and D). 
GfP staining indicates transfected cells (8 and E), and confirmed that nearly all 
cells transfected with ALK2-Q204D undergo apoptosis (E). Normal cells remained 
attached to the culture dish (C), whereas apoptotic cells rounded up and detached 
(F). Arrows indicate examples of apoptotic cells and arrowheads indicate examples 
of normal cells. 
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Figure 7.4. Constitutively active ALK2-induced apoptosis Increases In time. 
HEK-293 cells were transfecled with pSG5, Al.K2, or Al.K2-Q204D, together with a 
vector expressing p-galactosidase (p-GaD. p·Gal activity was measured at I, 7, 24 
and 30 h after transfection. In Al.K2-Q204D transfected ceils, no increase of p-Gal 
activity was observed 24 h after transfection. pSG5, open bars; Al.K2, grey bars; 
ALK2-Q204D, closed bars. 
Discussion 
Anti-Mullerian hormone (AMH) plays an essential role in the induction of 
Mullerian duct regression in male fetuses. This Mullerian duct regression is 
morphologically characterized by the whorled pattern of condensed 
mesenchymal cells surrounding the Mullerian ducts (Price et al., 1977), 
indicating that the mesenchymal cells are an important target in the action 
of AMH. Concomitant with the condensation of the mesenchymal cells, the 
basement membrane is disintegrating, allowing direct contacts between 
mesenchymal and epithelial Mullerian duct cells (Dyche, 1979; Price et al., 
1979; Trelstad et aI., 1982). At the electron microscopic level, an increase in 
the number of lysosomes in epithelial ductal cells was observed, which 
may be the first morphological event of the removal of epithelial Mullerian 
duct cells, followed by an invasion of the duct by macrophages from the 
adjacent mesenchyme. The lalter observations have led to the suggestion 
that Mullerian duct regression is initiated by programmed cell death or 
apoptosis (Price et al., 1977; Price et al., 1979). 
146 
AMH action Involves apoptosls 
Several members of the TGF~ family have been implicated to play a 
role in induction of apoptosis in various tissues, and in cultured cells. 
Activin induces apoptotic cell loss in rodent liver and in hepatocyte cultures 
(Hully et a1., 1994). Furthermore, apoptosis is induced in the liver of 0:-
inhibin-deficient mice, probably due to a relatively high activin level in 
these animals (Matzuk et al., 1992; Matzuk et al" 1994). In addition, activin 
signaling leads to apoptosis in myeloma cells, B cell hybridoma cells, and 
LNCaP (lymph node carcinoma of the prostate) cells (Koseki et al" 1995; 
Wang et al., 1996; Yamato et al., 1997). BMP4 action is associated with 
induction of apoptosis in neural crest cells and dental epithelia, and this 
factor is also required for apoptosis of interdigital tissue in developing 
chick limbs (Graham et al., 1994; Yokouchi et al., 1996; Zou and Niswander, 
1996; Macias et al., 1997; Jernvall et al., 1998). Furthermore, BMP4 induces 
cell death in fetal lung mesenchyme (Bellusci et al., 1996). TGF~ was shown 
to induce apoptosis in mink lung cells and in gonocytes in testis of 25-day-
old rats (Souchelnytskyt et al., 1996; Olaso et al., 1998). 
Since members of the TGF~ family can induce apoptosis, it is an 
obvious hypothesis that apoptosis in the regressing Mullerian ducts is 
triggered by AMH. To investigate whether apoptotic cell death plays a role 
in the series of events that follows AMH action on the Mullerian ducts, 
Mullerian ducts of fetal mice were studied for the presence of apoptotic 
bodies during the AMH sensitive period of Mullerian duct regression. 
Indeed, markers for apoptotic cell death were present in the Mullerian 
ducts of male fetuses, and were absent in female fetuses and AMH-
deficient male fetuses. These results perfectly correlate with the 
involvement of apoptotic cell death in the events evoked by AMH action on 
the Mullerian ducts. 
Previously, Catlin et al. (1997) have demonstrated induction of 
apoptosis in cultured female urogenital ridges upon AMH exposure, 
although only few cells were found to be apoptotic at a given time point in 
their experiments, leaving open the question whether apoptosis is the 
dominant pathway for male Mullerian duct regression. In the present study, 
ample numbers of apoptotic cells were observed, and we conclude that 
apoptosis is the main cellular mechanism of AMH-induced Mullerian duct 
regression. 
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Recently, we have reported that, Mullerian duct regression is 
progressing in a cranial to caudal direction (Visser et aI., 1998) and it was 
expected that also apoptosis would follow this pattern. However, apoptotic 
cells were detected along the entire cranial-to-caudal axis of the Mullerian 
ducts at E 13, suggesting that the apoptotic signal for regression precedes 
the morphological signs of Mullerian duct regression. 
The apoptotic cells are predominantly found among the epithelial cells 
of the Mullerian duct, although some apoptotic cells are found in the 
mesenchyme surrounding the Mullerian ducts. In vitro culture experiments 
with Mullerian duct epithelial and mesenchymal cells revealed an absence 
of a direct effect of AMH on epithelial cells, suggesting that the 
disappearance of epithelial cells is mediated via the surrounding 
mesenchymal cells (Tsuji et a1.. 1992). In support of these observations, 
AMHRII mRNA and also mRNA encoding ALK2, a candidate AMH type I 
receptor, are expressed in the mesenchymal cells surrounding the 
Mullerian ducts (Baarends et aI., 1994; Di Clemente et aI., 1994b; Visser et 
al., submitted). Since the epithelial cells undergo apoptosis, the 
mesenchymal cells most likely produce an apoptosis-inducing factor in 
response to AMH action on the mesenchymal cells. Members of the tumor 
necrosis factor family, such as Fas ligand, might be involved, since these 
factors can induce apoptosis on neighboring receptor-bearing cells 
(Nagata and Golstein, 1995). 
Next, it was studied whether the AMH-induced apoptosis in the 
Mullerian ducts can be mediated by ALK2. Many of the HEK-293 cells 
transfected with constitutively active ALK2-Q204D went into apoptosis, 
supporting the possible role of ALK2 as an AMH type I receptor. 
Transfection of HEK-293 cells with constructs encoding other constitutively 
active mutant type I receptors (ALKI-Q20lD, ALK3-Q233D, ALK4-T206D, 
ALK5-T204D and ALK6-Q203D) did not induce apoptosis (results not 
shown). The induction of apoptosis by ALK2-Q204D may be a cell-
autonomous effect, since apoptosis was restricted to cells that displayed 
green staining as a result of GFP expression. However, at 30 h after 
transfection, apoptosis was also detected in non-green staining cells. This 
result could be explained by the loss of GFP from leaky apoptotic cells, 
although it may also be suggested that ALK2-Q204D may signal to other, 
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nontransfected cells to switch on the apoptotic program, reflecting the 
mesenchymal-epithelial interaction in Mullerian ducts. 
In a previous study, we showed that AMH signaling mediated by an 
AMHRll/ALK2 complex resulted in inhibition of FSH-induced aromatase 
promoter activity (Visser et a1., submitted). That observation led us to 
propose that AMHRll and ALK2 form a functional AMH type ll/type I 
receptor complex that can transduce the AMH signal. Although HEK-293 
cells transfected with cDNAs encoding AMHRll and ALK2 do respond to 
AMH when the transcriptional activity of the aromatase promoter is used as 
a response parameter, these cells did not display any characteristics of 
apoptosis upon exposure to AMH. The absence of AMH-induced apoptosis 
in HEK-293 cells indicates that AMH-induced effects on the Mullerian ducts 
in vivo, that clearly do involve apoptosis, cannot be mimicked in vitro. 
Possibly, one or several factors are missing from these cells, which are 
essential for an AMH effect on apoptosis. Alternatively, signals that are 
conferred by the constitutively active ALK2 may be much stronger than the 
signal of a ligand-receptor complex. Indeed, although ALK2 may also 
function as a type I receptor f",r BMPs and activin (Attisano et 01., 1993; 
Armes and Smith, 1997), TGFp family members that induce apoptosis in 
some tissues, HEK-293 cells expressing the type II receptor together with 
ALK2 also do not display apoptosis upon addition of the relevant ligands. 
The importance of a fully activated type I receptor in ligand-induced 
signaling was demonstrated with a mutant TGFp type I receptor ALK5. The 
wild type ALK5 is phosphorylated at multiple serine and threonine residues 
in and outside the GS box (Wieser et a1" 1995; Souchelnytskyt et 01., 1996; 
Willis and Mathews, 1997). In a study by Souchelnytskyt et 01. (1996) it was 
shown that mutation of a serine residue at position 165 of ALK5, only 
abrogates an effect of TGFp on induction of apoptosis but not other 
signaling responses of ALK5. One might argue that the signaling responses 
of type I receptors are dependent on the phosphorylation state of the 
receptor, and that, in addition to ligand stimulation, cell specific factors 
play a role in determining the phosphorylation pattern. 
In conclusion, the present in vivo and in vitro observations on 
apoptosis strongly suggest that the action of AMH on regression of the 
Mullerian ducts in male fetuses involves apoptosis of the epithelial cells. 
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8.1 Introduction 
Early in development. the phenotypic sex of the fetus is morphologically not 
apparent. During this so-called indifferent stage, the formation of the 
gonadal anlagen and the Wolffian and Mullerian ducts takes place. 
Following testis determination, the Wolffian ducts in the male differentiate 
into epididymides, vasa deferentia and seminal vesicles, due to the action 
of testosterone from the testis. The Mullerian ducts, which form the anlagen 
of the Fallopian tubes, uterus and upper part of the vagina, appear to 
develop in the female without a need for action of estrogens; these 
hormones have their actions mainly during puberty and adult life in the 
female. The Wolffian ducts in the female fetus do not appear to be removed 
actively, but rather degenerate as a result of lack of stimulation in the 
absence of androgens. In contrast, regression of the Mullerian ducts is 
caused by the presence of the testicular product anti-Mullerian hormone 
(AMH) acting through its AMH type II receptor (AMHRII) and a type I 
receptor. Several clinical syndromes characterized by Mullerian anomalies 
exist, in which impairment and/or dysregulation of AMH action may play a 
role. Most cases of persistent Mullerian duct syndrome (PMDS), a rare form 
of male pseudohermaphroditism with structures derived from Mullerian 
ducts found in 46,XY boys, are caused by inactivating mutations in the AMH 
or AMHRII genes (Imbeaud ef aJ., 1994; Imbeaud ef aJ" 1995). Indeed, a 
similar phenotype has been observed in AMH and AMHRII knockout mice 
(Behringer ef aJ., 1990; Mishina ef aJ., 1996). Another syndrome, Mullerian 
duct aplasia, is characterized by complete absence of Mullerian duct 
derivatives in women (Shokeir, 1978). A similar phenotype is found in 
female transgenic mice overexpressing AMH (Behringer ef aJ., 1990), but it 
is not clear whether dysregulation of AMH action plays a causative role in 
the origin of Mullerian aplasia in women. 
In the next paragraphs, a possible role of dysregulation of AMH 
signaling in the origin of Mullerian duct anomalies is discussed, in the 
context of the results described in the previous chapters and data in the 
literature (paragraph 8.2). Subsequently, several suggestions for future 
research on the molecular mechanism of AMH signaling are given 
(paragraph 8.3). These suggestions are partially based on a few 
unpublished observations, which are included in this chapter. 
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8.2 Mullerian duct aplasia 
8.2.1 Clinical and genetic characteristics 
Congenital anomalies of the development of the Mullerian ducts are 
common, occurring with a prevalence of up to 2% (Golan et aJ., 1989). 
Several different types of Mullerian duct anomalies have been described. 
The pair of Mullerian ducts gives rise to the Fallopian tubes and, upon 
fusion, also to the uterus and upper part of the vagina (Grunwald, 1941). 
Failure of this fusion results in a septate uterus or a bicornuate uterus, with 
or without a septate vagina (Figure 8.1 G-I;Sarto and Simpson, 1978). 
Fusion of the Mullerian ducts occurs during week 9-12 of pregnancy in 
human and during E15-18 in the mouse (Grunwald, 1941; Sarto and 
Simpson, 1978). This process of Mullerian duct fusion may be associated 
with apoptosis, as indicated by the high number of apoptotic cells in the 
midline of the fusing Mullerian ducts at E 15 in female mice (Chapter 7, 
Figure 7.2). 
In addition to uterine fusion defects, anomalies are found that reflect 
partial or complete absence of Mullerian duct derivatives (Figure 8.1 B-F). 
This form of Mullerian duct anomalies is known as Mullerian aplasia, also 
referred to as the Mayer-Rokitansky-Kuster-Hauser (MRKH) syndrome 
(Sarto and Simpson, 1978; Shokeir, 1978; Golan et al., 1989). 
Figure 8.1. (next page) Anomalies of the female reproductive tract. 
A: Normal Mullerian duct differentiation into Fallopian tubes, uterus and vagina. B-F 
are schematic representations of the different forms of MUllerian aplasia, B: 
absence of the upper part of the vagina; C: rudimentary uterus and absence of the 
upper part of the vagina; D: complete absence of uterus and upper part of the 
vagina; E: absence of Fallopian tubes, uterus and upper part of the vagina, 
described by Shokeir (1978) as complete Milllerian aplasia. F: unilateral absence of 
Fallopian tubes, and complete absence of uterus and the upper part of the vagina. 
All appearances of MUllericm aplasia may be associated with abnormalities or 
absence of the kidneys. G-I represent examples of uterine fusion anomalies. G: 
septate uterus; H: bicornuate uterus; I: bicornuate uterus and septate vagina. 
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Mullerian aplasia patients have a 46,)CX karyotype, develop normal female 
external genitalia and secondary sex characteristics develop normally at 
puberty, which indicates the presence of functional ovaries. Because 
patients with Mullerian aplasia lack the upper part of the vagina, resulting 
in a blind ending vagina, they are diagnosed with primary amenorrhea 
(Shokeir, 1978; Lindenman et al., 1997). The degree at which other 
Mullerian duct structures (uterus and Fallopian tubes) are absent varies 
(Sarto and Simpson, 1978; Shokeir, 1978; Golan et aJ., 1989). Based on this 
variation, Stelling et al. (1997) divided Mullerian aplasia patients in two 
groups. The first group represents the classic MRKH syndrome, which is 
characterized by the presence of normal Fallopian tubes attached to 
symmetrical uterine buds, whereas in the second group, the atypical MRKH 
syndrome, also the Fallopian tubes are affected. In addition, the atypical 
form is frequently associated with extragenital abnormalities. One third of 
the Mullerian aplasia patients have renal abnormalities, such as absent or 
ectopic kidneys, or horseshoe kidneys (Stelling et al., 1997), and the body 
side of kidney abnormalities was found to correspond with the side of 
Mullerian defects (Tarry et al., 1986). When only one kidney is present, the 
ipsilateral Mullerian duct develops normally or partially, while the 
contralateral duct is absent or abnormal. In addition, the contralateral 
ovary was found to be absent in several cases of Mullerian aplasia. When 
both kidneys are present, the Mullerian defects are symmetrical (Tarry et 
aJ., 1986). Furthermore, spinal anomalies, such as asymmetric, fused or 
wedged vertebrae, and skeletal anomalies, such as absence of digits and 
syndactyly, are found in some of the Mullerian aplasia patients (Lindenman 
et al., 1997; Stelling et aJ., 1997). 
According to Shokeir (1978), a distinction in Mullerian aplasia can be 
made based on the complete or partial absence of the Mullerian ducts. In 
complete Mullerian aplasia, the uterus and upper part of the vagina are 
missing and Fallopian tubes are rudimentary or absent, whereas patients 
with partial Mullerian aplasia also lack the upper part of the vagina but 
have a rudimentary uterus and normal Fallopian tubes. In addition, renal 
and urinary malformations are found in patients with partial Mullerian 
aplasia (Shokeir, 1978). The classifications of Mullerian aplasia patients by 
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Shokeir (1978) and Stelling et 01. (1997) do not correspond completely, 
indicating the complexity of the syndrome of Mullerian aplasia. 
Familial analysis of 13 unrelated patients with complete Mullerian 
aplasia revealed that other female relatives were similarly affected, 
whereas no abnormalities in male relatives were described. Based on this 
study, Shokeir (1978) concluded that the pedigree· pattern of Mullerian 
aplasia patients was consistent with a sex-limited autosomal dominant 
inheritance. 
8.2.2 Possible causes of Miillerian aplasia 
The variability in the partial or complete absence of Mullerian duct 
derivatives in patients with Mullerian aplasia, complicates the identification 
of a direct cause. 
The presence of rudimentary Fallopian tubes or uterus in Mullerian 
aplasia patients, suggests that the Mullerian ducts did not completely fail to 
develop. Therefore, factors that play a role in early intermediate mesoderm 
induction and initial induction of formation of Wolffian and Mullerian ducts 
are not likely to be important. Factors that are involved in the formation of 
the Mullerian ducts themselves or their regression may be more relevant in 
this respect. Several hypotheses are discussed below. 
AMH 
In male fetuses, Mullerian duct regression is induced by AMH. In the 
female, however, the ovaries do not produce AMH until after birth 
(Munsterberg and Lovell-Badge, 1991). It has been suggested that 
mutations in the AMH gene promoter, resulting in ectopic expression of 
AMH also during the female fetal period, might cause complete Mullerian 
aplasia (Ltndenman et 01., 1997). Such a mutation would correspond with 
an autosomal sex-limited inheritance pattern, since the AMH gene is 
located on human chromosome 9 (Cohen-Haguenauer et 01., 1987). Ectopic 
expression of AMH in female mice indeed results in complete absence of 
Mullerian ducts (Behringer et 01., 1990). However, whereas Mullerian 
aplasia patients have normal ovaries, ectopic AMH expression in 
transgenic female mice resulted in aberrant ovarian development. 
associated with meiotic arrest, loss of germ cells, and presence of testis 
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cord-like structures (Behringer ef aI., 1990), which would argue against a 
role for AMH in Mullerian aplasia. It has to be taken into account, that the 
AMH level in AMH-overexpressing mice is very high (Behringer ef aI., 1990; 
Lyet ef aI., 1995). It is not known whether a low or a normal level of AMH in 
female fetuses may result in Mullerian duct regression but normal ovarian 
development. 
Aberrant expression of the AMH gene in the female fetus might be 
caused by a mutation in the AMH gene promoter, but may also result from 
changes in the factors that regulate AMH mRNA expression. As discussed 
in Chapter I, in an in vitro cell culture system, SF-I and WTI interact 
synergistically in the regulation of AMH gene expression, and this 
synergism is abrogated by DAX-I (Nachtigal ef aI., 1998). In the fetal ovary, 
this inhibitory effect of DAX-I may be essential for suppression of AMH 
gene transcription prior to the downregulation of SF-I, and it has been 
suggested that the relative levels of SF-I, WTI, and DAX-I regulate AMH 
mRNA expression (Chapter I). Both an increased level of WTI or a 
decreased level of DAX-I may cause upregulation of AMH mRNA 
expression in the human fetal ovary. Since absence of DAX-I action not 
only may cause aberrant expression of AMH, but also has been found to 
result in adrenal hypoplasia in human (Muscatelli ef a1., 1994; Zanaria ef 
aI., 1994), DAX-I is not a likely candidate for playing an active role in the 
development of Mullerian aplasia. WTl, a gene also involved in early 
kidney development (Reddy and Licht, 1996), may be of more interest, 
because Mullerian aplasia is often associated with kidney abnormalities. 
AMHRII 
It can be suggested that activating mutations in the AMHRII gene could be 
another cause for Mullerian aplasia (Lindenman ef a1., 1997). AMHRII is a 
member of the transmembrane serine/threonine kinase receptor family that 
consists of type II and type I receptors (Ten Dijke ef a1., 1994a). As 
described in Chapter 2, a type II receptor binds the ligand upon which a 
type I receptor is recruited into the complex. The type II receptor contains 
constitutive kinase activity but is unable to signal by itself, and signaling is 
achieved by activation of the type I receptor 0Nrana ef aI., 1994). Therefore, 
an activating mutation of the type II receptor should mimic the effect of 
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ligand binding. A somewhat similar mutation is found in the epidermal 
growth factor receptor (EGFR), a tyrosine kinase receptor that signals upon 
ligand-dependent receptor dimerization. A natural occurring mutation in 
the EGFR results in a receptor that lacks a portion of the extracellular 
ligand-binding domain due to deletion of exons 2 to 7 (Huang et a1., 1997). 
This mutation results in a mutant receptor that contains constitutively 
activated tyrosine kinase (Huang et a1., 1997; Antonyak et a1., 1998; Schmidt 
et a1., 1998). Furthermore, this ligand-independent activity of the mutant 
EGFR is independent of receptor homodimerization (Chu et a1., 1997). One 
could hypothesize that a similar mutation in a serine/threonine kinase type 
II receptor might result in a constitutively active type II receptor. Unlike 
tyrosine kinase receptors that form homodimers, SIT kinase receptors act 
as heterodimers. An activating mutation must therefore activate or unmask 
a type I association domain in the type II receptor, which normally occurs 
by binding of the ligand. Alternatively, the mutated type II receptor may 
signal directly without participation of the type I receptor. It is not known 
whether any of the type II receptors can signal in an alternative way, and 
so far no activating mutation in any of the type II receptors has been 
reported. 
The finding of an identical translocation, t(l2;14)(qI4;q31), in two 
unrelated women with complete Mullerian aplasia, suggests that a gene on 
chromosome 12 or 14 might be involved (Taneja et a1., 1986; Kucheria et a1., 
1988). AMHRII cannot be excluded as a candidate gene, since it is located 
at chromosome 12ql3 (Chapter 4; Imbeaud et a1., 1995; Visser et a1., 1995). 
Because we could not obtain DNA from the women with t(l2; 14)(q I 4;q3 I), 
we have analyzed the coding sequence and the intron/exon boundaries of 
the AMHRII gene of one of the 13 patients (patient 7149) wtth complete 
Mullerian aplasia described by Shokeir (1978). All eleven exons were 
analyzed by PCR, using primers in the flanking intron regions, followed by 
sequencing. No DNA alterations were found in the AMHRII gene, except for 
exon 9, in which an A to G change was found at position 1264 relative to the 
translation start site, which was not present in the genomic DNA of three 
control subjects. However, the base pair change did not result in an amino 
acid change, since the codons CGA and CGG both encode for arginine. To 
confirm that this silent mutation reflects a polymorphism, more control 
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samples should be analyzed. The polymorphism could be used as a 
marker in a study of allelic variation in Mullerian aplasia. 
ALK2 
In addition to AMHRIl, dysregulation of signaling by ALK2, the candidate 
AMH type I receptor (Chapter 6), could also be involved in Mullerian 
aplasia. ALK2 mRNA is expressed in the mesenchymal cells surrounding 
the Mullerian ducts, and in the fetal and adult gonads, which are target 
tissues of AMH (Chapter 6). In addition, ALK2 mRNA expression is found in 
other tissues, including kidney and bone (Verschueren et a1., 1995), which is 
of particular interest, since Mullerian aplasia is often associated with renal 
and skeletal abnormalities. The introduction of a constitutively active ALK2 
in Xenopus animal caps suggests that ALK2 can also function as a BMP 
type I receptor (Armes and Smith, 1997). It is of interest to note that 
disruption of the BMP7 signal leads to kidney and bone abnormalities 
(Dudley et aI., 1995). Thus, in addition to the analysis of the AMHRII gene, 
exon 5 of the ALK2 gene was screened in patient 7149 with complete 
Mullerian aplasia (see above). Exon 5 encodes the GS box, and it has been 
shown that replacement of glutamine residue 204 in ALK2 by an aspartic 
acid residue results in constitutive activity of the kinase domain (Chapters 6 
and 7). However, no DNA alterations were found in exon 5 of ALK2 of 
patient 7149. 
The reasoning that was used against a role for activating mutations in 
the AMH gene in Mullerian aplasia, based on the absence of an effect 
similar to the effect of ectopic AMH action on ovarian development, can 
also be put forward to predict the absence of an activating mutation in the 
AMHRII or ALK2 genes. Since AMH-deficient and AMHRil-deficient mice 
are exact phenocopies (Behringer et a1" 1994; Mishina et aI., 1996), 
indicating that AMH or AMHRII have no independent functions, one would 
expect that a constitutively activated AMHRII would result in a similar 
phenotype as observed in mice that overexpress AMH (Behringer et a1., 
1990). Therefore, it is anticipated that an activating mutation in AMHRII, or 
perhaps also in ALK2, might result in ovarian dysfunction (Behringer et a1., 
1990). However, normal ovarian function was observed in Mullerian aplasia 
patients (Shokeir, 1978). 
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An additional argument against a role for AMH signaling in Mullerian 
aplasia, is the pattern of Mullerian duct regression. The Mullerian ducts 
were shown to regress, in the mouse, in a cranial to caudal direction 
(Chapter 5). furthermore, it was found that AMHRII mRNA expression is 
lost after the critical period of Mullerian duct regression, even when 
remnants of the Mullerian ducts are still present. as 'in DES-exposed male 
fetuses (Chapter 5). Therefore, an incorrect timing of AMH action in the 
female fetus may result in incomplete regression of the Mullerian ducts, in 
particular incomplete regression of the caudal ends. However, in all 
patients with Mullerian aplasia, the caudal part of the Mullerian ducts 
(upper part of the vagina) is missing, whereas the variation in Mullerian 
aplasia is localized in the cranial part of the ducts. This does not 
correspond with the pattern of Mullerian duct regression as observed in the 
mouse. 
HOXgenes 
Other candidate genes for Mullerian aplasia may be found among the 
homeobox (HOX) genes. The HOX genes are the vertebrate homologs of 
the Drosophila homeotic selector genes that define positional values along 
the anterior-posterior axis and other developmental body axes (Krumlauf, 
1994). In mouse and human, Hox genes are organized in four rather similar 
genomic clusters (Hoxa, Hoxb, Hoxc, and Hoxd), containing closely linked 
genes. Genes within a cluster are expressed in anterior-posterior domains, 
with the order of anterior limits of expression reflecting the 3' to 5' order of 
the genes on the chromosome (Krumlauf, 1994). Gain-of-function mutations 
or targeted disruption of Hox genes in mice have shown that improper 
expression can lead to altered development or identity of the structure in 
which the gene is normally expressed (Krumlauf, 1994; Manak and Scott, 
1994; Capecchi, 1996). However, sometimes a structure is lost rather than 
homeotically transformed, implying that Hox genes are also needed to 
stimulate growih, in addition to controlling patterning processes (Morgan 
and Tabin, 1994; Duboule, 1995; Capecchi, 1996). 
The 5' members of the four Hox clusters (Hoxa 9 - Hoxa 13; Hoxb 9; 
Hoxc 9 - Hoxc 13; Hoxd 9 - Hoxd 13) are expressed in posterior domains of 
the developing mouse embryo, including the intermediate mesoderm 
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(Izpisua-Belmonte et al., 1991; Taylor et 01., 1997), and it has been 
suggested that the pattern and timing of expression of the Hoxa 9 - Hoxa 13 
genes are involved in the patterning of the Mullerian duct (Taylor et a1., 
1997). In the mouse, Hoxa 9 mRNA is expressed in the Fallopian tubes, 
Hoxa 10 mRNA in the uterus, Hoxa II mRNA in the uterus and uterine 
ceIVix, and Hoxa 13 mRNA in the upper vagina (Taylor et 01., 1997). Indeed, 
targeted disruption of Hoxa 10 results in a homeotic transformation of a 
part of the cranial part of the uterus into an oviduct-like tissue and anterior 
homeotic transformation of vertebrae (Rijli et 01., 1995; Satokata et 01., 
1995). The same HOXA axis is established in human (Taylor et 01., 1997) 
and mutation of the human gene HOXA 13 has been found to result in the 
hand-foot-genital syndrome, in which normal differentiation of the Mullerian 
ducts is disrupted, resulting in partially or completely divided uterus 
(Mortlock and Innis, 1997). The link between genital tract and limb 
abnormalities, resulting from mutation of several posterior Hox genes, as 
revealed in mice with disruption of Hoxa 10, Hoxa 11 or Hoxd 13 function 
(Dolle et a1., 1991; Dolle et a1., 1993; Hsieh-U et 01., 1995; Satokata et 01., 
1995) and in humans with a mutation in the HOXA 13 gene (Mortlock and 
Innis, 1997), illustrate the strong functional conservation of these posterior 
genes in evolution (Dickman, 1997). Skeletal malformations are also found 
in some of the Mullerian aplasia patients (Lindenman et 01., 1997; Stelling 
et 01., 1997). This fact and the results discussed above, strongly suggest a 
role for the posterior expressed Hox genes of the four Hox clusters in the 
origin of Mullerian aplasia. Furthermore, analysis of compound mutants of 
Hoxa 13 and Hoxd 13 demonstrated that these genes are partially 
redundant in function and act in a dose-dependent manner; removal of an 
increasing number of copies of these genes resulted in progressively more 
severe defects (Fromental-Ramain et a1., 1996; Warot et a1., 1997). If indeed 
HOX genes are involved in the development of Mullerian aplasia, the 
partial functional redundancy of the HOX genes of the four clusters, and 
the dosage effect of HOX gene expression may explain the phenotypic 
variability of Mullerian aplasia. 
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Genes involved in Mill/erian duct formation 
Although dysregulation of HOX genes might play an important role in the 
origin of Mullerian aplasia, this defect might also result from an arrest in 
Mullerian duct formation. The Mullerian ducts are formed in a cranial to 
caudal direction (Byskov and Hoyer, 1994; Chapter 5). It can be 
hypothesized that incomplete Mullerian duct formation can lead to 
absence of the upper part of the vagina, and depending on the timing of 
arrest, the absence of uterus and fallopian tubes. Although the genes that 
control Mullerian duct formation are not known, it is clear that disorders 
that affect kidney development often also affect the urogenital tract. 
Knockout mice for genes that are involved in the induction of intermediate 
mesoderm, such as Pax2 and Emx2, revealed the absence of kidneys and 
genital tracts (Torres et ai., 1995; Miyamoto et 01., 1997). However, both 
male and female mice were affected. Nevertheless, since the renal system 
and the genital system both originate from intermediate mesoderm (SaxEm 
and Sariola, 1987), genes that play a role in the differentiation of the 
intermediate mesoderm, among which WTl and SF-J (see Chapter 1), 
might be involved in Mullerian aplasia. It would be of interest to determine 
whether male relatives of female patients with Mullerian aplasia, might 
have kidney abnormalities, since such a finding would point in the direction 
of a subtle failure in intermediate mesoderm induction. 
8.3 Downstream factors in AMH signaling 
Smads 
The identification of ALK2 as a candidate AMH type I receptor (Chapter 6) 
enables the search for downstream factors involved in AMH signaling. It 
appears that the recently identified family of Smad proteins transduces the 
signal of TGf~ family members to the nucleus (Heldin et al" 1997). In some 
tumors, mutations have been identified in Smad4/Dpc4, which abolish the 
signal of TGf~ and allow enhanced proliferation of the tumor cells (Schutte 
et al., 1996; Takagi et aJ., 1996). With respect to the Smad proteins that may 
transduce signaling through ALK2, experiments by Chen et oJ. (l997b) 
showed that introduction of Smad8 mRNA in Xenopus embryos mimics the 
effect of a constitutively active ALK2. Whether Smad8 also transduces the 
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signal of an AMH-activated ALK2, and is expressed in the AMH target 
tissues, will be next steps to investigate. Another member of the Smad 
family, Smad5, is expressed at a relatively high level in the defined AMH 
target cells, which are the mesenchymal cells surrounding the Mullerian 
duct (Meersseman et a1., 1997). Therefore, also Smad5 is a candidate 
downstream factor in AMH signaling. However, most Smad proteins 
appear to have a ubiquitous expression pattern, and the fact that a Smad 
protein may be activated by several ligands [e.g. Smad2 functions in TGFIl 
and activin signaling (Chapter 2; Baker and Harland, 1996; Macias-Silva et 
a1., 1996)], and the observation that different type I receptors can activate a 
single Smad [e.g. ALK3 and ALK6 both activate Smadl (Chapter 2; 
Hoodless et a1., 1996)], suggest that other Smad proteins should not be 
excluded from AMH signaling. 
MAPKs 
In addition to the Smads, mitogen-activated protein kinases (MAPKs) have 
been suggested to play a role in the signaling of TGFIl family members 
(Chapter 2). Indeed, TAKI can activate the JNK/SAPK cascade in response 
to TGFlls and BMPs (see Figure 2:6; Yamaguchi et a1., 1995; Wang et a1., 
1997; Shibuya et a1., 1998). In a preliminary study we have investigated 
whether a constitutively active ALK2 can activate the MAPK cascade. A 
reporter system was used that measures the activity of ELKl, a member of 
the large family of Ets domain-containing transcription factors. ELKI is a 
substrate for all three distinct classes of MAPKs (ERKs, JNK/SAPKs and p38-
MAPK; Gille et a1., 1995a; Gille et a1., 1995b; Sugimoto et a1., 1998; Yang et 
a1., 1998). When the constitutively active mutant ALK2-Q204D was 
expressed in transfected cells, a five-fold increase in ELKI activity was 
measured. Wild type ALK2 did not have such an effect (Figure 8.2; Visser et 
a1., unpublished results). These preliminary results indicate that ALK2 may 
activate one of the MAPK signaling cascades. Whether ALK2 can induce 
the MAPK cascade in response to AMH remains to be studied. 
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Figure 8.2. ALK2-Q204D enhances ELK1 activity. 
Discussion 
HEK-Z93 cells were transfeded with Ga14·ELKl and Gal4·LUC together with the 
indicated expression vectors. After transfection, cells were kept on serum-free 
medium for 24 hours, prior to determination of luciferase activity. Luciferase activity 
was normalized for transfection efficiency. 
Induction of the MAPK cascade by ALK2 may be related to induelion of 
apoptosis, since MAPKs have been shown to mediate signals leading to 
apoptosis, such as the signals generated by TGF~s and BMPs (Shibuya et 
aI., 1998). Several members of the TGF~ family, in particular TGF~s, 
adivins and BMPs, have been shown to induce apoptosis (Graham et aJ., 
1994; Hully et aJ., 1994; Olaso et aJ., 1998) and it can be hypothesized that 
this apoptotic signal is mediated through MAPKs. The finding that ALK2· 
Q204D induces apoptosis and activates ELK I in vitro, points in this 
direction. Apoptosis is also involved in the regression of the Mullerian 
ducts, and the fael that apoptotic cells were not found in the Mullerian 
ducts of female fetuses and AMH·deficient male fetuses, indicates that the 
apoptotic signal is induced by AMH (Chapter 7). Since ALK2 can function 
as an AMH type I receptor, it will be of interest to study whether MAPKs are 
also involved in mediating AMH·induced apoptosis in the Mullerian duels. 
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To study the role of ALK2 in AMH signaling in vivo, the generation of 
ALK2-deficient mice will be an important tool. However, ALK2-deficient 
mice will show defects in signaling of several ligands, since ALK2 can also 
serve as a type I receptor for BMPs and perhaps several other TGFp family 
members. Furthermore, ALK2 is expressed during early embryogenesis 
(Verschueren et al., 1995), and therefore ALK2-deficient mice may show 
lethal defects in early embryogenesis. Since we are interested in the role of 
ALK2 in AMH target tissues, the generation of a conditional ALK2 knockout, 
using the Cre-LoxP system, promises to be a very useful approach. Cre is a 
DNA recombinase that recognizes LoxP sites, and splices out the DNA 
between LoxP sites. Two mouse lines need to be generated, one in which 
LoxP sites are introduced into the gene of interest, using homologous 
recombination, and a second line that expresses the Cre gene driven by a 
tissue-specific promoter. Cross breeding of the two lines will result in the 
disruption of the gene only in those cells that express Cre, while in other 
non-expressing cells the function of the gene is not disrupted (Gu et aJ., 
1994; Porter, 1998). To abrogate the ALK2 signal in the mesenchymal cells 
surrounding the Mullerian ducts and in the gonads, the use of the AMHRlI 
promoter might be a good approach, since AMHRII mRNA expression is 
restricted to these tissues. However, the possibility of interference of this 
transgenic AMHRII promoter with the endogenous AMHRII promoter, 
should be considered. 
The mouse AMHRlI gene was isolated, and luciferase reporter 
constructs that contain 2.5 kb, 1.2 kb, 1.0 kb or 0.6 kb of the sequences 
upstream of the translation start site were constructed. All constructs 
showed basal promoter activity upon transient transfection in HEK-293 cells 
or SKI I cells, a Sertoli cell line established from H-2Kb-tsA58 transgenic 
mice (Walther et aJ., 1996; Figure 8.3). The 0.6 kb AMHRlI promoter-
luciferase reporter construct showed the highest activity (Figure 8.3; Visser 
et al., unpublished results). However, whether this construct contains the 
elements that confer tissue-specific expression and can be used to direct 
Cre expression to all possible AMH target cells, remains to be 
demonstrated. 
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Figure 8.3. Basal activity of the mouse AMHRII promoter. 
A. AMHRII promoter-LUC constructs, in which the translation start site of the 
AMHRlI gene is replaced by that of the iud/erase gene, were transiently transfeded 
into HEK-293 or SKI I cells. Open bars: activity of the control luciferase plasmid; 
closed bars: activity of the AMHRII promoter constructs. The induction factor is 
indicated at the right side of the bars. 
B. Partial restriction map of the mouse AMHRII promoter. 
In addition to further evaluation of temporal and mechanistic aspects 
of the effect of AMH on the Mullerian ducts, the generation of conditional 
ALK2 knockout mice may prove to be useful to study possible AMH actions 
in the gonads, in particular in the ovary. AMH- and AMHRII-deficient mice 
did not show pronounced ovarian abnormalities (Behringer ef a1., 1994; 
Mishina ef a1., 1996), although both AMH and AMHRII mRNAs are 
specifically and strongly expressed in preantral and small antral follicles 
(Baarends ef al., 1995b). Since ALK2 is suggested to function as a BMP type 
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I receptor and/or an activin type I receptor (Attisano e/ aI., 1993; Armes and 
Smith, 1997), BMPs and act ivins may signal through ALK2 in the ovaries of 
AMH-deficient mice. Abrogation of the ALK2 signal in the ovary may reveal 
whether ALK2 functions as a specific AMH type I receptor or whether AMH 
in the ovary is functionally redundant. Similar experiments can be 
envisaged for the testis. 
The identification of ALK2 as a candidate AMH type I receptor is an 
important step to obtain more information about the exael signaling 
mechanism of AMH. Such experiments may contribute to improve our 
understanding of the mechanism of MUllerian duct regression and the 
functional importance of AMH action in the gonads. 
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SUMMARY 
During early embryonic development. the gonads are bipotential and can 
develop into testis or ovary. Furthermore, the precursors of both male and 
female reproductive tracts, the Wolffian and Mullerian ducts, respectively, 
are present during this early stage of development. In genetically male 
embryos, the presence of a Y chromosome determines that the 
undifferentiated gonads will develop into testes, which start to produce two 
testicular hormones. Testosterone causes the differentiation of the Wolffian 
ducts into epididymides, vasa deferentia and seminal vesicles. The other 
hormone, anti-Mullerian hormone (AMH) is responsible for regression of 
the Mullerian ducts. The Mullerian ducts are sensitive to AMH for a short 
period, and exposure before or after this period does not result in complete 
Mullerian duct regression. In the mouse, this critical period of Mullerian 
duct regression is between E13-E15 (days post coitum). In the female fetus, 
which does not produce AMH and testosterone, the Wolffian ducts 
degenerate, whereas the Mullerian ducts differentiate into the Fallopian 
tubes, uterus and upper part of the vagina, apparently independent of 
ovarian hormones. In the absence of AMH action, due to a mutation in the 
AMH gene, Mullerian ducts do not regress in male fetuses This phenotype 
is known as persistent Mullerian duct syndrome (PMOS), in which boys 
have normal internal male structures but also internal female structures. 
This thesis focuses on the molecular mechanism and developmental 
aspects of AMH action. 
In the General Introduction (Chapter I), most of the known regulatory 
factors of sex determination and differentiation are described. 
Furthermore, the regulation of AMH mRNA expression, and the role of AMH 
during pre- and postnatal life are described in this chapter. 
AMH is a member of the transforming growih factor P (TGFP) family of 
growth and differentiation factors. Members of the TGFp family signal 
through a receptor complex, consisting of a type I and a type II 
transmembrane serine/threonine kinase receptor. In addition to the family 
members and their receptors, the mechanism of receptor activation and 
the downstream factors are described in Chapter 2. 
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A novel type II receptor has been cloned that, based on its mRNA 
expression in the mesenchymal cells surrounding the Mullerian ducts, and 
in the gonads, encodes a candidate AMH type II receptor (AMHRII). 
Chapter 3 describes the generation of transgenic mice carrying a 
dominant negative AAMHRII, under the control of the zinc-inducible 
metallothionein promoter, to study the role of AMHRII during several 
developmental stages. Five transgenic mouse lines were generated, and 
although the transgene AAMHRlI is expressed in several tissues, including 
the AMH target tissues, no aberrant phenotype was found that would imply 
inhibition of AMH action. 'The possible shortcomings and improvements of 
our tested model are also discussed in Chapter 3. 
In Chapter 4, the structure and chromosomal localization of the human 
AMHRII gene are described. The coding region consists of II exons, 
divided over 8 kb, and the gene maps to chromosome IZqIZ-qI3. The 
results, described in Chapter 4, can be used for the identification of 
possible mutations in the AMHRII gene in PMOS patients. 
Some of the structures that can develop from Mullerian duct remnants, 
most pronounced in PMOS patients, are also found in man prenatally 
exposed to the synthetic estrogen diethylstilbestrol (DES). It has been 
hypothesized that the MUllerian ducts become less sensitive to AMH upon 
exposure to DES. Chapter 5 describes the effect of prenatal DES exposure 
on Mullerian duct development and on AMH and AMHRII mRNA 
expression, during male fetal mouse development. Upon exposure to DES, 
the formation of the Mullerian duct was delayed by approximately two 
days. A similar delay was found for the regression of the Mullerian ducts. 
Thus, it can be suggested that, in DES-exposed male fetuses, the 
development of the Mullerian ducts is delayed, resulting in an asynchrony 
in the temporal aspects of Mullerian duct formation, development and 
sensitivity to AMH, which may result in partial regression. However, 
prenatal exposure to DES does cause an increase in the mRNA expression 
of AMH and AMHRII at E13. The latter does not indicate an inhibition of 
AMH action at the level of ligand-receptor interaction. This raises the 
possibility that prenatal exposure to DES may inhibit the action of other 
factors, functioning downstream of AMH/AMHRlI. Possible downstream 
factors, and their families, are described in Chapter Z. 
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In Chapter 6, the identification of a candidate AMH type I receptor is 
described. To study AMH signaling, an in vitro model is developed based 
on an inhibitory effect of AMH on induction of aromatase activity. In this 
model, a constitutively active type I receptor that can signal in the absence 
of ligand, was used. The constitutively active mutant ALK2 can suppress the 
induced aromatase promoter activity, and a wild type ALK2 can form a 
functional complex with AMHRII that signals in response of AMH. 
Expression of ALK2 mRNA was found in the target tissues of AMH; in the 
mesenchymal cells surrounding the Mullerian ducts and also in the 
gonads. These results strongly suggest that ALK2 is a strong candidate 
AMH type I receptor. However, since ALK2 mRNA is not only expressed in 
AMH target tissue, but also in other tissues, it may serve as a type I 
receptor for other ligands as well. 
Chapter 7 describes the ability of a constitutively active ALK2 to induce 
programmed cell death or apoptosis in vitro. Since, ALK2 is a candidate 
AMH type I receptor, and therefore may be involved in the action of AMH 
on the Mullerian ducts, apoptosis in Mullerian ducts was studied, during 
the period of Mullerian duct regression. The TUNEL assay was used to 
detect apoptosis in histological· tissue sections. Apoptotic cells were 
present in the Mullerian ducts of male mouse fetuses. In Mullerian ducts of 
female fetuses and of AMH-deficient male fetuses, in which the Mullerian 
ducts do not regress, apoptosis was not detected. This indicates that 
apoptosis is involved in the regression of the Mullerian ducts, and may be 
induced by AMH. 
Abnormalities of the development of Mullerian ducts in the female 
occur frequently. In Chapter 8, the possible role of abnormal AMH 
signaling in the origin of Mullerian aplasia is discussed. Furthermore, the 
implications of ALK2 as an AMH type I receptor are discussed, in relation to 
the mechanism of AMH signaling, and suggestions for future research are 
given. 
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Gedurende de vroege embryonale ontwikkeling zijn de gonaden 
ongedifferentieerd, om zich vervolgens tot testes of ovaria te ontwikkelen. 
Tevens zijn in een vroeg stadium zowel de mannelijke als de vrouwelijke 
genitale traetus in aanleg aanwezig, de zgn. Wolffse en Miillerse gangen. 
In genetisch mannelijke embryo's bepaalt de aanwezigheid van het Y 
chromosoom dat de ongedifferentieerde gonaden zich zullen ontwikkelen 
tot zaadballen (testes), die vervolgens twee hormonen gaan produceren. 
Het hormoon testosteron zorgt voor de differentiatie van de Wolffse gangen 
tot de bijballen, de zaadleiders en de zaadblazen. Het andere hormoon, 
het anti-Miillerse gang hormoon (AMH), is verantwoardelijk voor het ten 
gronde gaan (regressie) van de Miillerse gangen. De MiilIerse gangen zijn 
gedurende een karte periode gevoelig voor AMH. Wanneer de gangen 
voor of na deze periode worden blootgesteld aan AMH vindt er geen 
volledige regressie plaats. Deze kritische periode van Miillerse gang 
regressie vindt in de muis plaats tussen dag 13 en 15 na de bevruchting. In 
de vrouwelijke foetus, waarin de ovaria geen testosteron en AMH 
produceren, verdwijnen de Wolffse gangen, terwijl de Miillerse gangen 
zich ontwikkelen tot eileiders, baarmoeder en het bovenste deel van de 
vagina. De differentiatie van de vrouwelijke genitale tractus lijkt niet 
afhankelijk te zijn van gonadale hormonen. Afwezigheid van AMH in een 
mannelijke foetus, bijvoarbeeld door een mutatie in het AMH gen, zorgt 
ervoor dat de Miillerse gangen niet verdwijnen. Ott verschijnsel staat 
bekend als het persistente Miillerse gang syndroom (PMOS), waarbij 
jongetjes naast inwendige mannelijke structuren tevens inwendige 
vrouwelijke strueturen bezitten. 
Het onderzoek, dat in dit proefschrift beschreven is, heeft zich gericht 
op het moleculaire werkingsmechanisme en ontwikkelingsbiologische 
aspeeten van de werking van AMH. 
In de Afgemene Introduetie (Hoofdstuk I) worden de meeste van de 
thans bekende faetoren die betrokken zijn bij de regulatie van 
geslachtsbepaling en geslachtsdifferentiatie beschreven. Verder wordt in 
dit hoofdstuk aandacht besteed aan de regulatie van AMH mRNA 
expressie en de functie van .A1vfH voor en na de geboorte. 
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AMH behoort tot de TGF~ familie van groei- en differentiatiefactoren. 
Leden van deze familie geven hun signaal door via een receptor complex 
dat bestaat uit type I en type II transmembraan serine/threonine kinase 
receptoren. Naast de familieleden en hun receptoren, worden ook het 
receptor-activatie-mechanisme en de factoren die betrokken zijn bij het 
doorgeven van het signaal beschreven in Hoofdstuk 2. 
In het voorgaande onderzoek werd een gen ge'identificeerd dat 
codeert voor een nieuw lid van de type II receptor familie. Op grond van 
mRNA expressie random de Mullerse gang en in de gonaden, werd 
verondersteld dat dit gen codeert voor een kandidaat AMH type II receptor 
(AMHRII). Hoofdstuk 3 beschrijft het ontwikkelen van transgene muizen 
waarin een niet-functionele receptor, tot expressie kan worden gebracht. 
De mutant receptor MMHRII zou de werking van de normale AMHRII 
dominant negatief moeten remmen. Het experiment werd uitgevoerd om de 
ral van AMHRII in het doorgeven van het AMH signaallijdens verschillende 
ontwikkelingsstadia te kunnen onderzoeken. Vijf transgene muizenlijnen 
werden gemaakt, en hoewel het transgen MMHRII tot expressie komt in 
verschillende weelsels, waaronder de AMH doelwitweefsels, werden geen 
aanwijzingen gevonden die zouden kunnen duiden op een remming van 
AMH werking. De mogelijke tekortkomingen en verbeteringen van het door 
ons geteste model worden tevens in Hoofdstuk 3 bespraken. 
In Hoofdstuk 4 worden de structuur en de chromosomale lokalisatie 
van het humane AMHRII gen beschreven. Het coderende gebied bestaat 
uit II exonen, verspreid over 8 kb, en het gen ligt op chramosoom 12q 12-
q13. De resultaten, zools beschreven in Hoofdstuk 4, kunnen worden 
gebruikt bij de identificatie van mutaties in het AMHRII gen bij PMDS 
patienten. 
Enkele structuren die zich kunnen ontwikkelen uit overblijfselen van de 
Mullerse gangen, zoals in het meest uitgesproken geval bij PMDS 
patienten, worden ook gevonden in mannen die prenataal zijn blootgesteld 
aan het synthetisch oestrageen diethylstilbestrol (DES). Er zijn aanwijzingen 
dat de Mullerse gangen minder gevoelig voor AMH kunnen worden na 
blootstelling aan DES. Hoofdstuk 5 beschrijft het effect van prenatale 
blootstelling aan DES op de ontwikkeling van de Mullerse gangen en op de 
mRNA expressie van AMH en AMHRII, tijdens de foetale ontwikkeling van 
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mannelijke muizen. Het bleek dat blootstelling aan DES tot gevolg heeft dat 
de vorming van de Mullerse gangen met ongeveer twee dagen wordt 
vertraagd. Deze vertraging werd ook waargenomen voor de regressie van 
de gangen. Verondersteld kan worden, dat in DES blootgestelde 
mannelijke foetussen, de ontwikkeling van de Mullerse gangen is 
vertraagd, zodanig dat er een discrepantie ontstaat tussen de temporale 
aspeelen van aanleg, ontwikkeling, en kritische periode van gevoeligheid 
voor AMH. Dil zou een oorzaak kunnen zijn voor de partiale regressie. WeI 
was in de DES behandelde foetussen, op het tijdstip 13 dagen na de 
bevruchting, de mRNA expressie van AMH en AMHRII verhoogd. Dil laatste 
wijst zeker niet op remming van AMH werking op het niveau van ligand-
receptor interaelie, ten gevolge van de DES behandeling. Blootstelling aan 
DES heeft mogelijk een remmend effeel op andere faeloren, zoals de 
intracellulaire factoren die betrokken zijn bij het doorgeven van het AMH 
signaa!. De families waartoe deze faeloren behoren zijn beschreven in 
Hoofdstuk 2. 
In Hoofdstuk 6 wordt de identificatie van een kandidaat AMH type I 
receptor beschreven. Een in vitro model werd ontwikkeld om de 
signaaltransductie van AMH te bestuderen. Dil model is gebaseerd op een 
remmend effeel van AMH op induelie van aromatase aeliviteit. Daarbij 
werd tevens gebruik gemaakt van een gemuteerde en daardoor 
constitutief actieve type I receptor, die een cellulair signaal doorgeeft in 
afwezigheid van het ligand. De constitutief aelieve mutant ALK2 kan de 
geinduceerde activiteit van de aromatase promoter rem men, en een 
normale ALK2 kan een funelioneel receptor complex met AMHRII vormen 
in de aanwezigheid van AMH. Expressie van ALK2 mRNA werd gevonden 
in de doelwitweefsels van AMH; in de mesenchymale cellen random de 
Mullerse gangen en oak in de gonaden. Deze resultaten suggereren zeer 
sterk dat ALK2 een belangrijke kandidaat is voor de AMH type I receptor. 
Omdat ALK2 niet alleen in AMH doelwitweefsels maar tevens in andere 
weefsels tot expressie komt, kan ALK2 mogelijk ook als een type I receptor 
voor andere Uganden functioneren. 
In Hoofdstuk 7 wordt beschreven dat een constitutief actieve mutant 
ALK2 gepragrammeerde celdood (apoptose) kan induceren in een cellijn. 
Omdat ALK2 een kandidaat AMH type I receptor is, en daarom betrakken 
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zou kunnen zijn bij de werking van AMH op de MiilIerse gang en, werd 
apoptose in MiilIerse gangen onderzocht ten tijde van de regressie van de 
gangen. Daarbij werd gebruik gemaakt van de TUNEL methode, voor 
deteclie van apoptose in histologische weefselcoupes. Gevonden werd, in 
muizen, dat apoptotische cellen aanwezig zijn in de Miillerse gangen van 
mannelijke foetussen. In Miillerse gangen van vrouwelijke foetus sen en van 
mannelijke AMH·deficiente foetussen, waarin de Miillerse gangen blijven 
bestaan, werd geen apoptose gevonden. Dit betekent dat apoptose 
inderdaad betrokken is bij de regressie van de Miillerse gangen, en dat 
AMH mogelijk apoptose induceert. 
Afwijkingen in de ontwikkeling van Miillerse gangen komen frequent 
voor bij de vrouw. In Hoofdstuk 8 wordt de mogelijke rol van verstoorde 
AMH werking bij het ontstaan van Miillerse gang aplasie besproken. Ook 
wordt de betekenis van de identificatie van ALK2 als een AMH type I 
receptor beschreven, in relatie tot het mechanisme van AMH signaal 
overdracht, en worden enkele suggesties voor vervolg onderzoek gegeven. 
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